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The Characterization of Hematopoiesis in Murine Fetal Bone Marrow
Abstract
Hematopoietic stem cells (HSCs) and their downstream progenitors are a heterogeneous population of
cells that are indispensable for lifelong hematopoiesis and are often utilized in the clinic for the treatment
of hematologic maladies via hematopoietic stem cell transplantation (HSCT). Over several decades, it has
been discovered that HSCs arise in the dorsal aorta of the developing embryo, migrate to the fetal liver
(FL), and undergo a large expansion before reaching their final resting place in the bone marrow (BM).
Many resources have been invested in understanding the roles of the different niches HSCs encounter
along their journey. A greater understanding of HSC niche regulation could provide clues for HSC
maintenance and expansion in vitro. One critical niche during HSC ontogeny that has been greatly
overlooked is the fetal BM (FBM), of which the hematopoietic and HSC niche compartments are poorly
understood. For this reason, we meticulously characterized the hematopoietic progenitor compartment of
the whole skeleton FBM from its colonization until after birth via competitive transplantation,
immunophenotypic analysis of the hematopoietic stem and progenitor cell (HSPC) compartment,
functional assessment of specific progenitor populations, and single-cell RNA-sequencing (scRNA-Seq)
of the hematopoietic and stromal FBM environment. Here, we provide the first report of the presence of
bona fide HSCs within the E15.5 FBM. We also found that HSCs were present in the all sources of BM,
including the forelimbs, hindlimbs, and trunk of E15.5 embryos. We are also the first to assess the BM
immunophenotypic HSPC compartment from initial seeding to adulthood and found that specific
multipotent progenitor (MPP) cells (MPP2s) are the predominant HSPC population in the FBM, appearing
to have the ability to migrate to and seed the FBM directly from the FL. Interestingly, immunophenotypic
MPP2s are not functional in vitro or in vivo until birth (E18.5-P0), and display reduced repopulating
capacity compared to adult BM and time-matched FL MPP2s. Also, the frequencies of the different FBM
HSPCs shift around birth from an MPP2-dominant phenotype to the MPP3/MPP4-dominant phenotype
seen in adult BM. To identify the intrinsic and extrinsic mechanisms controlling MPP2 functional
maturation, we isolated stromal and hematopoietic progenitor (HP) populations from E16.5, E18.5, P0,
and adult BM, and constructed the first known scRNA-Seq dataset spanning the HP and stromal
compartment across BM ontogeny. Preliminary analysis of our scRNA-Seq datasets show that the FBM
stroma and HP compartments are compositionally distinct from the adult BM compartments, and this
disparity in composition is even more drastic at E16.5, suggesting that the reduced function of FBM
MPP2s may be due to a semi-incompatible FBM niche. Our future studies will focus on identifying
intrinsic differences between immunophenotypic HSPC populations across FBM ontogeny in our HP
scRNA-Seq dataset, as well as defining putative niches for HSPCs in the FBM. We hope that these
analyses will identify novel hematopoietic factors in the FBM niche that can be therapeutically exploited
to enhance HSC expansion/function/differentiation in the clinic.
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ABSTRACT
Hematopoietic stem cells (HSCs) and their downstream progenitors are a
heterogeneous population of cells that are indispensable for lifelong hematopoiesis and
are often utilized in the clinic for the treatment of hematologic maladies via
hematopoietic stem cell transplantation (HSCT). Over several decades, it has been
discovered that HSCs arise in the dorsal aorta of the developing embryo, migrate to the
fetal liver (FL), and undergo a large expansion before reaching their final destination in
the bone marrow (BM). Many resources have been invested in understanding the roles of
the different niches HSCs encounter along their journey. A greater understanding of HSC
niche regulation could provide clues for HSC maintenance and expansion in vitro. One
critical niche during HSC ontogeny that has been greatly overlooked is the fetal BM
(FBM), of which the hematopoietic and HSC niche compartments are poorly understood.
For this reason, we meticulously characterized the hematopoietic progenitor compartment
of the whole skeleton FBM from its colonization until after birth via competitive
transplantation, immunophenotypic analysis of the hematopoietic stem and progenitor
cell (HSPC) compartment, functional assessment of specific progenitor populations, and
single-cell RNA-sequencing (scRNA-Seq) of the hematopoietic and stromal FBM
environment. Here, we provide the first report of the presence of bona fide HSCs within
the E15.5 FBM. We also found that HSCs were present in all sources of BM, including
the forelimbs, hindlimbs, and trunk of E15.5 embryos. We are also the first to assess the
BM immunophenotypic HSPC compartment from initial seeding to adulthood and found
that specific multipotent progenitor (MPP) cells (MPP2s) are the predominant HSPC
population in the FBM, appearing to have the ability to migrate to and seed the FBM
directly from the FL. Interestingly, immunophenotypic MPP2s are not functional in vitro
or in vivo until birth (E18.5-P0), and display reduced repopulating capacity compared to
adult BM and time-matched FL MPP2s. Also, the frequencies of the different FBM
HSPCs shift around birth from an MPP2-dominant phenotype to the MPP3/MPP4dominant phenotype seen in adult BM. To identify the intrinsic and extrinsic mechanisms
controlling MPP2 functional maturation, we isolated stromal and hematopoietic
progenitor (HP) populations from E16.5, E18.5, P0, and adult BM, and constructed the
first known scRNA-Seq dataset spanning the HP and stromal compartment across BM
ontogeny. Preliminary analysis of our scRNA-Seq datasets show that the FBM stroma
and HP compartments are compositionally distinct from the adult BM compartments, and
this disparity in composition is even more drastic at E16.5, suggesting that the reduced
function of FBM MPP2s may be due to a semi-incompatible FBM niche. Our future
studies will focus on identifying intrinsic differences between immunophenotypic HSPC
populations across FBM ontogeny in our HP scRNA-Seq dataset, as well as defining
putative niches for HSPCs in the FBM. We hope that these analyses will identify novel
hematopoietic factors in the FBM niche that can be therapeutically exploited to enhance
HSC expansion/function/differentiation in the clinic.
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CHAPTER 1.

INTRODUCTION

The Conceptual Origins of the Stem Cell
It was the German zoologist Ernst Haeckel who, after reading and being heavily
influenced by Charles Darwin’s work, began drawing Stammbäume—or “stem trees”—to
describe the phylogeny of all living organisms (Haeckel 1868, Haeckel 1874). This led
him to describe the unicellular organism from which he presumed all multicellular
organisms derived as a “Stammzelle,” or “stem cell” (Haeckel 1868, Haeckel 1874).
Haeckel, also a developmental biologist, simultaneously used the term to refer to the
fertilized egg of multicellular organisms (Haeckel 1877).
In 1885, August Weismann theorized that germ-plasm, a substance that is passed
down through generations via sexual reproduction, is transmitted via specialized “germ
cells” that are distinct from the rest of the body (Weismann 1885). This led the German
biologist Theodor Boveri to try to identify the earliest germ cells in nematodes via
microscopy. By tracing the cell lineages of fertilized Ascaris embryos in tree diagrams
(again, coined “Stammbäume”), Boveri noticed that the germline cells that were destined
to give rise to “somatic” cells displayed fragmentation and loss of chromatin as the cells
divided. However, the germline cells destined to give rise to germ cells appeared to
maintain the same compliment of chromatin along lineage commitment. Essentially,
Boveri used this observation to conclude that these cells maintained the chromatin so that
they could pass it on to the next generation. He called the cells that existed between the
fertilized cell to the fully committed germ cells, “stem cells” (Boveri 1887, 1892a,
1892b). Around the same time, Häcker identified a cell in Cyclops embryos that become
internalized upon gastrulation and underwent asymmetric cell division to produce a
mesodermal precursor and a germ cell precursor and called it a “stem cell” (Häcker
1892). However, Häcker also used the term for cells that produce oocytes in the gonad
later in development (Häcker 1892).
It was not until 1896 that the term “stem cell” became popularized in the English
language by Edmund Wilson’s “The Cell in Development and Inheritance,” in which he
reviewed Boveri’s and Häcker’s works (Wilson 1896). However, the conceptual
definition of the “stem cell” was still geared toward a description of a cell that facilitates
the production of germ cells.
In this introduction, I will review the origins and current state of hematopoietic
stem cell (HSC) research. HSCs are the most well-characterized stem cell population to
date, and their properties are often used as a standard for identifying stem cell
populations of other tissues. The discovery of HSCs and their properties have also led to
their widespread clinical use in hematopoietic stem cell transplantation (HSCT). Here, I
will discuss the discovery and characterization of HSCs, the developmental origins of
HSCs, and the regulatory niches that HSCs interact with during development and steady
state. Finally, I will introduce the primary study central to this dissertation: characterizing
the establishment of hematopoiesis in the fetal bone marrow (BM)

1

What Is an HSC?
Unitarians versus dualists
Once Paul Ehrlich established staining techniques for leukocytes using alkaline,
acid, and neutral dyes (Ehrlich, 1879), different white blood cell lineages could be
observed. This led to years of research in which hematologists were divided as to the
origins of different blood cell lineages (Maximow, 1924). Unitarians believed there was a
common cell of origin for granulocytes, erythrocytes, and lymphocytes. Meanwhile,
dualists believed that myeloid cells arose from common precursors in the BM and
lymphoid cells derived from common precursors in the lymphatic glands/spleen. This
made sense at the time, because the lymphatic system was the first tissue believed to
harbor hematopoietic activity (Müller, 1844), while the BM was thought to be the
primary site of hematopoiesis in the adult (Neumann, 1868). Therefore, many dualists
(including Ehrlich) believed that different committed cells could be coming from distinct
sources of hematopoietic tissue (Cooper, 2011).
Based on Ehrlich’s staining protocols, it was clear that lymphocytes differed from
other leukocytes and erythrocytes phenotypically. It was also noted that lymphocytes
resembled more immature cells (e.g. the progenitor cells), therefore the first names given
by the unitarians for a putative hematopoietic cell of origin took on lymphocytic
nomenclatures [e.g., nongranular undifferentiated lymphocytes (Dantschakoff, 1908);
lymphoidocytes (Pappenheim 1908)], although other terms were given [e.g. primary
wandering cells (Saxer, 1896); hemocytoblasts (Zoja, 1910)].
Alexander Maximow is typically credited with coining the term “stem cell” to
refer to the common hematopoietic cell of origin (1909), although it had been used as
early as 1896 by Pappenheim (Pappenheim 1896) to describe a precursor cell capable of
giving rise to both red and white blood cells. Neumann—who first hypothesized that the
BM is the primary source of hematopoiesis in adults—also used the term “stem cell” to
describe such a cell (Neumann, 1912), and he and others thought that the only way to
determine if the unitarians or dualists were correct was to somehow assay the potential of
the “stem cells” in in vitro culture. Therefore, at this time the term “stem cell” was used
to at least describe both 1.) the cell of origin for germ cells and 2.) the common cell of
origin for hematopoietic cells.
Experimental evidence for the theoretical HSC
Until the 1960s, there was no experimental evidence of a clone with HSC
properties, namely, the ability to self-renewal and differentiate into all blood lineages.
From 1945-1961, several studies focusing on transplantation led to the unequivocal
discovery of HSCs. In 1945, Ray Owen looked for the presence of inherited cellular
antigens in the blood of fraternal twin calves and found that the majority of twins have
identical blood types, meaning that one twin had a portion of cells similar to the other
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twin and vice versa (Owen 1945). Owen postulated that since the only time there was
interchange of blood was during embryogenesis, there must be some sort of cell from one
twin—the “donor”—that establishes itself as a source of hematopoietic tissue in the other
twin—the “host”—and continues to produce blood cells throughout adulthood (Owen
1945).
At the same time, the atomic bombings of 1945 in Japan shed light on the effects
of total body irradiation on the hematopoietic system, as many civilians died of
hematopoietic failure after being exposed. Therefore, many researchers focused on
methods to shield the body from the effects of irradiation on the hematopoietic system. In
1950, Jacobson found that total body irradiation (600 rads) incurs severe anemia in mice,
mostly as an effect of BM destruction. However, this could be ameliorated by a
compensatory mechanism from the spleen, as mice that are given irradiation after
splenectomy followed by reintroduction of the spleen show recovery of anemia after a
recovery of BM hematopoiesis (Jacobson 1950). Irradiating the spleens prevents this
compensatory mechanism from happening, but shielding the spleens with ¼ inch lead
prevents the spleens from becoming compromised by the irradiation (Jacobson 1950).
Lorenz showed that injection of heterologous and homologous BM into lethally irradiated
mice and guinea pigs allowed for a recovery from radiation-induced death in recipients
(Lorenz 1951). It was also noted that intravenous injections of homologous BM produced
a greater incidence of survival (Lorenz 1951). Lorenz speculated that the factor providing
protection from mortality was probably humoral, but he did not rule out the possibility of
a cellular factor (Lorenz 1951).
In another study of cattle twins, Billingham tested whether skin grafts of twins
from heterozygous and monozygotic twins would be accepted, with the assumption that
monozygotic twins would perform better (Billingham 1952). However, they found that
the grafts were accepted regardless of zygosity. They relied on the work of Owen to
speculate that this acceptance was due to the “confluence of foetal circulations of cattle
twins” (Billingham 1952). One year later, Billingham proposed the hypothesis of
“acquired tolerance,” by injecting fetal mice/chicks with cells from a different strain,
followed by skin graft in adulthood. They showed that the creation of chimeras in the
prenatal period allowed for immunological tolerance to skin grafts in adulthood from the
same strain they were inoculated against (Billingham 1953). This led Main in 1955 to
inject lethally irradiated mice of one strain with the BM of a different strain, followed by
an attempted skin graft from the donor strain to see if the creation of a BM chimera
would facilitate a successful skin graft (Main 1955). They were successfully grafted, thus
suggesting the creation of murine “tolerant chimeras.” However, there was still no
confirmation of a humoral or cellular effect that allowed for tolerance of the graft (Main
1955).
In two groundbreaking studies, Nowell and Ford confirmed that the source of
radioprotection in mice after BM or spleen injection was of cellular origin, as they
showed via chromosomal marker staining that the donor cells established in the recipient
BM and showed continued hematopoietic output (Nowell 1956, Ford 1956). The same
year, mice were transplanted with isologous (same genetic background), homologous
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(same species), or heterologous (different species) BM following lethal irradiation to
confirm that isologous and homologous BM offered the greatest protection (Trentin
1956). Shortly thereafter, the first human BM transplant was performed by E. Donnall
Thomas (Thomas 1957). Importantly, human transplants showed that donor BM was able
to engraft following moderate doses of radiation, and engraftment seemed to be
prolonged after a radiation dose strong enough to produce bone-marrow aplasia in the
patient had been administered. While instrumental to driving HSCT forward, these
studies still did not confirm the existence of an HSC.
It was not until the 1960s that Ernest MuCulloch and James Till provided the first
evidence of a true HSC. In one of their first studies, McCulloch and Till irradiated murine
BM in vivo or ex vivo, diluted the irradiated cells to a known concentration, and injected
the cell suspensions into lethally irradiated recipients in a series of limiting dilutions
(McCulloch 1960). To quantify the number of protected repopulating cells, they used the
percentage of surviving mice as a readout (McCulloch 1960). They also tested the
number of radioprotected repopulating cells in the BM by subjecting their cell
suspensions (or cells in vivo) to various doses of irradiation (McCulloch 1960). This was
a key step to uncovering a quantitative method for identifying HSCs.
One of the defining moments in discovering the potential HSC was the
observation that ~10 days after injecting mice with unirradiated BM cells, the spleens of
the recipients formed several distinct nodules (Till 1961). McCulloch and Till called the
cells that produced these nodules Colony Forming Units, or “CFU” (subsequently
referred to as CFU-S for “CFU-Spleen”). They could also use the CFU-S in recipients as
a readout to quantify the number of CFU-S in the injected donor BM, providing another
quantification method for potential HSCs (Till 1961). Since there was a positive
correlation between the number of CFU-S in recipients and the number of marrow cells
injected, the prevailing notion was that the CFU-S were arising from single clones.
In a landmark study, McCulloch and Till induced chromosomal aberrations in
donor BM to produce putative chromosomal markers of clonality in the BM resident
CFU-S, followed by injection of BM and an observation of the clonal markers in cell
suspensions of the recipient CFU-S (Becker 1963) (Figure 1-1). They found that the
CFU-S was indeed a single clone, as nearly 100% of cells in a colony presented identical
chromosomal markers (Becker 1963). This was the first proof of a hematopoietic clone in
mouse BM. McCulloch and Till then wanted to show that the CFU-S had the ability to
self-renew, a critical property of stem cells. Therefore, they isolated the CFU-S from
primary recipients and secondarily transplanted them into new recipients to see if new
CFU-S could be formed (Siminovitch 1963). They found that in some secondary
recipients, new CFU-S were formed, confirming that the CFU-S had the stem cell
property of self-renewal.
For the remainder of the decade, other key properties of the modern-day HSC
were described using CFU-S as a model. Becker tested cells from different sources for
their presence in S phase via exposure to thymidine followed by assaying them for CFUS ability and found that a large proportion of CFU-S from FL and from proliferating
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Figure 1-1.

Till and McCulloch identify clonal hematopoietic progenitors

The experimental schematic used in Becker 1963 to identify the first hematopoietic clone
in the mouse bone marrow. Injected bone marrow was irradiated within partially
irradiated hosts to induce chromosomal abnormalities in donor cells, which could later be
tracked for clonal contribution in CFU-S.
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transplants were in S phase, while adult spleen and BM CFU-S showed little to no cells
in S phase (Becker 1965). This suggested that the CFU-S in adult BM was a quiescent
population. In 1966, it was found that chemotherapeutic compounds most effective
against cells undergoing division had less effect on the CFU-S ability of normal
hematopoietic cells from mouse BM, suggesting that CFU-S are primarily in a “resting”
or quiescent state (Bruce 1966). CFU-S were determined to be multipotent progenitors
via the production of mature erythroid, megakaryocyte, granulocyte, and macrophage cell
lineages in colonies (Wu 1967). Using the genetic labelling technique of Becker 1966,
CFU-S were thought to have lymphoid potential via formation of lymphoid cells in the
thymus of recipients of donor BM (Wu 1968a). This was the first demonstration of a
progenitor with lymphoid, myeloid, and erythroid potential, although BM HSCs were
likely the source of these donor lymphocytes.
While the CFU-S assay was critical for driving the search for the true HSC
forward, it was eventually discovered and confirmed that the CFU-S was not the true
HSC population. In 1979, the existence of a “pre-CFU-S” was hypothesized based on the
observation that upon injecting 5-fluorouracil (5-FU) treated BM cells, there was an
increase in the CFU-S potential of 5-FU recipient BM compared to untreated BM, and
CFU-S showed a delay in formation in 5-FU treated BM recipients (Hodgson 1979). In a
critical study, it was discovered that many of the CFU-S from 7-9 days post-transplant
are not found 9-12 days post-transplant (Magli 1982). It was also found that only the 9-12
day CFU-S contain “primitive progenitors,” while the 7-9 day CFU-S display an
erythroid bias in in vitro colony forming assays (Magli 1982). It was therefore concluded
that the notion that CFU-S are maturing and colonies are gaining more progenitors is
likely not due to the nature of the clones to self-renew, but rather the appearance of new
clones coming from some other source (Na 2002).
In the late 70s and early 80s, HSC transplantation was accelerating as a therapy
for maladies of the hematopoietic system. Therefore, it was understood that HSCs were
likely to exist and contribute to the regeneration of the hematopoietic system of transplant
recipients, but there was broad agreement in the field that several progenitors contributed
to regeneration. In turn, there was a shift in research aims from proving the existence of
an HSC to isolating the HSC, with the defining features of HSCs—influenced by the
incredible groundwork provided by McCulloch and Till and others—being single cells
that display multipotency and self-renewal capacity (Weissman 2008).
Development of assays for identifying properties of HSCs
The ability to test for hematopoietic multipotency and self-renewal capacity was
heavily supported by the development of protocols to assay these properties from
different cell types via in vitro culture. These assays also paved the way for
conceptualizing the presence of intermediate progenitors between the HSC and mature
blood lineages. The primary limitation was that these assays only allowed for detection of
myeloid output. In 1965, Pluznik plated spleen cells at limiting dilutions on agar with
embryonic “feeder” cells and found that there was a positive correlation with the number
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of cells plated and the number of mast cell colonies formed (Pluznik 1965). This helped
established an in vitro clonal assay for hematopoietic cells of the
granulocyte/macrophage (GM) lineages (CFU-C). This was later replicated for mouse
(Bradley 1966) and human (Senn 1967) BM. Later, CFU-S cells were plated in the same
assay and CFU-C were observed, suggesting that there was a close relationship between
the two types of CFU (Wu 1968b). To determine if the CFU-S and CFU-C assays
detected the same cell type, equilibrium density gradient centrifugation and velocity
sedimentation were used to separate mouse BM into various fractions, which were then
tested for CFU potential via the in vivo and in vitro CFU assays (Worton 1969). Some
cells displayed CFU potential in vivo but not in vitro (and vice versa), suggesting that at
least some of the cells responsible for CFU-S are not identical to the cells responsible for
CFU-C (Worton 1969). This was one of the first experimental demonstrations of different
“classes” of stem and progenitor cells and questioned the validity of the CFU-S method
to detect HSCs. However, there was still no conclusive evidence as to what the CFU-C
were. CFU-C assays provided the first evidence for a theoretical class of progenitor cells
that lay somewhere between an “HSC” (considered the CFU-S at the time of CFU-C
discovery) and differentiated granulocytes (Eaves 2015). Later assays that allowed for the
detection of other myeloid lineages reinforced this theory (Gregory 1973, Gregory 1976).
Assays for the lymphoid potential of progenitor cells were not possible until the work of
Dexter in 1977. Here, a co-culture system was developed in which hematopoietic cells
were plated with “feeder” cells consisting of BM cells isolated from the femurs of mice
(Dexter 1977). Culturing at 33°C and periodically replenishing the media and feeder cells
allowed for CFU-S and CFU-C potential of the hematopoietic cells to be maintained for
several months (Dexter 1977). This was used as a starting point for subsequent studies of
ex vivo B-potential and long-term repopulating potential. Indeed, a BM culture method
influenced by Dexter was devised in 1981 that allowed for differentiation and
maintenance of the B-cell lineage (Whitlock 1982). It was later discovered that clonal
lines from this culture method could differentiate adult BM towards the B cell lineage
and maintain progenitor cultures for 4 weeks (Whitlock 1987). This provided a way to
assay hematopoietic BM for B cell potential ex vivo, as well as a confirmation that this
culture method could maintain CFU-S for 3-4 weeks.
In an attempt to identify thymic precursors in the murine BM (established by Wu
1968a), Lepault utilized fluorescently labelled fluorescin isothiocyanate (FITC+) BM
cells and injected them into mice, followed by isolation of various tissues in recipients to
see where the FITC+ cells were found (Lepault 1981). Most of the cells homed to the BM
in levels proportional to the number of injected cells, and curiously, Thy1-antibody
treatment of BM didn’t seem to affect homing. This was initially an establishment of a
protocol to detect “lymphoid-specific” BM progenitor cells, but was later recognized as a
critical paper in identifying bona fide HSCs. It was also found that Thy1+ cells from
donor BM could be visualized in recipient thymus using Thy1 congenic mouse strains.
Many assays were also devised to test for self-renewal properties of HSCs, as well
as to assess the absolute number of HSCs in a given tissue. The ex vivo stromal co-culture
methods devised by Whitlock (Whitlock 1987) allowed researchers to assay
hematopoietic cells for “cobblestone formation” after adding limiting dilutions of BM
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cells to supportive stroma. These “cobblestones” consisted of a stromal cell base with a
clonal colony above and below, and had long-term (>4 weeks) myeloerythroid/B cell
potential (Whitlock 1987), and limiting dilutions could be used to calculate the number of
these multipotent cells in a given cell solution (Ploemacher, 1989). Self-renewal could, in
part, be defined by the ability of transplanted cells to repopulate an irradiated host “longterm” in the BM. In 1980, Harrison reported the “competitive repopulation assay” by
mixing murine BM from donors with distinguishable hemoglobin and then monitoring
the respective cells in the recipient peripheral blood (PB) (Harrison 1980). This allowed
for monitoring of the potential stem cell compartment for several years (Shen 1985, Shen
1986). Today, the standard technique for determining the absolute number of HSC in a
particular pool of cells in vivo is the competitive repopulating unit (CRU) assay, which
relies on injecting a limiting dilution of cells into an irradiated host to calculate the
absolute numbers of HSC based on reconstitution kinetics (Miller 2008).
Together, these in vitro and in vivo techniques and observations—which solidified
HSC characteristics and defined the CFU-S assay as primarily a marker of progenitor
cells—paved the way for isolation of HSCs via modern techniques such as fluorescenceactivated cell sorting (FACS).
HSC isolation and establishment of a hematopoietic hierarchy
The development of monoclonal antibodies to label specific hematopoietic
lineages followed by FACS was instrumental for the modern-day identification of HSCs.
Single cells or populations of cells could be sorted and tested for in vitro and in vivo
functional potential. For instance, Coffman developed the B-cell lineage antibody, RA32C2, which marked nearly 100% of sIg+ B cells and most plasma cells (Coffman 1981a).
RA3-2C2 did not label the CFU-S, but it did label an sIg- population in the mouse BM
that contained B cell precursors, based on the ability of these cells to give rise to sIg+
cells in vitro (Coffman 1981a). That same year, Coffman would also report development
of the B-cell antibody B220 (Coffman 1981b).
In 1986, the B220 antibody was used in conjunction with the Thy1 antibody—
which was thought of as a potential HSC marker at the time (Lepault 1981, Ezine
1984)—to isolate two early B lymphocyte precursor populations (Müller-Sieburg 1986).
B220- Thy1- populations contained B cell precursors that only showed short-term
potential in Whitlock-White cultures (Whitlock 1987) and produced pre-B and B cells
(Müller-Sieburg 1986). Incredibly, the addition of Thy1lo cells to Whitlock-White
cultures resulted in long-term culture and differentiation into several lineages (MüllerSieburg 1986). This led to the hypothesis that the long-term culture initiation Thy1lo cells,
being devoid of B-cell lineage markers, may also be negative for other lineage markers.
Indeed, they found that Thy1loLineage- cells were enriched for long-term culture
initiation, CFU-S potential, long-term repopulation potential, and could give rise to all
lineages in the spleen, BM, and thymus of irradiated hosts (Müller-Sieburg 1986). These
cells also showed self-renewal capacity via serial transplantation (Müller-Sieburg 1986).
Therefore, Thy1loLineage- cells were considered one of the first true HSC populations.
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In an attempt to further enrich the HSC, Spangrude et al. obtained several
monoclonal antibodies produced against Thy1+ BM hybridomas (Aihara 1986) and found
that an antibody recognizing the surface marker now designated as “stem cell antigen-1”
(Sca-1) separated the murine Thy1loLineage- population into two subsets: ~20-30% Sca1+ and ~70-80% Sca-1- (Spangrude 1988). The Sca-1+ population appeared to contain all
of the HSC capacity, and they only needed to inject 40 Thy1loLineage-Sca-1+ cells to
achieve multilineage reconstitution of irradiated murine hosts (Spangrude 1988). It was
subsequently shown via single-cell transplants that 1/13 Thy1loLineage-Sca-1+ cells
showed >1% multilineage reconstitution from 3-7 weeks post-transplantation, and a
smaller subset showed long-term reconstitution (>20 weeks) (Smith 1991). This showed
that only a subset of the newly defined HSC population were true HSC based on
multipotency and self-renewal (Smith 1991). It would also later be confirmed (Uchida
1994) that these cells contributed to both short-term and long-term engraftment in
irradiated mice. Shortly thereafter a monoclonal antibody for c-Kit—a receptor tyrosine
kinase important for hematopoiesis—was produced (Ikuta 1992). When added to the
Thy1loLineage-Sca-1+ cell surface repertoire of HSCs, c-Kit was found to contain all cells
with long-term multilineage reconstitution potential in the murine adult BM and fetal
liver (FL) (Ikuta 1992).
In 1994, Morrison first isolated a “subset” of HSCs, termed the “long-term HSC”
(LT-HSC) which, by in vivo reconstitution assays, was reported to be c-Kit+Mac-1-CD4(Morrison 1994). Other subpopulations [c-Kit-Mac-1loCD4- (short term-HSCs “STHSCs”) and c-Kit-Mac-1loCD4lo (multipotent progenitors “MPPs”)] were shown to be
enriched for transiently reconstituting cells post-transplantation, and the LT-HSC subset
was also shown to be in cell cycle less frequently (Morrison 1994). Through a series of
transplantation assays, Morrison was able to show that LT-HSCs give rise to ST-HSCs
and MPPs, while MPPs cannot self-renew in the BM of recipient mice (Morrison 1997).
This established one of the first hierarchies of hematopoietic stem and progenitor cells
(HSPCs), with LT-HSCs established at the top of the hierarchy, followed by ST-HSCs
and MPPs. Around the same time, other multipotent and oligopotent progenitors were
isolated and assayed for differentiation and self-renewal capacity. In 1997, a common
lymphoid progenitor (CLP) that could reconstitute lymphoid but not myeloid cells in vivo
at levels >1% for ~14 weeks was isolated based on expression of the Il-7 receptor and
reduced Sca-1 and c-Kit expression (Kondo 1997). Shortly thereafter, a hierarchy of
myeloid progenitors was identified through CFU-C and in vivo repopulating assays
(Akashi 2000), in which a common myeloid progenitor (CMP) gives rise to
granulocyte/macrophage progenitors (GMP) and megakaryocyte/erythroid progenitors
(MEP). These studies provided the basis for the classical model of hematopoiesis, in
which HSCs sit atop the hierarchy and give rise to progenitors that become progressively
more specified for production of mature hematopoietic lineage cells (Figure 1-2).
However, this classical model relied on immunophenotype to identify cell types and was
also primarily established on the functional abilities of bulk cell types. Further
enrichment of the HSC compartment provided clues that perhaps the contribution of the
HSPC compartment to the hematopoietic hierarchy is more complicated than previously
appreciated.
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Figure 1-2.

The classic model of hematopoiesis

The classic model of hematopoiesis established in the early 21st century, in which the
HSC sit atop the hierarchy and gives rise to progressively differentiated progeny. HSC,
Hematopoietic stem cells; MPP, Multipotent progenitor; CMP, Common myeloid
progenitor; CLP, Common lymphoid progenitor; MEP, Megakaryocyte/erythroid
progenitor; GMP, Granulocyte/macrophage progenitor
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A revised model of hematopoiesis
Several efforts were made—and are still ongoing—to enrich the LT-HSC
compartment for cells with the most potent self-renewal and differentiation properties,
primarily through the use of different cell surface markers followed by tests for potency
via BM transplant assay. The phosphoglycoprotein CD34 was recognized as a marker to
isolate murine HSCs, as CD34-Lineage-Sca-1+c-Kit+ (CD34lo/-LSK) BM cells contained
all of the long-term multilineage reconstituting potential in murine BM, and
transplantation of single cells showed that the CD34lo/-LSK population had a LT-HSC
frequency of ~20% (Osawa 1996). CD34 had previously been identified as a positive
marker on human HSPCs (Baum 1992). Morrison identified a family of cell surface
receptors (SLAM) that could be utilized to differentiate between highly purified HSCs
and MPPs lacking self-renewal ability (Kiel 2005). All long-term multilineage
repopulating cells within the LSK compartment were CD150+, CD244-, and CD48-, and
similarly to the CD34lo/- population (Osawa 1996), ~20% of LSKCD48-CD150+ (SLAM)
cells had long-term multilineage potential (Kiel 2005). CD48-CD150- cells were
considered “MPPs”, and the majority of LSKs were found to fall in the CD48+CD150compartment (Kiel 2005). While experimenting with the vital dye, Hoescht 33342,
Goodell identified a small population of cells that was apparent when visualizing dye
fluorescence simultaneously at the red and blue emission wavelengths (Goodell 1996).
This “side population” (SP) of cells showed low expression of lineage markers and high
expression of Sca-1, and showed a 1000-fold enrichment of long-term multilineage
reconstitution compared to whole BM. By subsetting the Hoescht SP based on
Rhodamine 123, which had been used previously to prospectively identify HSCs with
blue wavelength Hoescht dye, (Wolf 1993), others were able to further enrich the SP
HSC population to a level in which ~22% of mice injected with single SP cells showed
long-term multilineage engraftment (Uchida 2003). After performing microarray analysis
for differentially expressed genes in murine BM, it was found that endothelial protein c
receptor (Epcr) was upregulated in HSCs, and it was found that EPCR+ cells contain
functional LT-HSCs (Balazs 2006). Later, it was found through single cell transplants
that EPCR+SLAM cells (ESLAM) cells showed long-term multilineage repopulation in
~30% of irradiated recipients (Kent 2009). These studies provided the basis for how we
isolate murine HSCs to this day.
Even within the enriched HSC subpopulations, functional heterogeneity can be
observed. By culturing HSCs with a supportive stromal cell line to produce clonallyderived colonies and injecting clonal colonies into mice to visualize their self-renewal
and lineage reconstitution capacities, it was found that clonal HSCs have intrinsic
properties that are continued through serial transplantation, including reconstitution
dynamics and lineage bias (Müller-Sieburg 2002). Indeed, three subtypes of HSCs could
be identified: Lymphoid-biased (Ly-bi), Myeloid-biased (My-bi), and Balanced HSCs,
based on repopulation kinetics (Müller-Sieburg 2002). These HSCs produce long-term
multilineage repopulation but are skewed towards enhanced production of a particular
lineage. My-bi HSCs appeared to persist longer in serial transplantation assays in terms
of their white blood cell production, produced a reduced number of lymphoid precursors
in ex vivo stroma co-culture, and lymphoid progeny from My-bi HSCs (post-transplant)
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displayed reduced levels of IL7 receptor (IL7R) expression (Müller-Sieburg 2004).Using
the SP definition, Dykstra isolated HSCs and injected as single cells or as in vitro
generated clonal colonies into recipients followed by serial transplantation to identify the
longevity and lineage output of clones (Dykstra 2007). Interestingly, he identified
several subtypes of HSCs, including myeloid-biased αHSCs, balanced βHSCs, lymphoidbiased γHSCs, and short-term repopulating, lymphoid biased δHSCs (Dykstra 2007). It
was also later found that αHSCs appear to be underrepresented in fetal tissues at the
expense of lymphoid-biased HSCs (Benz 2012). von Willbrand factor (vWF+) HSCs
display a significant bias towards platelet/myeloid production after transplantation, and
appear to be upstream of vWF- HSCs during development, based on the lack of vWFHSCs in the E14.5 FL but presence of vWF- HSCs in the adult BM (Sanjuan-Pla 2013).
vWF is a glycoprotein involved in platelet aggregation. Several other studies have
identified lineage-biased HSCs in murine BM (Benveniste 2010, Morita 2010, Lu 2011,
Oguro 2013).
There also exists evidence for unipotent and/or bi-potent long-term repopulating
cells within different immunophenotypically defined HSC compartments. Yamamota et
al. established a theory of “myeloid-bypass” in the CD150+CD31-LSK murine BM
compartment via single-cell transplantation assays (Yamamota 2013). They identified
myeloid -restricted progenitors with long-term repopulating activity (>16 weeks, and in
some cases, could be secondarily transplanted) in their immunophenotypic HSC
compartment by visualizing all lineages with a fluorescent genetic marker (Yamamota
2013). This helped reshape the way people thought about how the hematopoietic
hierarchy is established. The SLAMCD34-CD41hi subpopulation of HSCs displayed
unipotent, transient reconstitution of irradiated recipients for the megakaryocytic lineage,
again suggesting that there is a subset of HSCs that bypass other differentiation programs
(Haas 2015). Interestingly, lineage fate did not seem to be affected by inflammatory
stress, but this population could be activated to replenish platelets under inflammatory
stress (Haas 2015). Using genetically labelled vWF+ HSCs in single cell transplantation
assays followed by monitoring the long-term reconstitution and lineage potential of the
cells for all lineages, it was found that vWF+ HSCs have long-term unipotent platelet and
bipotent platelet/erythrocyte potential (Carrelha 2018). The lineage relationships between
vWF+ HSCs and downstream progenitors in recipient bone marrow reflected the
reconstitution kinetics seen in the peripheral blood (PB) (Carrelha 2018). These studies
suggest that there are subsets of HSCs that maintain self-renewal potential while
simultaneously restricting their lineage potential.
The utilization of modern techniques such as single cell RNA-sequencing
(scRNA-Seq) to define the transcriptional landscape of the heterogeneous HSPC
compartment has provided evidence that lineage commitment may be a continuous
process. scRNA-Seq and unbiased clustering of several HSPC populations in the murine
BM identified HSCs as clustering in part with MEPs, as well as lymphoid-primed
multipotent progenitors (LMPPs) (Moignard 2013). In another study,
scRNA-Seq of several murine BM progenitor cells revealed semi-distinct transcriptional
signatures between HSCs and downstream progenitors but revealed that there seems to be
a gradual regulation of gene expression across HSPC commitment (Nestowara 2016).
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This supports a model in which the HSPC hierarchy resembles more of a “continuous”
commitment process verses a “stepwise” commitment process, and this continuous
process was also observed in human BM CD34+ cells via combined scRNA-Seq and
single cell ATAC-Seq data (Buenrostro 2018)
.
Compositional and functional heterogeneity has also been observed in the
progenitor compartments downstream of HSCs. After previously showing that the
receptor tyrosine kinase Flt3 labels one-half of the LSK compartment and that Flt3+ LSK
primarily display lymphoid commitment (Adolfsson 2001), Adolfsson et al. enriched for
LSKFlt3+ cells and showed that they possessed lymphoid and myeloid lineage production
capacity in vitro and in vivo (Adolfsson 2005). However, LSKFlt3+ cells do not have the
capacity to produce megakaryocyte/erythroid lineages. They termed this LSKFlt3+
population the “LMPP,” and suggested that it is downstream from ST-HSCs, gives rise to
all lymphoid cells, and either replaces CMPs or has the potential to give rise to GMPs
(Adolfsson 2005). This was one of the first challenges to the bi-directional model of
lineage production in the hematopoietic hierarchy. However, the concept of an LMPP
was challenged a year later, when Forsberg and colleague showed that transplanted
LMPP do give rise to platelets and erythroid cells using a fluorescent genetic marker
(Forsberg 2006). This same group would later claim that all hematopoietic cells during
steady state arise from a Flt3+ precursor, suggesting Flt3 expression is integral to blood
production (Boyer 2011).
Some groups have even further subdivided the MPP compartment downstream of
the HSC. The lab of Andreas Trumpp identified 4 subpopulations of MPPs based on cell
surface expression and varying functional assays: MPP1 (LSKCD34+CD48-CD150+Flt3), MPP2 (LSKCD34+CD48+CD150+Flt3-), MPP3 (LSKCD34+CD48+CD150-Flt3-), and
MPP4 (LSKCD34+CD48-CD150+Flt3+) (Wilson 2008). Via label-retaining studies during
homeostasis, they found that the HSC (LSKCD34-CD48-CD150+Flt3-) at the top of the
hierarchy was dormant, and they hypothesized that upon activation, CD34 expression
increases and differentiation down the pathway (MPP1-MPP4) begins (Wilson 2008).
The Morrison lab utilized CD229 and CD224 SLAM markers to subset the ST-HSC
compartment and found that CD229-CD224- (MPP1) cells appeared to sit at the top of the
MPP hierarchy, as upon transplantation they were able to give rise to MPP1,
CD229+CD244- (MPP2), and CD229+CD244+ (MPP3) (Oguro 2013). Meanwhile, MPP2
and MPP3 cells could not give rise to other MPP populations, but were able to transiently
reconstitute irradiated recipients and self-renew in the BM (Oguro 2013). In perhaps the
most accepted study of different MPP populations, Pietras et al. sorted 3 MPP
populations and tested in vitro and in vivo lineage potential, as well as lineage hierarchy
among the MPP populations and the dynamics of MPP production by LT-HSCs (Pietras
2015). They found that LSKCD48+CD150+Flt3- (MPP2) cells displayed a myeloid bias—
particularly towards the megakaryocyte/erythroid lineages—in CFU assays and after
transplantation (Pietras 2015). LSKCD48+CD150+Flt3- (MPP3) cells also displayed
myeloid bias but had lower meg/erythroid lineage potential, while MPP4 cells
(LSKCD48+CD150-Flt3+) were lymphoid-primed with minor myeloid potential (Pietras
2015). Importantly, they showed that HSCs could produce all MPP subtypes, but MPPs
could not produce other MPPs in transplantation assays (Pietras 2015). Also, in in vitro
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differentiation assays and presumably after transplantation, HSCs establish the myeloid
biased MPPs (MPP2/3) first, followed by establishment of MPP4s to reconstitute the
lymphoid lineage (Pietras 2015). The nomenclature used to describe the MPP subtypes
put forth by Pietras et al. is currently the most widely accepted.
Heterogeneity in the HSC and MPP compartments in the BM have led to a revised
model of the hematopoietic hierarchy, in which multiple HSPC subtypes contribute to a
variety of lineages, and even some HSCs can bypass differentiation into progenitor
subtypes to produce mature cells of the megakaryocytic lineage (Figure 1-3).
Summary
The discovery of HSCs took decades to uncover, and the process for their
discovery is the model by which many other stem cell biology fields follow to identify
stem cells. HSCs have come to be defined as a cell that has self-renewal and multilineage
potential, and the gold standard for assaying these properties has become HSCT.
Therefore, the standard HSC definition has also come to include the ability to home and
repopulate the BM of an irradiated recipient, although recent studies suggest that HSC
function during steady state and transplantation may widely vary. Immunophenotypic
HSCs are clearly a heterogeneous group of cells that may not all conform to the
properties derived from HSCT, and ongoing work even suggests that the transplantable
HSC may be a unique HSC subtype itself. Nevertheless, the utility of HSCT in the clinic
has drastically improved the lives of patients with hematological maladies. Finally, the
composition and trajectory of the hematopoietic hierarchy—especially at the level of the
HSPC compartment—is constantly being challenged by the identification of new cellular
subtypes and the boom of single cell analysis techniques. More research is needed to
elucidate the nuances of the hierarchical structure of hematopoietic cells.
Where Do Hematopoietic Cells Come From?
The observation of blood within the yolk sac (YS) of many species during early
embryonic development (termed “blood islands”) in the late 19th century suggested that
the hematopoietic system had an extraembryonic origin (Medvinsky 2011). It wasn’t until
1975 that this was seriously challenged, when Francoise Dieterlen-Lievre grafted whole
quail embryos to chick blastoderms and showed that quail hematopoietic organs were not
colonized by hematopoietic cells from the chick yolk-sac (Dieterlen-Lievre 1975). He
also showed that, when grafting quail spleen or thymus into the chick embryo coelom, the
hematopoietic organs of the quail were populated by chick blood cells (Dieterlen-Levre
1975). Dieterlen-Lievre performed these grafts at pre- and post-circulation timepoints and
found similar results and suggested that the YS blood islands only contain primitive
erythrocytes while the embryo proper contain “definitive” stem cells (Dieterlen-Lievre
1975). Since Dieterlen-Lievre’s work, hematopoietic establishment in the embryo has
been thought to occur in successive waves: two “primitive” waves and a “definitive”
wave. An establishment of the properties of a bona fide HSC (reviewed above) has
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Figure 1-3.

The revised hematopoietic hierarchy

The revised model of hematopoiesis established by enrichment and functional assessment
of different HSC and HSPC compartments. This model suggests the presence of lineagebiased and lineage-bypassing HSCs, as well as a more fluid production of the different
committed downstream progenitors. LT, Long-term; ST, Short-term; IT, Intermediateterm; HSC, Hematopoietic stem cells; MPP, Multipotent progenitor; CMP, Common
myeloid progenitor; CLP, Common lymphoid progenitor; MEP,
Megakaryocyte/erythroid progenitor; GMP, Granulocyte/macrophage progenitor.

15

allowed researchers to assay embryonic tissues for the origins and presence of the
“definitive HSC” (dHSC), marking the beginning of definitive, lifelong hematopoiesis. In
short, a dHSC is defined as a cell that has long-term multilineage reconstituted potential
in an irradiated recipient. Here, I will review the primitive and definitive waves of
hematopoiesis, with some speculation on whether the dHSC represents the true cell that
sustains lifelong hematopoiesis throughout the life of the organism.
The first primitive wave is established by the hemangioblast
In 1920, Sabin noticed that YS blood islands could first be seen in mice at
embryonic day 7.5 (E7.5) and appeared to be clusters of erythrocyte progenitors
surrounded by endothelial progenitors (Sabin 1920). This generated a hypothesis of the
“hemangioblast,” which is a bipotent progenitor of endothelial and blood cells. It is worth
noting that the term “blood island” in murine embryos has since been deemed a
misnomer by many in the field (Medvinsky 2011). Discrete islands were enticing to
researchers searching for the presence of hemangioblast “clones,” but the appearance of
multiple islands was due in part to the sectioning method of mouse embryos, as whole
mount sections showed that the blood “islands” were actually a single blood “band”
encircling the E7.5 embryo (Ferkowicz 2005). However, this did not negate the
possibility of the islands being formed from a bipotent progenitor.
In 1997, an avian monoclonal antibody targeting vascular endothelial growth
factor receptor-2 (VEGFR2)—a tyrosine kinase receptor required for endothelial and
hematopoietic production in mice—was developed to isolate VEGFR2+ mesodermal cells
that eventually colonize the YS from gastrulating chick embryos (Eichmann 1997).
These mesodermal cells could produce either hematopoietic or endothelial colonies in
vitro, but not both (Eichmann 1997). A similar conclusion—that hematopoietic and
endothelial cells had different developmental origins in the YS—was also proposed in the
mouse (Kinder 1999). The first experimental evidence of the hemangioblast came from
an in vitro embryonic stem cell culture system, in which individual blast cell colonies
from embryoid bodies were exposed to VEGF and produced endothelial and
hematopoietic precursors (Choi 1998). These “blast colony adherent cells,” expressed
endothelial markers, including CD31, and were considered the hemangioblast (Choi
1998). The existence of a hemangioblast was later also demonstrated using human ES
cell cultures (Kennedy 2007).
Drake et al. demonstrated that hematopoietic and endothelial cells of the E7-E7.5
mouse YS blood island show co-expression of some genes, particularly the transcription
factor Tal1, which is also expressed by embryonic-derived “angioblasts,” thought to be
the precursors to endothelial cells (Drake 2000). In 2004, Huber performed pivotal
experiments in which portions of the YS, posterior/distal primitive streak, anterior region,
and lateral domains of E7-7.5 mouse embryos were dissected to try to determine where
the hemangioblast was located in vivo (Huber 2004). They cultured these tissues in a
similar manner as Choi to see which tissue contained hemangioblasts. Incredibly, they
noted that the greatest hemangioblast potential came from Flk1+(Vegf)Brachyury+ cells in
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the primary primitive streak (Huber 2004). They also concluded that these cells arise
from mesodermal (Brachyury+) cells in the distal primitive streak and have endothelial,
hematopoietic, and vascular smooth muscle potential (Huber 2004). This suggested that
by the time the hemangioblasts have entered the YS from the embryo proper they have
essentially all segregated into either hematopoietic or endothelial potential, showing that
the hemangioblast is specified independently of the YS. Subsequent studies used genetic
lineage tracing to suggest that not all endothelial cells in YS blood islands come from
hemangioblasts, but rather a committed endothelial progenitor (Ueno 2006). However,
this was not performed in embryos de novo, but rather using ES cells placed in normal
blastocysts to form tetrachimeras (Ueno 2006). Together, these studies confirmed the
presence of a hemangioblast that could give rise to endothelial and hematopoietic cells,
and the current model for the generation of YS blood islands includes seeding of the YS
by embryo-derived hemangioblasts (Figure 1-4).
The first primitive wave: Blood cell types and their fate
Primitive red blood cells (RBCs) are perhaps the best studied cell type of
primitive hematopoiesis. Primitive erythrocytes differ from their adult counterparts
(which do arise in the fetus) via the hemoglobin chains they express. Primitive RBCs
express βH1 and ε chains, whereas adult RBCs mainly express β and α hemoglobins
(Craig 1964, Wong 1983). The primitive erythrocytes are nucleated and dominate the
circulating blood at E12, whereas adult erythrocytes are enucleated and are the
predominant RBC by E15. (Craig 1964, Wong 1983). In an elegant demonstration,
McGrath et al. stained for erythroblasts in the YS and embryo proper at early time points
and found that erythroblast presence occurs right around the time the embryonic heart
starts beating, ~E8.25 (McGrath 2003). In 2004 it was found that primitive βH1+
erythrocytes can be found circulating in the postnatal day 5 (P5) blood of mice and
enucleate around E12.5-E16.5, so they may not necessarily require an erythroblastic
island and central macrophage for enucleation (Kingsley 2004). It was later found that
primitive erythrocytes home to and preferentially reside in the FL around the time of
enucleation, and it is thought that they interact with erythroblastic islands surrounding FL
macrophages to induce enucleation (Isern 2008, McGrath 2008). Thus, primitive RBCs
are thought to originate from the YS blood islands, enter the embryo proper around the
time of circulation, continue to be present in neonatal tissues, and finish their maturation
process in the FL niche.
Megakaryocytes are also thought to arise during the first primitive wave of
hematopoiesis. Primitive, low ploidy megakaryocytic progenitors can be detected in
mouse YS from E7.5-E10.5, with little to no primitive megakaryocytic progenitors in the
embryo body or FL (Xu 2001). Meanwhile, megakaryocyte progenitors thought to arise
from the definitive hematopoietic wave have been reported in the YS at E10.5 and may
be the dominant progenitor type in the E13.5 FL (Xu 2001). Tober et al. found that E7.5
hemangioblasts contained megakaryocytic potential, and they used CFU assays coupled
with immunohistochemical analysis for megakaryocytes and primitive/definitive
erythrocytes to show that at E7.25, a primitive MEP arises in the YS, followed by what
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Figure 1-4.

The first primitive wave of hematopoiesis

The first primitive wave of hematopoiesis is thought to be mostly confined to
hemangioblast-derived yolk sac blood islands. These yolk sac blood islands produce
primitive erythroblasts, macrophage progenitors, megakaryocyte progenitors, and
putative lymphoid progentiors around E8-E9 in the mouse. Interestingly, the lymphoid
progenitors may also arise from the embryo proper at ~E9.
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they claimed to be a definitive MEP (also in the YS) that contributes to definitive
megakaryopoiesis and erythropoiesis (Tober 2007). Platelets were found to be circulating
in the embryonic vasculature at E10.5, and the site of megakaryocyte progenitors shifts
from the YS to the FL at E10.5 (Tober 2007). Primitive megakaryocytic progenitors
would later be termed “diploid platelet-forming cells” (DPFCs) due to their reduced
ploidy (Potts 2014). It was later shown that DPFCs actually appeared in the YS at E8.5,
followed by migration to the embryo body, placenta, and PB by E9.5 (Potts 2015).
Highly polyploid megakaryocytes did not emerge until E10.5 in the FL, so all platelet
production at earlier time points was due to primitive megakaryocyte progenitors (Potts
2015). In the most interesting revelation from this study, DPFCs and definitive
megakaryocytic progenitors displayed similar transcriptional programs, but DPFCs did
not require thrombopoietin (TPO) for platelet production while definitive megs did (Potts
2015). In an even more recent study, embryonic megakaryocytes appeared to be CD45while adult BM megakaryocytes are CD45+ (Cortegano 2019). Together these studies
suggest that megakaryocytes from the first primitive wave are TPO-independent, lowploidy, CD45- cells that can still produce a wave of platelets by E8.5, and definitive
megakaryopoiesis occurs in the FL after either a maturation of the primitive lineage or
production of a new wave of megakaryocytic progenitors from a different embryonic
tissue.
Two papers from Naito and Takahashi identified the first macrophages in the
mouse embryo. In 1989, Takahashi showed that primitive macrophages first arise in the
YS blood islands at E9, and appear to differentiate immediately into what were termed
“fetal macrophages,” at E10 (Takahashi 1989). The fetal macrophages don’t appear to
have phagocytic properties and are specified prior to primitive monocytes (which arise
after E10), suggesting that they bypass the typical myelopoietic pathway of macrophage
production seen in the adult BM (Takahashi 1989). The next year, Naito found fetal
macrophages—presumably derived from migratory primitive macrophages from the
YS—in the E10 FL (Naito 1990). However, they also found a “definitive” macrophage
population that appeared to be derived from monocytes, similar to the differentiation
pathway seen in the adult BM (Naito 1990). Therefore, they hypothesized that there were
two “waves” of macrophage production, which definitively have YS origins but may also
have FL origins (Naito 1990). Later, Bertrand et al. showed that the “primitive”
macrophages described by Naito and Takahashi were actually maternally derived via a
biallelic mating scheme (Bertrand 2005a). They also proved via genetic fluorescent
labelling of macrophages in vivo that a population of c-Kit+ macrophage progenitors in
the E7.5-8 YS are the first true “primitive” macrophage precursors, as they gave rise to
unipotent macrophage colonies in methycellulose assays (Bertrand 2005a). These cells
were found to be in the YS as late as E10 and were shown to mature through a monocytic
pathway like the “definitive” macrophages of Naito and Takahashi (Bertrand 2005a).
Finally, macrophages derived from the YS-derived primitive macrophage precursors at
E8 appeared to enter circulation and invade the embryo proper by E9, as determined by a
macrophage-specific fluorescent marker in transgenic mice (Ovchinnikov 2008). In sum,
the YS is the initial site of the first primitive wave of macrophages at E8, which appear to
follow a differentiation pathway that is similar to adult macrophages.
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There is also some evidence that a population of lymphoid progenitors arises
during the first primitive wave. E9 YS and para-aortic splanchnoleura (P-Sp, a tissue that
will eventually give rise to the dorsal aorta and urogenital ridges) from Ncx1-/- mice,
which lack a heartbeat, were transplanted into the peritoneal cavity of neonatal mice to
assay for the presence of B-cell progenitors (Yoshimoto 2011). Interestingly, both tissues
could produce functional B1 progenitors that primarily gave rise to B1a cells, and that
cells positive for the endothelial marker VE-Cadherin from these same tissues could
produce B1 progenitors in vitro (Yoshimoto 2011). The same lab would perform similar
experiments in 2012 and discover transient reconstitution of host (neonatal) thymus, and
that these progenitors could arise from embryonic VECadherin+ cells (Yoshimoto 2012).
Later, dHSC-deficient mice (McGrath 2015) were used to confirm these findings, as well
as showing that these dHSC-independent B1 progenitors populate the FL (Kobayashi
2014a).
The first primitive erythroid, megakaryocytic, and macrophage lineages are YSspecific, and are thought to derive from a tri-potent “hemangioblast” that originates in the
primitive streak of the embryo proper followed by migration to the YS (Figure 1-4).
These cells appear to have different properties from their adult counterparts, which may
be due to their relatively rapid expansion in the pre-circulation embryo in preparation for
oxygen transport or tissue maintenance. Meanwhile, the first primitive lymphoid
progenitors appear to have the ability to arise from endothelial cells of the YS and P-Sp
prior to dHSC formation (Figure 1-4).
The second primitive wave: Multipotent progenitors that are distinct from dHSCs
The second primitive wave of hematopoiesis is mainly characterized by the
production of erythromyeloid progenitors (EMPs) in the YS. In 2001, James Palis
identified high-proliferative potential colony forming cells (HPP-CFC) in the E8.25 precirculation YS, which produce large, multilineage colonies in methylcellulose culture
(Palis 2001). This confirmed that there is a first primitive wave of hematopoiesis, as
several unipotent progenitors can be found in the YS prior to E8.25 (Palis 2001). These
HPP-CFC appeared in the bloodstream of the embryo proper after circulation but were
still predominantly found in the YS until the FL became the main site of HPP-CFC
production at E11.5 (Palis 2001). When cultured in methylcellulose, HPP-CFC produced
erythroid/macrophage colonies, suggesting they had erythromyeloid potential (Palis
2011). These were considered the first multipotent progenitors found in the developing
mouse embryo and would later be called EMPs.
After the discovery of the EMP, attempts were made to draw similarities with the
population and the dHSC (reviewed below). It was previously found that deletion of the
transcription factor Runx1 (Okuda 1996) and its binding factor Cbfβ in mice resulted in
the depletion of cells that would be later considered EMPs (Okuda 1996) as well as
dHSCs, with only primitive erythropoiesis remaining. In 2004, Hadland et al. found that
mice lacking the Notch1 receptor, which is involved in cell fate decisions throughout
development, produced EMPs but did not produce dHSCs via CFU-assay (Hadland
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2004). This was thought of as a potential developmental checkpoint in the pathway to
achieving a dHSC in vivo but could certainly have also meant that EMPs and dHSCs
required different transcriptional mechanisms for their generation. EMPs would later be
isolated from E10.5 YS as CD45locKit+AA4.1+ cells, as this population contained nearly
all of the EMP potential via CFU assays (Bertrand 2005b). This was also considered the
immunophenotypic dHSC population at the time, since these cells could also form
lymphoid colonies in vitro (Bertrand 2005b). It would later be found that EMPs could be
enriched via cell-surface expression of CD16/32 (McGrath 2015), which is not expressed
on dHSCs (Bertrand 2005b). To determine if the cellular origins of EMPs and dHSCs
were similar, Chen et al. 2011 constructed a Runx1-/- mouse that could also express a
Runx1-GFP fusion protein from either Tie2+ (a marker for venous endothelium) or Sca-1+
(marks arterial endothelium) endothelium to see the effect of different hemogenic
endothelium sources on EMP and dHSC formation (Chen 2011). They found that EMPs
were rescued by Runx1 expression in Tie2+ endothelium while dHSCs were rescued by
Runx1 expression in Sca-1+ endothelium, suggesting that EMPs and dHSCs arise from
different hemogenic endothelial sources (Chen 2011). This was further confirmed via the
differential expression of hepatic leukemia factor (Hlf), which is required for dHSC
specification but not for EMP specification (Yokomizo 2019). Importantly, it was also
shown that dHSCs and YS are functionally distinct in vivo via transplantation of explant
cultures of YS and P-Sp (which is the precursor to the dHSC niche, reviewed below)
from pre-circulation embryos (Cumano 2001). YS showed only transient myeloid
reconstitution, while P-Sp showed long-term multilineage reconstitution of recipients
(Cumano 2001).
It was also determined that upon generation in the YS, EMP migrate to the FL and
constitute a heavy presence by E10.5 (McGrath 2015). It is also suggested that EMPs
begin differentiating in the FL, as granulopoietic cells were not seen circulating in the
embryo until E11.5, although this data is correlative (McGrath 2015).Therefore, the EMP
is the first known multipotent progenitor that arises in the murine embryo, and early
attempts to compare it to dHSCs showed that while it does share some properties of
developmental regulation (e.g. Runx1-expression) and even likely shares niche space with
dHSC in the FL, it is immunophenotypically and functionally distinct, and it almost
certainly arises from a different tissue source than the dHSC during development (Figure
1-5).
There is also speculation that lymphomyeloid precursors may exist in the YS as
early as E9.5. Boiers et al. immunophenotypically identified a cell with B, T, and
Myeloid (but no megakaryocyte/erythroid) potential via liquid culture in the E11.5 FL
that was Lin-Kit+Il7R+Flt3+ (Boiers 2013). They used a fluorescent marker to label the
cells in vivo and found them in the E9.5 YS but not in other tissues, and these YS
lymphomyeloid progenitors expressed transcripts associated with lymphoid and GM
priming, but not megakaryocyte/erythroid priming (Boiers 2013). To prove that these
cells originate in the YS, they performed explant culture of pre-circulation YS and P-Sp
from transgenic mice and saw that only the YS produced lymphomyeloid progenitors in
the explant culture (Boiers 2013). Further research needs to be conducted to verify the
presence of this YS-derived lymphomyeloid progenitor.
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Figure 1-5.

The second primitive wave of hematopoiesis

The second primitive wave of hematopoiesis is confined to the yolk sac (YS), and
primarily consists of the production of YS-derived erythromyeloid progenitors (EMPs)
which migrate to and expand in the ~E10.5 fetal liver (FL). There is also evidence of
lymphomyeloid precursors (lacking megakaryocytic/erythrocytic potential) arising from
the YS around the same time as EMPs.
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The development of the AGM
The onset of definitive hematopoiesis is thought to occur primarily in the aorta
gonad mesonephros (AGM), a region consisting of the dorsal aorta (DA)—the accepted
site of definitive hematopoiesis generation—and the urogenital ridges (UGR), of the
developing embryo. Using non-mammalian embryos such as zebrafish or Xenopus,
several groups were able to easily characterize AGM formation during embryogenesis.
After noticing that Flk-1 knockout (KO) in mice prevented vessel and blood
formation (Shalaby 1995), Fouqet et al. cloned the zebrafish Flk-1 homolog to perform in
situ RNA hybridization in zebrafish embryos to determine the dynamics of Flk-1+ cell
formation and fate (Fouquet 1997). They found that soon after gastrulation in the
zebrafish embryo, Flk-1+ cells arise in the posterior lateral mesoderm (PLM) and begin to
migrate medially within the embryo (Fouquet 1997). These Flk-1+ cells will go on to
form the DA below the notochord of the zebrafish embryo, as well as other vessels
(Fouquet 1997). It was later found that these PLM Flk-1+ cells also expressed the
hematopoietic TFs Scl and Gata2, as well Pax2, a pronephric duct marker (Gering 1998).
They also express Lmo2, which interacts with Scl and is critical to hematopoietic
development (Dooley 2005). Therefore, these PLM cells that will eventually give rise to
the DA appeared to be specified towards an endothelial and hematopoietic fate prior to
DA formation. Flk1+ cells were also found in Xenopus embryos in a similar area as in
zebrafish embryos prior to the formation of the DA (Cleaver 1998). Specifically, in situ
hybridization showed that these cells were found in dorsolateral strips of mesoderm
(termed the dorsolateral plate (DLP)) and appeared to migrate medially during
development to form the DA (Cleaver 1998). Interestingly, Cleaver et al. also found that
Vegf (the ligand for Flk1) was a chemoattractant for DLP cells towards the midline of
Xenopus embryos (Cleaver 1998). This was later confirmed (Ciau-Uitz 2010), as Vegf is
regulated by the Ets transcription factor Etv6. In the absence of Vegf or Etv6, Flk1+ DLP
cells lack Scl and Gata2 expression, and do not migrate medially to form the DA in
Xenopus embryos (Ciau-Uitz 2010).
Later, it was found that loss of Notch-signaling in zebrafish embryos via Notchsignaling mutants or injection of Notch inhibitors does not prevent the formation of the
DA in the AGM, but does seem to shift its transcriptional mechanisms, showing an
increase in venous with a decrease in arterial gene expression (Lawson 2001). This
suggested that Notch signaling is important for proper formation of the DA (Lawson
2001). This was later confirmed, as Burns et al. utilized transgenic zebrafish that
displayed no definitive hematopoiesis due to lack of expression of the transcription
factors Runx1 and c-Myb in the DA to show that Notch is required for the formation of
definitive hematopoiesis through rescue expreiments in which Notch was ectopically
expressed (Burns 2005).
By utilizing several Hedgehog (Hh) signaling pathway mutants and Hh inhibitors
in zebrafish embryos, Gering et al. found that Hh is required for both the migration of
Flk1+ cells to form the DA, as well as the prospective induction of endothelial programs
once the DA has been formed (Gering 2005). Again using zebrafish embryos, Rowlinson
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and colleagues found that the transcription factor Hey2 is expressed in the PLM prior to
DA generation, but requires Scl expression as well as Hh and Vegf signaling for its
expression (Rowlinson 2010). By using several Hey2 morpholinos to disrupt Hey2
mRNA, they found that Hey2 is not required for DA formation, but is required for Notch
expression in the DA (Rowlinson 2010). Therefore, Hey2 acts downstream of Flk1+ PLM
specification and migration, but upstream of the Notch programs necessary for definitive
hematopoiesis from the DA.
In summary, zebrafish and Xenopus embryos were critical in deciphering the
mechanisms behind the formation of the DA in the AGM region, which appears to
contain the programs necessary for definitive hematopoiesis. DA forms via the Hh and
Vegf-mediated medial migration of Flk1+ lateral mesoderm that expresses endothelial and
hematopoietic factors. Notch signaling then induces the necessary endothelial programs
required for proper DA contribution to definitive hematopoiesis.
The AGM is the sole source of dHSC formation
In 1994, Müller et al. performed a series of experiments that were critical for
defining the AGM as the sole site of dHSC formation. They isolated several tissues from
E10 and E11 mouse embryos to find that the AGM contained long-term multilineage
repopulating cells via primary and secondary transplantation assays (Müller 1994). They
injected one embryo equivalent (e.e.) AGM into each recipient and found that 3/96
recipients of E10 AGM and 11/19 recipients of E11 AGM showed long-term
multilineage engraftment (Müller 1994). Interestingly, no other tissues transplanted (YS,
FL, or PB) showed long-term multilineage engraftment at E10, and while their definition
of multilineage engraftment was not as stringent as later papers, this was the first
evidence that the dHSC was generated in the AGM around E10 (Müller 1994).
A few years later, Medvinsky developed a critical technique for ex vivo culture of
embryonic tissues, in which whole tissues are cultured on 0.65um filters for 2-3 days in
myeloid long-term culture media, dissociated with collagenase after culture, then injected
into irradiated recipients (Medvinsky 1996a). The rationale behind the assay was that
explant cultures would allow for an expansion of any dHSCs that were present in fresh
tissues. Using this explant culture and transplantation assays, Medvinsky found that the
AGM was the sole site of dHSC formation at this time point. Later, the explant culture
system was used to show that peak expansion of dHSC in the AGM seems to occur at
E12, and then dissipates by E13 (Kumaravelu 2002). In contrast, expansion of dHSC in
the FL seemed to increase at E13 (Kumaravelu 2002). Importantly, it was also
determined that the number of dHSC in the total embryonic body at E10 and E11 via
limiting dilution assays was < 3, suggesting a very small number of dHSCs arising from
the AGM at the initial dHSC generation timepoints (Kumaravelu 2002). This helped
establish the concept of the dHSC arising in the AGM followed by migration and
expansion in the FL. Of note, future studies also isolated placenta from early time points
in the mouse but could not find dHSC potential until E11 (Ottersbach 2005).
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Sub-dissection of the AGM region followed by transplantation of either fresh or
explant culture tissues determined that all of the dHSC activity at E11 was contained in
the DA and umbilical/vitelline arteries, while the UGR contained no dHSC until E12 (de
Bruijn 2000). This suggested that the arterial regions of the AGM were the sites of dHSC
generation, and further confirmed speculation that dHSC had endothelial origins.
Recently, our lab found that dHSC activity could be produced from long-term explant
cultures of the pre-circulation embryo body but was not found in pre-circulation YS
(Ganuza 2018). This potential in the pre-circulation body presumably comes from the PSp, as previous studies showed that short-term explant cultures of this region in precirculation embryos gave rise to multipotent but low-repopulating cells (Cumano 2001).
In sum, the AGM is thought to give rise to the first dHSCs, as no other embryonic
tissues show dHSC potential as early as ~E10. Also, this potential may already present in
the pre-circulating embryo, and dHSCs appear to first arise exclusively from an
intraembryonic origin.
How does the AGM generate dHSCs?
Via immunostaining, it was determined that the ventral wall of the DA contains
cell clusters in mice (Medvinsky 1996b) and humans (Tavian 1996), and it was
determined in chick embryos that these cells were CD45+, suggesting that they were
hematopoietic clusters (Jaffredo 1998). Crucially, Jaffredo et al. proposed that the
clusters were of endothelial origin via lineage tracing of embryonic endothelial cells,
showing that the clusters were derived from the endothelium (Jaffredo 1998).
Interestingly, the floor of the DA contained similar cells, and some cells were even found
in the underlying mesenchyme of the DA (Jaffredo 1998). This suggested that dHSCs in
the DA arise from an endothelial progenitor with hematopoietic potential, termed the
“hemogenic endothelium.”
The ventral wall of the DA in Xenopus and zebrafish display expression of several
markers of hematopoietic specification, including Scl, Gata-2, cMyb, and Ikaros, but two
critical regulators of cluster and dHSC formation in the AGM are Runx1 and Notch1. In
1999, North et al. used a Runx1-reporter mouse to identify Runx1+ cells in the developing
mouse embryo (North 1999). They showed that Runx1+ cells are present in the DA
clusters, some endothelial cells in the ventral wall of the DA, and in the underlying
mesenchyme. Most strikingly, Runx1-/- mice did not form clusters in the DA at E10.5,
suggesting that Runx1 is required for the generation of hematopoietic clusters from
hemogenic endothelium (North 1999). Later studies confirmed the need for Runx1 in
zebrafish aortic cluster formation (Kissa 2010), as well as hematopoietic generation from
ES-cell derived hemogenic endothelium (Lancrin 2009). It was later found that Notch1-/embryos contain no in vivo repopulating activity from E9.5 P-Sp, as well as impaired
formation of vasculature and hematopoietic cells in organ cultures (Kumano 2003). This
suggested that Notch1 was important for the generation of AGM-derived hematopoietic
cells (Kumano 2003). Indeed, chimeric mice created with Notch1-/- cells at the blastocyst
stage showed that Notch1 is dispensable for primitive hematopoiesis, but KO cells failed
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to contribute to definitive hematopoiesis in the FL or BM after E15.5, suggesting that
Notch1 is critical for definitive hematopoiesis (Hadland 2004). Finally, immunostaining
for Notch1 in E9.5 and E10.5 mouse embryos showed that Notch1 is expressed in the
ventral wall of the DA, and even in what appears to be some hematopoietic clusters
(Robert-Moreno 2005). KO mice deficient in the transcription factor bound to activated
Notch1—which is required for Notch1-specific transcriptional programs—were deficient
in Runx1, Scl, and Gata2+ hematopoietic clusters in the E9.5 DA (Robert-Moreno 2005).
This suggests that Notch1 is required for both definitive hematopoiesis and cluster
formation in the AGM.
Subsequent efforts were focused on solidifying the hemogenic origin of DA
clusters, as well as proving they contained dHSCs. In a groundbreaking study, North et
al. used a Runx1 reporter mouse to isolate Runx1+ cells from the AGM and
vitelline/umbilical arteries of embryos and found that at 10.5, only the Runx1+ cells
contained long-term multilineage repopulating cells, albeit at low levels of reconstitution
(North 2002). DA clusters were Runx1+ at E11.5, and the majority were CD45-, although
some cells were CD45+ (North 2002). Interestingly, at E10.5, all long-term repopulating
cells (dHSCs) from the AGM and vitelline/umbilical arteries were CD45-, whereas by
E11.5 CD45+ and CD45- Runx1+ cells contained dHSCs (North 2002). The authors then
decided to assess endothelial marker expression in the Runx1+ DA clusters, and found
that some, but not all, Runx1+ cells expressed endothelial markers at E10.5 and E11.5,
while a portion of cells express both endothelial and hematopoietic lineage markers or
neither (North 2002). They assumed that the Runx1+CD45-Endothelial- cells were
mesenchyme. Upon transplantation of several tissues with varying degrees of
hematopoietic and endothelial marker expression, they found that VE-Cadherin and
CD45 in combination with Runx1 were the best markers to delineate dHSCs in the E10.5E11.5 DA (North 2002). At E10.5, only Runx1+CD45-VE-Cadherin- cells appeared to
contain HSCs, and by E11.5, Runx1+CD45+/-VE-Cadherin+/- cells all contained dHSCs
(North 2002). They also found that adult markers of HSCs, namely Sca-1 and c-Kit, were
expressed on dHSCs in the AGM by E11.5, with all dHSCs expressing c-Kit (North
2002). Because of the apparent co-expression of hematopoietic and endothelial markers
in dHSCs of the mouse DA, this pivotal work strongly supported a Runx1-mediated
endothelial origin of dHSCs from the ventral wall of the DA.
The work by North et al. was reproduced by Taoudi et al., as they found that the
CD45+VE-Cadherin+ fraction of E11.5 AGMs contained the majority of myeloid
progenitor potential in methylcellulose assays, all of the hematopoietic progenitor
potential in long-term culture initiating cell assays, and displayed no in vitro endothelial
potential (Taoudi 2005). They also showed that the E11.5 AGM CD45+VE-Cadherin+
population contained all dHSCs, and that this functional population could still be found in
the E13.5 FL (Taoudi 2005) (which was later confirmed by Kim 2005). However, by
E12.5 in the AGM, dHSCs were present in the VE-Caderin- cell compartment, and VECadherin+ dHSCs were absent from the adult BM (Taoudi 2005). While it was possible to
confirm the existence of dHSCs around the time of their generation, dHSCs in the
CD45+VE-Cadherin+ cell compartment are still extremely rare as determined by limiting
dilution assays, with ~1dHSC/AGM at E11.5 (Taoudi 2005). This work was important
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for showing that dHSC in the E11.5 AGM express VE-Cadherin but are exclusively
hematopoietic cells that contain the dHSC.
Both the North and Taoudi studies strongly suggested an endothelial origin of
dHSCs in the mouse embryo and two subsequent studies attempted to validate this
hypothesis. In 2008, Zovein et al. used a tamoxifen inducible VE-Cadherin-CreERT2
mouse crossed to a β-gal reporter mouse and induced labelling of VE-Cadherin+ cells
during dHSC formation in the mouse embryo (Zovein 2008). They claimed that all
definitive hematopoiesis derives from VE-Cadherin+ endothelial cells by observing VECadherin+ progeny in all blood cell types (including HSCs) of the FL and adult BM. A
year later, Chen et al created a VE-Cadherin-Cre mouse and crossed it to Runx1fl/fl mice
to show that Runx1 expression in VE-Cadherin+ cells is required for dHSC formation
(Chen 2009). VE-Cadherin-Cre+Runx1floxed mice showed a reduction in c-Kit+ cells in the
E11.5 FL, reduced CFU potential in E11.5 FL and AGM, harbored no dHSC activity via
transplantation in the E11.5 AGM, and did not form DA clusters (Chen 2009). In
contrast, they also created a Vav1-Cre mouse (which is supposed to be restricted to
expression in the hematopoietic lineage) and showed that Runx1 expression is not
necessary in hematopoietic cells for dHSC formation, and attributed this to the
conclusion that all dHSCs arise from an endothelial origin (Chen 2009). Three labs
simultaneously confirmed that dHSCs specifically arise from the ventral wall of the
dorsal aorta using time-lapse (Bertrand 2010) and live imaging (Kissa 2010) in zebrafish
embryos, as well as live imaging in E10.5 mouse embryos (Boisset 2010), solidifying the
concept that dHSCs arise from a hemogenic precursor in the ventral wall of the DA
(Figure 1-6).
Interestingly, while the dHSCs in the CD45+VE-Cadherin+ compartment of the
E11.5 are extremely rare (Taoudi 2005), the number of c-Kit+ clustered cells in the DA
number ~700 around the same time (Yokomizo 2010). To address this issue, Solaimani
Kartalaei et al. showed that the majority of the c-Kit+ cells in the E11 AGM are contained
in a Sca-1- compartment, and likely represent hematopoietic progenitors, not dHSCs
(Solaimani Kartalaei 2015).
Together, these studies solidified the concept of dHSC generation from an
endothelial origin (Figure 1-6) while also rapidly expanding the techniques needed for
proper visualization of DA clusters. Over the next decade, several studies focused on the
use of single cell sequencing technologies to further understand the transition from the
DA ventral endothelium to dHSCs, and several “pro” and “pre” HSC subtypes were
characterized that represented semi-discrete stages of dHSC generation from hemogenic
endothelium (Rybtsov 2011, Gordon-Keylock 2013, Swiers 2013, Liakhovitskaia 2014,
Rybtsov 2014, Boisset 2015).
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Figure 1-6.

The definitive wave of hematopoiesis

The definitive wave of hematopoiesis and generation of definitive HSCs (dHSCs) occurs
at E10.5 in the mouse embryo, with dHSCs being specified from the hemogenic
endothelium of the ventral wall of the dorsal aorta (DA).
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Is the dHSC the foundational hematopoietic cell for steady state hematopoiesis?
While HSCT was instrumental in identifying and standardizing the definition of a
bona fide HSC, it has recently come into question for its ability to identify the true
progenitors and contributors to lifelong hematopoiesis during steady state. One of the
first challenges to HSCT being the gold-standard assay for HSC identification was
performed by the lab of Fernando Camargo (Sun 2014). Here, they developed a method
to track clonal contributions of hematopoietic stem and progenitor cells to in vivo blood
production in adult mice. These mice harbored a hyperactive Sleeping Beauty (HSB)
transposase, a doxycycline-dependent transcriptional activator (M2) of the HSB, and a
non-mutagenic transposon on three different alleles (Sun 2014). Doxycycline
administration facilitated the mobilization of the transposon to a random site in the
genome, as well as dsRed expression after the excision of the transposon. Therefore,
doxycycline removal results in random, stably tagged and fluorescently labelled clones
(Sun 2014). The contribution of these clones to blood production could then be assayed
by DNA-sequencing. Interestingly, the Camargo lab found that steady-state
hematopoiesis is maintained by thousands of clones that individually show minor
contribution to mature blood lineages, and these clones do not appear to be progenitors
downstream of HSCs (Sun 2014). This study seriously challenged the notion that a small
number of HSCs were the sole contributors to native hematopoiesis, which was inferred
based on transplantation assays. In the following years, several groups utilized in vivo
clonal tracking techniques to challenge Sun 2014 (Sawai 2016, Chapple 2018, Sawen
2018). Therefore, there is still debate about the contribution of classically defined HSCs
to native hematopoiesis.
Our laboratory recently used a multicolored reporter allele to lineage trace the
contribution of specific murine embryonic tissues to lifelong blood production (Ganuza
2017). We crossed Flk1-, VE-Cadherin-, and Vav1-Cre lines with the Cre-inducible
Confetti allele (Snippert 2010) to label cells of mesodermal (Flk1, ~E7.5), endothelial
(VE-Cadherin, ~E8.5-E10.5), or hematopoietic (Vav1, ~E10.5-adult) origin in the
embryo, and noted their contribution to adult hematopoiesis. (Ganuza 2017). Importantly,
we were able to use the sample-to-sample variance in the distribution of Confetti
fluorescent markers to quantify the number of initiating events, allowing us to estimate
the number of precursors that give rise to lifelong murine hematopoiesis (Ganuza 2017).
We found that the hematopoietic system is initiated by ~600 precursors, regardless of the
Cre employed, which far exceeds the ~1-2 dHSCs previously thought to arise in the
E10.5 AGM, and suggests that the assay employed to temporally determine the number
and/or presence of true HSCs in the mouse embryo may be biased for a subset of
transplantable HSCs (Ganuza 2017). Using a similar system, (Henniger 2017) the same
phenomenon was observed in zebrafish, finding that ~20-30 progenitors of lifelong
hematopoiesis form around the time of HSC emergence.
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Summary
Many decades of work uncovered the existence of several waves of embryonic
hematopoiesis: two “primitive” waves mostly characterized by blood production of
transient unipotent or multipotent progenitor cells in the YS, followed by a “definitive”
wave of dHSCs that eventually seed adult tissues and provide lifelong blood production
(Figure 1-7). Both waves appear to be generated from an endothelial cell with
hematopoietic potential that arises from specified mesoderm: the hemangioblast in
primitive hematopoiesis and the hemogenic endothelium in the dorsal aorta in definitive
hematopoiesis. It is critical to note that HSCs do not immediately home to their resting
place in the BM after specification in the AGM. HSCs journey throughout the
mammalian embryo and are exposed to a variety of niches before finally colonizing and
maintaining their presence in the adult BM.
The HSC Niche Across Development
The final destination of HSCs in mammals is the BM, where they are thought to
reside for the remainder of the life of an individual. However, as mentioned above, their
contribution to steady-state hematopoiesis is still under debate. Insights into the study of
developmental hematopoiesis discovered that, while HSCs are specified in the dorsal
aorta of the AGM region during development, they only stay in this niche for ~1-2 days
before migrating to other tissues. In the murine system, HSCs migrate from the AGM to
the FL around E12.5, where they are thought to undergo an expansion and then migrate
to the fetal spleen and BM shortly after (Medvinsky 2011). It is also thought that HSCs
migrate to the placenta shortly after generation in the AGM, although the AGM as a
migratory versus an origination niche is still debated. It was Schofield in 1978 who first
conceptualized the existence of an HSC niche (Schofield 1978). He noticed that cells
derived from CFU-S colonies could not reconstitute hematopoiesis indefinitely, while
BM-derived cells could. He therefore hypothesized that when HSCs left the BM niche
and resided in the spleen niche, they lost their “immortality” (Schofield 1978). Earlier, it
was also described that long-term culture of hematopoietic cells was only sustainable in
the presence of a layer of BM feeder cells (Dexter 1977). For decades, scientists have
tried to uncover the mechanisms of HSC niche control, in part to find the critical factors
needed for HSC generation and/or expansion in cell culture for clinical purposes (Crane
2017, Gao 2018). In the next section I will explore the developmental path HSCs embark
on after specification in the AGM, followed by a closer look at the most well
characterized HSC niche—the adult BM—and the most understudied HSC niche—the
fetal BM (FBM).
The placenta: A site for HSC generation?
The origins of resident HSCs in the placenta are mired in controversy. Using a
transgenic mouse in which only embryonic tissue was fluorescently labelled, the presence
of fetal-derived multipotent myeloid colony forming cells (CFU-GEMM) were found in
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Figure 1-7.

Developmental ontogeny of definitive hematopoiesis

HSCs are specified in the AGM and migrate to the fetal liver (FL) where they are thought
to undergo a ~30-fold expansion. AGM-derived HSCs are also thought to seed the
placenta shortly after generation. FL HSCs then seed the spleen and fetal BM during late
ontogeny. HSCs will remain in the BM for the remainder of the life of an individual.
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the placenta as early as E9 (Alvarez-Silva 2003). While only a few CFU-GEMM were
found at this time point (~4-5), the number increased to ~400 by E10.5—the same time
that HSCs are thought to be specified in the AGM (Alvarez-Silva 2003). Interestingly,
the authors also found the expression of key hematopoietic TFs such as Runx1, Scl, and
Tel/Etv6 in E9 placentas, suggesting that the placenta may be a site of HSC specification
(Alvarez-Silva 2003). It should be noted that while HSCs can produce CFU-GEMM, it is
not a bona fide test for HSCs. However, this discovery suggested that the placenta should
be considered a major hematopoietic organ in mammals.
Two subsequent studies in 2005 determined that HSCs were present very early in
the mouse placenta. Gekas et al. transplanted E10.5-E12.5 placenta and found that longterm reconstitution with donor contribution >1% first occurred from E11 tissue,
suggesting that bona fide HSCs are present at very early time points in the murine
placenta (Gekas 2005). Via limiting dilution transplantation assays, they discovered that
the numbers of HSC are very low at this time point, and peak to ~50 HSCs around E12.5,
with a considerable drop-off until E15.5 at which point almost no HSC are present
(Gekas 2005). The same year, Ottersbach et al. used a Ly-6A (Sca-1)-GFP transgene to
find that all placental HSCs at E12 were Sca-1+, which was shown previously for AGMderived HSCs (de Bruijn 2002) (Ottersbach 2005). They also found CD31/CD34+Sca-1+
cells as early as E10 in the placenta, suggesting that HSC generation may be occurring de
novo (Ottersbach 2005). It is important to note that while HSCs can be assayed in the E11
placenta, this is after both circulation and the proposed specification in the AGM, and no
other tissues dissected at E10.5 or co-cultured in tissue explants have been known to
generate HSCs (Medvinsky 2011).
The question of whether HSCs were specified de novo in the placenta led
researchers to search for the presence of hemogenic endothelium in placental tissues. It
was shown that placenta from E10-E11 Ncx1-/- mice, which lack a heartbeat, contain
CD41+CD31+ hematopoietic precursors in the stromal vasculature of the placenta—
although Ncx1-/- mice did show lower numbers of these precursors, suggesting that the
placenta may be colonized by HSCs as well as contain de novo generation potential
(Rhodes 2008). Also, pre-circulation placenta tissue can produce all lineages in vitro after
co-culturing with FBM stromal cells (OP9 and OP9-DL1) but cannot produce cells
capable of reconstituting irradiated hosts (Rhodes 2008). Recently, a putative population
of hemogenic endothelium (Prom1+Sca-1+CD34+CD45-, PS34 cells) was identified in the
E10.5 AGM and subsequently decreased in frequency over 1-2 days (Pereira 2016). This
population expressed hematopoietic and endothelial markers and displayed long-term
lymphoid potential in immunodeficient mice after OP9-DL1 co-culture (Pereira 2016).
Importantly, it was shown that PS34 cells were not maternal in origin via whole mount
immunofluorescence (Pereira 2016). Together, these data suggest that the placenta
appears to harbor hemogenic endothelial potential, but HSC generation is still unclear.
There is evidence that specific placental niche cells may regulate resident
placental HSCs. Sasaki et al. identified prospective hematopoietic clusters in E10.5
murine placenta that were CD31+CD34+c-Kit+ via immunofluorescence, then used lasercapture microdissection to dissect surrounding tissues (Sasaki 2010). They found that the
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surrounding tissue was mainly endothelial and expressed high levels of Scf, suggesting
that hematopoietic clusters of the AGM lie in an Scf-producing endothelial niche (Sasaki
2010). A similar model was confirmed in humans, as placenta-derived HSPCs displayed
expansion and prolonged function when co-cultured with human umbilical vein cells
(HUVECs), but not mesenchymal progenitors (Raynaud 2013).
Together, these studies show that HSCs exist and expand in the placenta early
after HSC generation, and that their presence may be influenced by an Scf-dependent
endothelial niche. Whether HSCs are generated de novo in the placenta remains unclear.
The fetal liver: A niche for HSC expansion
After several decades of research, the current model for HSC ontogeny after
generation in the AGM is that HSCs migrate to the FL and subsequently undergo a
dramatic expansion before seeding other tissues. In 1975, Johnson and colleagues
isolated E9.5 FL and E11.5 FL and placed the tissues under the kidney capsule of
irradiated adult hosts to see when the hematopoietic potential of the FL began (Johnson
1975). They observed no hematopoietic potential in E9.5 FL, but hematopoietic potential
was observed from E11.5 FL, and they suggested that the FL did not have de novo HSC
generating power on its own but was rather seeded by some other source (Johnson 1975).
Their conclusions corresponded with what would subsequently be known about AGMspecific HSC generation. These results were confirmed in 1981 using mouse liver and
avian embryos, but it was also shown that when “pre-migration” liver tissue was cultured
in vitro with HSCs, FL tissue hematopoiesis could be achieved (Houssaint 1981). This
helped solidify the hypothesis that FL hematopoiesis depends on the migration of HSCs
from an exogenous source.
In the intervening years, much work was done to identify the FL niche as an
expansion niche. Morrison compared the differences between FL and adult BM HSCs in
terms of their ability to reconstitute an irradiated host, absolute frequency in the sorted
HSC compartment, and cell cycle status (Morrison 1995). Through limiting dilution
transplant assays, he found that the immunophenotypic HSC was highly enriched in the
FL (~70%), and that ~30% of the HSCs were cycling from E12.5-E15.5 (Morrison 1995).
He also noted that, upon transplanting a similar dose of FL HSCs and adult BM HSCs,
the FL HSCs showed a much greater repopulating ability via peripheral blood
contribution than adult BM HSCs (Morrison 1995). Transplants competing FL and adult
BM cells showed that FL outcompetes adult BM by 5-fold in terms of repopulating
potential (Harrison 1997). This led the authors to conclude that the FL contained more
HSCs than adult BM, but, as seen earlier (Morrison 1995), transplanting equal numbers
of enriched HSCs still results in higher repopulating capacity of FL HSCs. Therefore, FL
HSCs likely represent a more potent repopulating HSC pool in primary transplantation.
In an elegant and important study, Ema et al. performed a series of competitive
repopulating limiting dilution transplantation assays with FL cells from E12-E18, and
found that there was a massive expansion of HSC as determined by primary
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transplantation from E12-E16, followed by a subsequent decreased in HSC frequency
from E16-E18 (Ema 2000). They determined that the number of FL HSC increased from
~50 to1500 from E12 to E16, respectively, a ~30-fold increase (Ema 2000). They
confirmed their results with a true limiting dilution assay, showing that there were ~40
and ~1500 HSC at E12 and E16, respectively. In a series of critical papers, Connie
Eaves’ group assayed the cycling potential of fetal HSCs compared to adult BM HSCs. In
2006, they showed that FL HSCs are primarily cycling, as upon injection of pregnant
mothers with 5-fluorouracil—which preferentially affects cycling cells—no HSCs could
be found at E14.5 or E18.5 from FL after transplantation (Bowie 2006). They also
showed via transplantation assays that almost all HSCs in the E14.5 FL were in the G1
phase, whereas nearly all HSCs in the adult BM were in G0 (Bowie 2006). To confirm
their results, they transplanted 10 HSCs into irradiated recipients from E14.5 FL and
adult BM, then collected BM and performed limiting dilution analysis in secondary
recipients to determine the cycling potential of HSCs in vivo (Bowie 2007). They
reported that E14.5 FL HSCs displayed significant expansion 1-2 weeks post-transplant,
but if the same number of E14.5 FL and adult HSC were isolated from primary recipients
6 weeks post-transplant and assessed for expansion capacity in secondary and tertiary
recipients, the E14.5 FL HSCs appeared to have the same proliferative capacity as adult
HSCs (Bowie 2007). This suggested that there are niche-specific factors that can control
the regenerative capacity of HSCs, and that the adult BM niche appears to have the
ability to induce a more quiescent phenotype.
To dissect the properties of the FL niche responsible for HSC maintenance,
Wineman et al. isolated and immortalized >200 cell lines from E14.5 murine FL stroma
and found a small subset of cell lines that, upon co-culturing with mouse BM, could
maintain HSCs for 3 weeks in culture (Wineman 1996). They later characterized a single
clone, AFT024, that could maintain mouse and human repopulation capacity from BM
and FL enriched for LSK cells after 4-7 weeks of culture (Moore 1997a, Moore 1997b,
Theimann 1998, Nolta 2002). It was also found that AFT024 secreted the Notch ligand,
Dlk1, and that overexpression of Dlk1 in stromal lines unsupportive of HSC maintenance
enhanced their ability to maintain HSCs (Moore 1997b). A similar relationship to Notch
signaling was observed in human FL stromal cell lines, which also were able to enhance
HSC maintenance in vitro (Martin 2005). Another population of murine E15.5 FL cells,
constituting less than 2% of FL cellularity, was shown to expand E15.5 LSKs by 2-fold
after culturing for 3 days (Zhang 2004). Interestingly, these cells expressed a range of
cytokines important for HSC maintenance, including Scf, Igf-2, Tpo, and Angptl2/3
(Zhang 2004). This population was further refined to be Scf+Dlk+ cells, and it was found
that they are the main fetal stromal population that expresses Cxcl12, which is a homing
factor for HSCs (Chou 2010). 2-3 weeks of co-culture of Scf+Dlk+ stroma with sorted
HSCs resulted in a ~20-fold increase in HSPCs and a slight increase in HSCs (Zhang
2004). More recently, the transcription factor and developmental regulator Aft4 was
found to be critical for HSC migration to the FL via the reduction of HSC present in
E12.5-E15.5 Atf4-/- mice (Zhao 2015). Importantly, they also isolated stromal and
endothelial cells from Atf4-/- E15.5 FLs, co-cultured with E15.5 FL HSCs, and showed a
reduction in repopulation capacity of HSCs co-cultured with KO cells verses WT cells
(Zhao 2015). Therefore, several in vitro co-culture assays have demonstrated that the FL
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is an HSC-supportive microenvironment, although more work is needed to identify the
critical factors needed for HSC expansion.
In 2016, Khan et al. provided an in vivo analysis of the FL HSC niche by utilizing
a Nestin-GFP transgenic mouse, which labels endothelial cells and rare, Nestin+ pericytes
in the E14.5 FL (Khan 2016). They found that these pericytes surrounded endothelial
cells on portal vessels of the FL via immunostaining, and they also discovered that
Nestin+ pericytes expressed Dlk1 and were likely mesenchymal stem cells due to their
ability to produce several stromal lineages in CFU assays (Khan 2016). Importantly, they
also showed through whole-mount immunostaining that FL HSCs were in close
proximity to Nestin+ pericytes, and that depletion of these cells in vivo reduced HSC
numbers (Khan 2016). Finally, they observed that the number of total niche cells in the
FL expanded in correlation with the number of HSCs from E12.5-E14.5, which led them
to hypothesize that it is an expansion of the niche and not a transcriptional change in the
niche itself that allows for expansion of HSCs (Khan 2016). This is one of the only
studies that critically assesses changes in the FL niche in vivo.
In summary, the FL is populated by HSCs around E12.5, appears to be a niche for
expansion of HSCs from E12.5-E16.5, and the contribution of its niche cells to HSC
expansion and maintenance still needs to be elucidated.
The spleen: A limited source of HSCs
The spleen appears to be a temporary site for HSCs during late ontogeny. By
performing CFU assays in methylcellulose and competitive transplants for spleen cells
across ontogeny, Wolber et al. saw little CFU-GEMM potential at E18, with an increase
from P2 to P14 (Wolber 2002). They also observed that at P2 and P4, HSCs were present
in the mouse spleen, and splenectomies on neonates showed that CFU and transplant
reconstitution potential were unaffected in other hematopoietic tissues like the BM and
liver (Wolber 2002). In a more rigorous study, Christensen et al. assayed spleen for the
presence of HSCs via a series of competitive transplants across late fetal development
(E14.5-E17.5), and found that HSCs can be found in the spleen as early as E14.5, but that
appreciable repopulation of irradiated recipients from 1 e.e. spleen does not happen until
~E16 (Christensen 2004). They were able to detect immunophenotype HSPCs (LSK
cells) in the spleen at E17.5, albeit at very low levels. Interestingly, they also showed that
transient progenitors could be found in the E14.5 spleen, as irradiated recipients
displayed B-cell—but not myeloid—reconstitution at 4 weeks post-transplant
(Christensen 2004).
When testing for differences between adult spleen and BM HSCs, it was found
that there were fewer spleen HSCs via immunophenotype and competitive
transplantation, yet transplanting the same number of immunophenotypic HSCs from
each tissue showed that HSC repopulating ability appeared to be similar between spleen
and BM HSCs (Morita 2011). Adult spleen HSCs can even be secondarily transplanted,
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and spleen HSCs are twice as likely to be cycling via an in vivo BrdU labelling assay
(Morita 2011). Therefore, splenic HSCs have the ability to home to the BM niche.
Ara et al. assessed the homing ability of HSCs in chemokine receptor Cxcl12-/mouse embryos and found that Cxcl12-/- E18.5 spleens had reduced numbers of all
mature hematopoietic cells except Ter119+ blood cells, lower numbers of repopulating
units as assayed by competitive transplants, and this reduced repopulating capacity could
be rescued by enforced expression of Cxcl12 in Tie2+ endothelial cells (Ara 2003). This
suggests that chemotaxis induced by Cxcl12 in response to the gradient of its ligand
Cxcr4 is required for proper migration of HSCs into the spleen, and that Tie2+ endothelial
cells may be responsible for production of Cxcl12 in the fetal spleen niche (Ara 2003).
To determine if fetal spleen could produce HSCs de novo, E13 murine spleens
were maintained in explant culture for 4 days to assess HSC development, with E13 FL
explant cultures as a control (Bertrand 2006). No HSCs could be generated from E13
spleens via competitive transplantation assay (Bertrand 2006). The authors also isolated
stromal cell lines from E14.5 spleen to test the ability of the spleen microenvironment to
maintain and/or expand HSCs, and plating FL HSCs on to the fetal spleen stroma resulted
in a marked expansion and maintenance of macrophages, but not HSPCs (Bertrand 2006).
Together, these studies help to define the spleen as a temporary destination of
fetal HSCs during late ontogeny in the mouse. Homing of HSCs to the fetal spleen
appears to be dependent on Cxcl12 production in the spleen, and the splenic niche during
gestation does not seem to be sufficient for HSC generation, maintenance, or expansion.
The complexity of the adult bone marrow niche
It was the work of Lambertson and Weiss in 1984 that helped determine the way
we conceptualize the adult BM niche. They showed via colony forming assays that the
distinct organization of the adult murine BM provided several “zones” for progenitor
cells, and that progenitors could behave differently depending on the zone they resided
in. By sub-fractioning the BM space, they determined that the greatest progenitor
potential was near the endosteal surface of the bone, as well as near the central marrow
(Lambertson 1984). They also proposed the existence of four niches: 1.) the endosteal
zone, encompassing 0-0.02mm of space from the bone surface, 2.) the subendosteal zone,
encompassing 0.02-0.08mm of space from the bone surface, 3.) the central zone,
encompassing the cylindrical space in the center of the marrow surrounding the central
sinus vein and extending throughout the length of the bone, with a radius of 0.1mm, and
4.) the intermediate zone, encompassing the space between the subendosteal and central
zones (Lamberston 1984). In the intervening years researchers have incorporated other
niches consisting of arteriolar, sinusoidal, and perivascular zones, with
arteriolar/sinusoidal niches located in the central/intermediate zone and perivascular
niches located throughout the BM space (Crane 2017). Therefore, the BM niche is an
incredibly heterogenous space, and many efforts have been focused on identifying the
niche cells and factors responsible for HSC and HSPC maintenance.
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The osteolineage. Osteoblasts were some of the first adult BM niche components
to be identified as critical for HSC regulation. In the mid-90s, Taichman and Emerson
first proposed the existence of an osteoblastic HSC niche (Taichman 1994, Taichman
1996). In 1994, they isolated osteoblasts from the endosteal region of human trabecular
bone and co-cultured with human CD34+ hematopoietic progenitor cells, finding that this
co-culture expanded numbers of CD34+ cells, but did not test for retention of function
(Taichman 1994). Interestingly, they showed that granulocyte-colony stimulating factor
(G-CSF) neutralization in these cultures diminished this expansion, suggesting that
osteoblasts may act on CD34+ cells via a G-CSF mechanism (Taichman 1994). Two
years later, they reported the use of functional assays on CD34+ cells to confirm that coculture with osteoblasts expands CD34+ cells for 2 weeks in vitro, and they observed an
increase in CFUs and LTC-ICs from CD34+ cells cultured on osteoblast monolayers
versus mixed BM stroma co-cultures.
By knocking-out the bone morphogenic receptor type IA (Bmpr1a), Zhang et al.
noticed an increase in the presence of spindle-shaped N-Cadherin+ CD45- osteoblasts
(SNOs) in the endosteum of mouse bones, particularly in the trabecular sections (Zhang
2003). They also noticed that, although Bmpr1a-/- mice had reduced BM cellularity, the
number of HSCs increased by two-fold, and they appeared to be in close proximity to
SNOs via immunostaining (Zhang 2003). Following these observations, Calvi et al.
activated osteoblasts therapeutically in transgenic mice and showed an increase in
trabecular bone formation, trabecular bone-associated osteoblasts, and an increase in the
number of LSK and HSC cells via LTC-IC and transplantation assays (Calvi 2003). They
also noted that therapeutically activated osteoblasts produced enhanced levels of the
Notch1 ligand Jagged1, and that inhibition of the Notch1 pathway in transgenic mice
resulted in an ablation of the observed HSC expansion (Calvi 2003).
In a more recent study, therapeutically ablated osteoblasts in a transgenic mouse
line resulted in a significant reduction in the capacity—but not the number—of BM
HSCs to repopulate primary recipients, with an almost complete loss of secondarytransplantable HSCs (Bowers 2015). By transplanting fluorescently labelled HSCs into
transgenic neonates with GFP-labelled osteolineage, others were able to identify distal
and proximal osteolineage cells and profile them by scRNA-Seq (Silberstein 2016). They
found that proximal osteolineage cells expressed higher levels of important HSC
maintenance factors like Cxcl12 and Angpt1, but also expressed high levels of two new
putative regulators: Angiogenin (Ang), a secreted RNase, and Embigin (Emb), an
adhesion molecule (Silberstein 2016). They subsequently identified both factors to be
critical for osteolineage regulation of HSC activity by knocking out the factors in
osteolineage cells. Interestingly, knocking out Ang in osteolineage cells enhanced HSC
cycling and decreased repopulation capacity, while mature Ang-/- osteoblasts only
displayed lymphoid progenitor defects, suggesting different cells in the osteolineage
interact with distinct HSPCs (Silberstein 2016). The same group later found that Ang
expression in osteolineage cells has specific roles for HSCs and myeloid progenitors,
facilitating quiescence of HSCs while simultaneously working to increase expansion of
myeloid progenitors (Goncalves 2016).
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Together, these studies identify osteoblasts and cells of the osteolineage, which
are exclusively found in the endosteal BM and are enriched in the trabecular bone, as
critical of murine and human HSPCs maintenance.
The BM vasculature. The endothelial network in the adult BM is critical for
proper maintenance of HSC function, primarily as a scaffold for other niche cell types.
For instance, Tie2+ BM endothelial cells express low levels of Cxcl12, and selective
deletion of Cxcl12 in Tie2+ cells results in a slight decrease in the repopulating capacity
of HSCs but has no appreciable effects on HSC numbers or cell cycle status (Greenbaum
2013). Therefore, Cxcl12-expressing endothelial cells are not a critical component of the
HSC niche. However, BM endothelial cells do express stem cell factor (Scf), and
selective deletion of Scf in Tie2+ endothelial cells from mouse BM results in a significant
decrease in the number of HSCs via competitive transplantation assays (Ding 2012).
Therefore, Scf-expression in Tie2+ endothelial cells appears to be a more important factor
for HSC maintenance. It was later discovered that arterial endothelial cells are the
primary Scf-secreting endothelial cells in the mouse BM (Xu 2018), as selective deletion
of Scf in arterial endothelial cells reduced HSC numbers and repopulation efficient while
depletion of Scf in sinusoidal endothelial cells had little effect on HSC maintenance (Xu
2018).
To determine the ability of BM endothelial cells to maintain HSPCs ex vivo,
Butler et al. co-cultured mouse BM derived endothelial cells with HSCs and observed an
expansion of the LSK compartment, along with a retention of CFU and long-term
repopulating function via transplantation after 28 days of culture (Butler 2010). They
then determined that secretion of Notch ligands by the endothelial cells in the co-culture
system were responsible for HSC maintenance, as using endothelial cells from
Notch1/Notch2 double KO mice abrogated this effect (Butler 2010). Interestingly, they
also found that HSCs in which the Notch signaling pathway was activated were in close
physical contact with sinusoidal endothelial cells in the mouse BM, suggesting that
sinusoidal endothelial cells are a niche for Notch1/2 activated HSCs (Butler 2010). This
was further confirmed by observing that selective deletion of the Notch1 ligand Jagged-1
in BM endothelial cells resulted in a 3-fold decrease in BM HSCs via limiting dilution
transplant assays (Butler 2010). Several other in vitro studies have confirmed that coculturing murine and human HSPCs with endothelial cells fosters varying levels of
expansion and maintenance (Butler 2012, Raynaud 2013, Sandler 2014, Gori 2017, Lis
2017). However, extrapolating these results to BM-derived endothelial cells requires
caution, as these co-culture systems were developed using induced pluripotent stem cells
(iPSCs) or HUVECs.
Together, these studies showed that BM endothelial cells can be a critical source
of Scf and Notch-ligands for the maintenance of HSCs, and sinusoidal and arterial
endothelial cells may constitute specific HSC niches. However, the effect of selective
depletion of secreted factors in BM endothelial cells does not seem to have a strong effect
on HSC maintenance, suggesting that they may be more important as a scaffold for other
cell types.
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The sympathetic nervous system: Non-myelinating Schwann cells. One of the
first studies to show that the sympathetic nervous system was important for HSPC
maintenance in the BM was performed by Katayama and colleagues. They noted that a
compound known to mobilize HSPC from BM was similar in structure to other
compounds naturally synthesized in mammalian cells by an enzyme found in
oligodendrocytes and Schwann cells (Katayama 2006). They observed that deletion of
this compound in mice caused a failure of HSPCs to respond to mobilization agents such
as G-CSF and was not due to reduced levels of the BM niche retention and homing
factor, Cxcl12 (Katayama 2006). Later, it was observed that circulating HSCs are most
prevalent in the bloodstream of mice 5 hours after exposure to light and are least
prevalent after 5 hours in darkness, suggesting a circadian rhythm to HSC retention and
mobilization (Mendez-Ferrer 2008). This was due to adrenergic signals sent to stromal
cells from nerves in the BM, which facilitated downregulation of Cxcl12 (Mendez-Ferrer
2008). Yamazaki et al. observed that Tgfbr2-/- HSCs in mice had reduced repopulating
capacity, as well as increased proliferation in the BM (Yamazaki 2011). They therefore
searched for Tgfβ-producing cells in the BM niche, and found that non-myelinating
Schwann cells, which form sheaths around nerves in the BM, are the primary source of
BM Tgfβ (Yamazaki 2011). They also noted that HSCs were in close proximity to
Schwann cells, and surgical denervation of the BM resulting in a decrease in
transplantable HSCs (Yamazaki 2011). Together these studies suggest a role for the
nervous system in BM HSC regulation, particularly in the Tgfβ-signaling axis, although
more studies are needed to elucidate the power of this niche.
Perivascular CAR cells. Perhaps some of the most interesting niche cells due to
their tight association with HSC maintenance, perivascular cells wrap themselves around
endothelial cells and are thought to exhibit properties of mesenchymal stem cells
(MSCs). While many perivascular cells have been identified as important HSC
regulators, they all express high levels of Cxcl12 and are colloquially referred to as
“Cxcl12-abundant reticular” (CAR) cells.
In 2010, Mendez-Ferrer et al. identified a rare population of Nestin+ (typically
expressed in nerve cells) MSCs that appeared to contain all of the CFU-Fibroblastic
potential in the mouse BM and were in close proximity to both adrenergic nerve fibers
and HSCs (Mendez-Ferrer 2010). Importantly, Nestin+ MSCs expressed high levels of
several HSC maintenance factors, including Scf, Cxcl12, and Angpt1, and depletion of
Nestin+ MSCs in vivo reduced the LTC-IC potential of HSCs. Transplanted HSCs also
appeared to home to Nestin+ MSCs post-transplantation (Mendez-Ferrer 2010). Together,
these results identified Nestin+ MSCs as a rare but important HSC niche component, and
in the following decade many groups tried to identify similar cell types as well as factors
expressed in these cells.
Morrison’s group depleted Scf from several niche cells and found that Scfdepletion from Nestin+ cells had no effect on the function and frequency of HSCs,
whereas Scf-depletion from a subset of perivascular cells that expressed the Leptin
receptor (Lepr+) reduced immunophenotypic and functional HSC numbers (Ding 2012).
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Interestingly, they observed a preponderance of Nestin+ cells around larger vessels in the
BM, with a few Nestin+ cells surrounding sinusoids. Scf+ cells were mostly concentrated
around sinusoids, suggesting Lepr+ cells are preferentially located around this vasculature
in the BM (Ding 2012). Another group selectively deleted Cxcl12 in several BM niche
cells and found that Cxcl12 expression in another subset of perivascular cells that
expressed Prx1, a transcription factor important for limb bud development, was required
for proper HSC maintenance (Greenbaum 2013). However, Cxcl12 expression appeared
to be dispensable in Nestin+ cells. Paul Frenette’s lab identified a sub-population of
Nestin+ cells that also expressed the pericyte marker NG2 (Kunisaki 2013). These NG2+
pericytes expressed higher levels of Nestin and were closely associated with small
arterioles, while other pericyte populations (Nestinlo and Lepr+) were associated with
sinusoidal vessels (Kunisaki 2013). Through whole-mount imaging of murine BM, they
showed that HSCs appeared to be in closer proximity to NG2+ cells compared to other
perivascular cell types, and in vivo BrdU tracing showed that the NG2+-associated HSCs
were highly quiescent (Kunisaki 2013). They also selectively depleted NG2+ cells and
showed that HSCs moved from the NG2+ arteriolar niche to the Lepr+ sinusoidal niche
and displayed increased cycling and reduced capacity for repopulating irradiated
recipients (Kunisaki 2013). Together, these results suggested that NG2+ pericytes and
arterioles in the subendosteal BM constitute the niche for quiescent HSCs, and this was
later supported by the finding that sinusoidal endothelium in the BM appears to facilitate
trafficking of HSPCs and other blood types compared to the arteriolar niche, which may
explain why quiescent HSCs are more closely associated with arterioles (Itkin 2016).
Finally, in an attempt to dissect the different roles of Nestin+ cells in the mouse BM, the
Frenette group selectively deleted Scf and Cxcl12 in NG2+ and Lepr+ cells to determine
the effects on HSC maintenance in the BM (Asada 2017). They found that Cxcl12
deletion in NG2+ cells but not Lepr+ cells cause a reduction in HSC numbers and a
relocalization of HSC cells away from arteriolar niches. In contrast, Scf deletion in Lepr+
cells but not arteriolar NG2+ cells caused a marked reduction in HSC numbers from the
BM (Asada 2017).
Together, these studies highlight the heterogenous but critical roles of several
perivascular CAR cell populations in maintaining HSC quiescence, BM retention, and
repopulating capacity.
Adipocytes. Little is known about the role of adipocyte-specific HSC regulation
within the adult BM niche. One study noted that different portions of murine vertebrae
were populated with varying levels of adipose tissue (Naveiras 2009). In particular, the
tail vertebrae showed enhanced numbers of adipocytes. Through transplantation assays it
was discovered that the fatty BM of the tail contained fewer but more quiescent HSCs,
and that HSPCs expand at a faster rate post-irradiation in “fatless” mice, suggesting that
adipocytes regulate HSC cycling in the BM niche (Naveiras 2009). However, a later
study showed that enhanced adipogenesis in the murine BM has no effect on HSC
maintenance (Spindler 2014). Therefore, the role of adipocytes as regulators of HSCs in
the BM niche is still unclear.
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Hematopoietic cells. While it is enticing to think of non-hematopoietic stroma as
the sole regulator of HSC activity in the BM, hematopoietic cells have been shown to
actively regulate BM HSCs.
Macrophages. Macrophages have been identified as critical BM-HSPC
regulators. Winkler et al. reported that that upon granulocyte-colony stimulating factor
(G-CSF) mobilization of HSCs, osteoblasts in the endosteal zone of mouse BM become
depleted, as well as a population of macrophages that reside in the endosteum
(osteomacs) (Winkler 2010). Upon depletion of osteomacs via transgenic mice or by
chemical induction, HSCs were highly mobile and osteoblast depletion occurred in the
endosteum, suggesting that osteomacs are a critical part of the endosteal HSC niche
(Winkler 2010). At the same time, it was discovered that depletion of CD169+ but not
CD169- macrophages in the mouse BM caused a concomitant reduction in Cxcl12, Scf,
and other HSC maintenance factors in Nestin+ BM cells, as well as enhanced
mobilization of HSCs in response to G-CSF (Chow 2010). This suggested that multiple
macrophage subtypes may affect different HSC niches. Selective depletion of BM
macrophages has been shown to result in an expansion of HSCs in the murine BM
(McCabe 2015). It has also been observed that experimental bacterial infections of mice
increase macrophages and decrease the HSC pool, and depletion of macrophages after
infection recovers HSC numbers, presumably through an IFN-γ-mediated pathway
(McCabe 2015). Finally, transgenic mice in which only cells of the monocytic lineage
express G-CSF receptor were treated with G-CSF and HSPC mobilization was still
induced, suggesting that cells of the monocytic lineage in the murine BM are sufficient
for HSPC mobilization (Christopher 2011).
Together, these studies identify BM-resident macrophages as an important
mediator of HSC retention, but more work needs to be performed to determine if they
affect other HSC properties
Megakaryocytes. As mentioned earlier, megakaryocytes and HSCs appear to be
related in terms of particular cell surface markers, transcriptional programs, and
differentiation pathways. Therefore, researchers have speculated mechanistic
relationships between megakaryocytes and HSCs within the adult BM niche. By using
3D whole-mount imaging, the Frenette lab found that HSCs are often in close proximity
to megakaryocytes, and that their spatial relationship to megakaryocytes does not come at
the expense of their relationship to arteriolar niches (Bruns 2014). Incredibly, selective
deletion of megakaryocytes in transgenic mice resulted in loss of HSC quiescence and an
expansion of functional HSCs (Bruns 2014). They suggested that the megakaryocytic
influence on HSCs is predominantly due to excretion of the chemokine, Cxcl4, as BM
megakaryocytes express Cxcl4 at high levels (Bruns 2014). Indeed, injection of Cxcl4
increased BM HSC quiescence, while Cxcl4-/- mice displayed higher numbers of
proliferating HSCs (Bruns 2014). Therefore, the Frenette lab has suggested a model in
which megakaryocytes help maintain HSCs in the arteriolar niche. This model was
supported by another study in 2014, which also suggested that BM HSC-associated
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megakaryocytes influence HSC quiescence via enhanced Tgfβ signaling (Zhao 2014).
Finally, another group in 2015 identified TPO production by megakaryocytes as another
regulator of HSC quiescence in the BM niche (Nakamura-Ishizu 2015). Together, these
studies highlight the role for megakaryocytes to potentially act on HSC quiescence in the
arteriolar BM niche, although more work is needed to solidify megakaryocytes as critical
HSC regulators.
Other hematopoietic cells. T-regulatory cells (T-regs) have been implicated in the
protection of HSCs from immune responses (Fujisaki 2011). Through in vivo imaging of
mouse BM, a population of endosteal T-regs that were closely situated next to HSPCs
after transplantation were identified (Fujisaki 2011). Interestingly, depletion of T-regs in
transgenic mice ablated the ability of HSCs to short-term engraft non-irradiated
recipients, suggesting that T-regs may protect HSCs from acute immune responses
(Fujisaki 2011).
Neutrophil clearance is the process by which specified neutrophils exit the BM to
perform tissue-specific functions, then return to the BM cavity for destruction (CasanovaAcebes 2013). Effects of neutrophil clearance on the HSPC BM niche have been
observed, as HSPCs appear to follow neutrophilic migration patterns: HSPCs are more
likely to exit the BM during neutrophil circulation and more likely to be retained during
neutrophil depletion via mobilization assays (Casanova-Acebas 2013).
Using a transgenic reporter mouse, Chen et al. identified a population of histidineproducing myeloid cells that were in close proximity to histidine-high, myeloid-biased
HSCs (Chen 2017). Together, these histidine producing cells were also in close proximity
to CAR cells (of undescribed type), and the authors showed that histidine production
from adjacent myeloid cells was critical for the maintenance of histidine-high myeloidbiased HSCs (Chen 2017).
The fetal bone marrow: An understudied but crucial niche in HSC ontogeny
The adult BM is an incredibly complex niche for HSCs and contains a myriad of
cells (Figure 1-8) that produce factors important for HSC retention, expansion, and
functional integrity, the majority of which still need to be explored and potentially
exploited for therapeutic purposes. Given the importance the adult BM as the final and
major source of lifelong hematopoiesis, it is curious that the fetal BM (FBM) is such an
understudied niche.
Some of the first assays testing for HSC and HSPC function in the FBM were by
Wolber et al. in 2002. They determined that no appreciable amount of CFU-GEMM or
HSC activity via transplantation could be observed in the BM until P2, with the number
of CFU-GEMM exponentially increasing from P2 to P50+ (Wolber 2002). One year
later, the Nagasawa group performed critical experiments to determine the mechanisms
necessary for HSC migration to the FBM. Utilizing Cxcl12-/- mice, they reported that

42

Figure 1-8.

The adult BM niche

The adult BM cosists of a myriad of cell types that provide structural and humoral niches
for HSCs. The endosteal niche is thought to be composed of osteoblasts, regulatory TCells (T-regs), and a subset of macrophages (Osteomacs). Quiescent HSCs are thought to
be primarily located in arteriolar or sinusoidal niches within the central BM, and closely
associate with CXCL12-abundant reticulocytes (CARs).
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Cxcl12 is required for HSC homing to the FBM at E18.5 (Ara 2003). Interestingly, they
also showed that HSC appear to be accumulating in the peripheral blood (PB) of Cxcl12-/embryos at E18.5, suggesting proper release from the FL occurred, but HSCs could not
enter the FBM space (Ara 2003). Importantly, enforced Cxcl12 expression in Tie2+ cells
of Cxcl12-/- mice recovered this homing defect, suggesting that Tie2+ endothelial cells are
important for homing of FL HSCs to the FBM niche (Ara 2003). However, these results
are still unclear due to the large increase in FBM HSCs from enforced Cxcl12 expression:
~2 HSCs in WT animals and >10 in rescue animals (Ara 2003). Nevertheless, this is one
of the first hypotheses regarding the importance of niche components in the FBM
influencing early HSC maintenance.
In another critical set of experiments, the Weismann group performed several
competitive transplants of early FBM tissue to determine that the first HSCs colonize the
FBM at E17.5, although they did note the presence of what appeared to be transient
lymphoid progenitors in the FBM as early as E15.5 via the production of B cells in
recipients at 4 weeks post-transplant (Chistensen 2004). It is important to note, however,
that the authors were transplanting low numbers of cells: only the FBM from the long
bones of the leg, and never more than 2 embryo equivalents. They also showed for the
first time that immunophenotypic HSCs from the E14.5 FL could migrate in response to
Cxcl12 and Scf via a transwell migration assay, suggesting that production of these
factors in the FBM niche may be important for migration from the FL to the FBM
(Christensen 2004).
Connie Eaves’ group identified an important developmental checkpoint that
occurs in the BM. By treating pregnant mothers with 5-FU and then assaying tissues for
number of HSCs via limiting dilution assay, they found that HSCs in the E18.5 FBM are
primarily cycling (Bowie 2006). Their analyses suggested the presence of ~10 cycling
HSCs in 106 FBM cells at E18.5. (Bowie 2006). Interestingly, they discovered that BM
HSCs switch from a cycling to a predominantly quiescent phenotype at 3 weeks postbirth, as all HSC appear to be in the G1 fraction of E18.5 FBM and 3 week-old BM while
nearly all HSCs are in the G0 fraction of 4 week-old BM (Bowie 2006). This was
confirmed in a subsequent publication (Bowie 2007), suggesting that FBM HSCs are
exclusively cycling, and do not become quiescent until ~4 weeks post-birth.
Karen Hirschi’s lab has performed the best characterization of the FBM to date
(Coşkun 2014) by dissecting the FBM niche in conjunction with the onset of HSC
activity. They injected dissected fetal femurs with Dextran-FITC and noted that
functional blood vessels were first formed in the diaphysis at E16.5, and they also noted
that bone calcification first began in the diaphyseal regions of femurs at E16.5 via
alizarin red staining (Coşkun 2014). Concomitant with vessel formation and calcification,
CFU-GEMM could be found in the femur diaphysis at E16.5, but not in proximal or
distal epiphysis until E17.5 (Coşkun 2014). FBM progenitors from E16.5-E18.5 showed
greater cycling via Pyronin Y staining, and E16.5 FBM showed the first—albeit
reduced—potential to repopulate irradiated recipients in a competitive transplant (Coşkun
2014). After noting that Col1a1+ osteoblasts were present throughout the bone at E17.5,
they hypothesized that osteolineage cells may be an important component of the FBM
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HSC niche. Therefore, they utilized Osterix-/- mice, which lack osteolineage cells, to test
for HSPC and HSC function in the FBM. They observed that Osterix-/- E17.5 FBM did
not contain transplantable HSCs, while Osterix-/- E17.5 FL appeared to be more highly
enriched in repopulating cells than WT E17.5 FL (Coskin 2014). Interestingly, Osterix-/FL HSCs did not display homing defects, while FBM HSCs did. They performed qRTPCR on E17.5 FBM and saw upregulation of genes associated with vasculature and
concluded that deletion of osteolineage cells from the FBM creates a more “endotheliallike” niche, which facilitates enhanced cycling and a decrease in homing (Coşkun 2014).
More recently, the Frenette lab hypothesized that the major remodeling of the FL
portal vessel around birth and subsequent reduction in Nestin+ pericytes—a proposed
niche for FL HSCs—results in the egress of HSCs from the FL at this time, which
correlates with the expansion of HSCs seen in the fetal/neonatal BM (Khan 2016).
However, they used this observation to primarily make conclusions about the postnatal
migration of FL HSCs to the BM, and since the FL portal vessel is still intact at early
timepoints associated with FBM HSC activity (Khan 2016), its egress is probably not
responsible for the seeding of HSCs seen in E16.5-E18.5 FBM.
Interestingly, the lab of Ralf Adams used confocal imaging of murine fetal femurs
across development to identify the first formation of vasculature in the BM cavity at
~E15-15.5 (Langen 2017). This is one day earlier than observed by the Hirschi lab. The
Adams lab also identified a new endothelial cell subtype in the fetal and early postnatal
bone via CD31 and Endomucin (Emcn) expression coined “type E” endothelium (Langen
2017). Type E endothelium is the most abundant endothelial cell subtype at E16.5, but is
virtually non-existent by P14, and appears to support Osterix+ cells in the FBM (Langen
2017).
While these studies offer clues to the dynamics of hematopoiesis in the fetal and
early neonatal BM, more work is needed to solidify the importance of this critical niche
during hematopoietic development.
The Present Study
HSCs and their downstream progenitors are a heterogeneous population of cells
that are indispensable for lifelong hematopoiesis and are often utilized in the clinic for the
treatment of hematologic maladies via HSCT. Over several decades, it has been
discovered that HSCs arise in the dorsal aorta of the developing embryo, migrate to the
FL, and undergo a large expansion before reaching their final resting place in the BM
(Figure 1-7). Many resources have been invested in understanding the roles of the
different niches HSCs encounter along their journey, as well as the adult BM niche. A
greater understanding of HSC niche regulation could provide clues for HSC maintenance
and expansion in vitro. A critical niche during HSC ontogeny that has been greatly
overlooked is the FBM. Current research asserts that the FBM is colonized by HSCs at
E16.5 in a Cxcl12/Cxcr4-dependent manner (Ara 2003, Coşkun 2014). HSCs in the FBM
appear to be predominantly cycling and continue to cycle until a shift toward quiescence
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at 4 weeks post-birth (Bowie 2006). It is still unknown which BM niche cells are
important for HSC maintenance, or how the BM niche develops around birth to become
the primary source of hematopoiesis in the adult. Furthermore, the immunophenotypic
and functional assessment of the array of HSPCs known to be present in adult BM has yet
to be performed in the FBM and early neonatal time points. For these reasons, we have
meticulously characterized the hematopoietic progenitor compartment of the whole
skeleton FBM from its colonization until after birth via competitive transplantation,
immunophenotypic analysis of the HSPC compartment, functional assessment of specific
progenitor populations, and single-cell RNA-sequencing of the hematopoietic and
stromal FBM environment. We hypothesize that a thorough understanding of the
hematopoietic potential and cellular composition of the FBM niche will be
instrumental in revealing novel factors for HSC maintenance, expanding the
available toolset for HSC-focused therapies.
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CHAPTER 2.

METHODS

Mice
C57BL/6J (CD45.2), B6.SJL (CD45.1), and UBC-GFP+/T mice were purchased
from The Jackson Laboratory and housed in a pathogen-free facility. Transplant recipient
mice (F1 progeny of CD45.2 x CD45.1 crosses) were generated at St. Jude Children’s
Research Hospital. For all timed pregnancies, 1-2 female CD45.2 mice were placed with
a single CD45.2 male overnight, followed by assessment for a vaginal plug before 10
a.m. the next morning. Positive females were separated, and embryos were designated
embryonic day 0.5 (E0.5). For all animal experiments, special care was taken to follow
the procedures approved by the St. Jude Children’s Research Hospital Institutional
Animal Care and Use Committee.
Isolation of Hematopoietic and Stromal Cells
To isolate hematopoietic cells in adult mice, tibias, femurs, pelvic bones, and
spines were removed and bone marrow (BM) was released by crushing in ice cold
phosphate buffered saline (PBS), followed by passage through 70μm filters. Cells were
then resuspended in red blood cell lysis buffer for 5-10 minutes, washed with PBS/2%
fetal calf serum (FCS), and resuspended in PBS/2% FCS. To isolate stromal cells in adult
mice, crushed bone fragments were cut into small chips, combined with a portion of the
released BM fraction, and placed in pre-warmed digestion media (PBS/2% FCS/0.4%
collagenase II/0.02% DNaseI) followed by gentle shaking (75RPM) at 37oC for 1 hour.
After digestion, cells were passed through a 70μm filter and lysed for 5-10 minutes,
washed with PBS/2% FCS, and resuspended in PBS/2% FCS.
Dissection of fetal tissues was performed under a dissection microscope in ice
cold PBS. Briefly, fetal livers (FL) were removed and placed in ice cold PBS, followed
by removal of all internal tissues and the skin. The fetal skeleton (except the bones of the
head) was carefully removed and cleaned of any remaining tissues, washed in PBS, and
placed in a dish of ice cold PBS for further processing. The isolation of hematopoietic
and stromal cells from the fetal BM (FBM) followed the same protocol used for adult
BM with the exclusion of the lysis step, as there was little trace of red blood cells. To
isolate hematopoietic cells from FL, livers were gently crushed on a 70μm filter with the
rubber end of a 1ml syringe while passing ice cold PBS over the tissue. Following this
isolation step, FL hematopoietic cells were lysed, washed with PBS/2% FCS, and
resuspended in PBS/2% FCS.
Bone Marrow Transplantation
For all experiments, recipient mice (CD45.2/CD45.1) were lethally irradiated with
two doses of 5.8 Gy on the same day as transplantation. Donor (CD45.2) and support
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(CD45.1) BM cells were isolated and counted using a hemacytometer, with trypan blue
used to assess viability. For whole BM (WBM) transplantation experiments, 1.5 x 106
donor WBM cells were combined with 2 x 105 support WBM cells and intravenously
injected into the tail vein of recipient mice. Recipients were maintained on antibiotics for
10 days following injection. For transplantation of different bone sources, cells were
isolated from separate bones from a single donor E15.5 embryo and the entire cell
suspension was injected into the tail vein of a lethally irradiated recipient. For limiting
cell transplants of UBC-GFP+/T multipotent progenitor 2 (MPP2) cells, 100 donor MPP2s
were sorted into 1.5ml tubes containing PBS/2% FCS, 2 x 105 sorted support WBM cells
were added, and the entire cell suspension was injected intravenously into the tail vein of
recipient mice. All sorts were performed on a BD Aria cell sorter. For secondary
transplantation, five aliquots of 5 x 106 WBM cells were isolated from a single primary
recipient and injected into the tail vein of five lethally irradiated secondary recipients.
Peripheral Blood Analysis
Transplant recipients were periodically assessed for donor cell contribution to the
peripheral blood (PB). PB was collected from the retro-orbital plexus in heparinized
capillary tubes, followed by lysis in red blood cell lysis buffer. Cells were then
resuspended in PBS/2% FCS and analyzed by flow cytometry for donor and lineage
contribution on a BD LSR Fortessa. For WBM primary and secondary transplants and
separate bone transplants, PB was stained with CD45.1-FITC, CD45.2-v500, [B220,
CD11b, Gr-1]-PerCP-Cy5.5, and [B220, CD4, CD8]-PE-Cy7. The myeloid lineage was
considered CD11b+Gr-1+, the B-cell lineage was considered B220+, and the T-cell
lineage was considered CD4+CD8+. For MPP2 limiting cell transplants, we also included
a separate analysis of non-lysed PB stained with CD41-PerCPe710 (platelets) and
Ter119-PECy7 (erythrocytes). A full list of antibodies can be found in Table 2-1. All
data were analyzed using FlowJo version 10.
Recipient BM Analysis
At a terminal (>20 weeks) timepoint after transplantation, recipients of WBM
were euthanized and hematopoietic cells were isolated from the BM. Cells were assessed
via flow cytometry on a BD LSR Fortessa for the presence of donor-derived common
myeloid progenitors (CMP, Lineage-c-Kit+Sca-1-CD34+CD32/16lo),
granulocyte/monocyte progenitors (GMP, Lineage-c-Kit+Sca-1-CD34+CD32/16hi),
megakaryocyte/erythroid progenitors (MEP, Lineage-c-Kit+Sca-1-CD34-CD32/16-),
common lymphoid progenitors (CLP, Lineage-c-KitmidSca-1midCD127+), long-term
hematopoietic stem cells (LT-HSC, Lineage-Sca-1+c-Kit+ (LSK)Flt3-CD48-CD150+),
short-term HSCs (ST-HSC, LSKFlt3-CD48-CD150-), MPP2s (LSKFlt3-CD48+CD150+),
MPP3s (LSKFlt3-CD48+CD150-), and MPP4s (LSKFlt3+CD48+CD150-). In all cases, the
Lineage- fraction showed low expression of CD4, CD8, B220, Gr-1, and Ter119.
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Table 2-1.

List of antibodies

Antibody
B220
B220
B220
CD11b
CD127
CD150
CD150-CITE-Seq
CD184 (CXCR4)
CD32/16
CD34
CD34
CD4
CD4
CD41
CD45
CD45.1
CD45.2
CD48
CD48-CITE-Seq
CD8
CD8
c-Kit
Flt3
Flt3-CITE-Seq
Gr-1
Gr-1
Sca-1
Sca-1-CITE-Seq
Ter119
Ter119

Fluorophore
BV605
PE-Cy7
PerCP-Cy5.5
PerCP-Cy5.5
PE-Cy7
PE-Cy7
NA
FITC
A700
A647
FITC
BV605
PE-Cy7
PerCPe710
PE
FITC
v500
A700
NA
BV605
PE-Cy7
APC780
APC
NA
BV605
PerCP-Cy5.5
PerCP-Cy5.5
NA
BV605
PE-Cy7
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Clone
RA3-6B2
RA3-6B2
RA3-6B2
M1/70
A7R34
TC15-12F12.2
TC15-12F12.2
L276F12
93
RAM34
RAM34
RM4-5
RM4-5
eBioMWReg30
30-F11
A20
104
HM48-1
HM48-1
53-6.7
53-6.7
2B8
A2510
A2510
RB6-8C5
RB6-8C5
E13-161.7
E13-161.7
TER119
TER119

A full list of antibodies can be found in Table 2-1. All data were analyzed using FlowJo
version 10.
Analysis of Hematopoietic Stem and Progenitors Across Bone Marrow Development
Liver and entire skeleton BM hematopoietic cells were isolated from E15.5postnatal day 0 (P0), P2, P4, P6, P8, P14, P21, and P28 CD45.2 mice and assessed via
flow cytometry on a BD LSR Fortessa for the presence of LT-HSCs, ST-HSCs, MPP2s,
MPP3s, and MPP4s. A full list of antibodies can be found in Table 2-1. All data were
analyzed using FlowJo version 10.
CXCR4 Cell-Surface Expression
Hematopoietic cells from E15.5-P0 livers were isolated and assessed via flow
cytometry on a BD LSR Fortessa for the presence of LT-HSCs, ST-HSCs, MPP2s,
MPP3s, and MPP4s, as well as cell-surface Cxcr4. A full list of antibodies can be found
in Table 2-1. All data were analyzed using FlowJo version 10.
CXCL12 Migration Assays
FL LT-HSCs, ST-HSCs, MPP2s, MPP3s, and MPP4s were sorted on a BD Aria
cell sorter and dispensed into the top portion of a 24-well transwell plate containing
StemSpanTM Serum-Free Expansion Medium (SFEM) with no supportive cytokines.
Meanwhile, the bottom portion of each transwell contained either 0ng/ml or 100 ng/ml
soluble CXCL12 in SFEM. After a 5 hour incubation, the bottom portion of the transwell
was collected and plated in 3ml M3434 Methocult to determine colony forming unit
(CFU) potential. At the same time, a known number of sorted cells which were not
placed in transwells were also plated into M3434 Methocult to determine the input CFU
frequency. After 10-12 days, CFUs were counted, and the migration potential of each
population was calculated using the following formula:
(# of migratory CFU)/[(Frequency of input CFU) * (# input cells used in transwell
assay)]
Single Cell CFU Assays
Single MPP2s from E16.5-P0 FL/FBM and adult BM were sorted on a BD Aria
cell sorter directly into 96-well plates containing 100ul of M3231 Methocult
supplemented with 25ng/ml SCF, 25ng/ml Flt3L, 25ng/ml IL-11, 10ng/ml IL-3, 10ng/ml
GM-CSF, 25ng/ml TPO, and 4U/ml EPO. After 10-12 days of culture, wells were scored
for the presence and phenotype of CFUs.
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Single Cell RNA Sequencing
E16.5, E18.5, P0, and adult BM hematopoietic progenitors (CD45+Lineage-cKit+) and stromal cells (CD45-Ter119-) were isolated as described above and sorted on a
BD Aria cell sorter. Prior to sorting, hematopoietic and stromal cells were stained with a
panel of CITE-Seq antibodies for downstream sequencing analyses. Post sort viability
was determined, and samples with less than 80% viability were removed before
generating sequencing libraries. mRNA expression libraries were constructed according
to the Chromium single cell 3’ reagent v3.1 protocol, while CITE-Seq expression
libraries were constructed according to the protocol described in Stoeckius et al.
(Stoeckius 2017). Both libraries were sequenced using Illumina technology.
Analysis of Single Cell Data
Following Illumina sequencing, the raw data was processed with the CellRanger
pipeline provided by 10x Genomics. Count matrices were imported into R version 4.0
and all analysis was performed using the Seurat R package version 3.1.5 (Butler 2018).
Clustering was performed according to the default instructions in the Seurat R package.
To aid in the annotation of clusters, we used the FindAllMarkers function in Seurat to
provide a list of gene expression comparisons among clusters, as well as the percentage
of cells in each cluster with significant levels of gene expression. We also utilized ROCtest based statistics to define the key genetic markers in each cluster. Finally, we
compared the gene expression patterns seen in our clusters to previously compiled single
cell RNA-Sequencing datasets of adult BM stroma and hematopoietic cells (CabezasWallscheid 2014, Dahlin 2015, Kowalczyk 2015, Paul 2015, Wilson 2015, de Graf 2016,
Dwyer 2016, Nestowara 2016, Cai 2017, Chhiba 2017, Velten 2017, Dahlin 2018, Giladi
2018, Rodriguez-Fraticelli 2018, Tusi 2018, Zheng 2018, Baccin 2019, Baryawno 2019,
Mende 2019, Pellin 2019, Severe 2019, Tikhonova 2019, Wolock 2019). All UMAP and
expression plots were generated using packages in R Version 4.0.
.
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CHAPTER 3.

RESULTS

Long-Term Repopulating Cells Can Be Found in E15.5 FBM
HSCs are thought to be generated in the ventral wall of the dorsal aorta in the
E10-E10.5 murine embryo, followed by migration to the FL where they undergo an
expansion from E12-E15 (Medvinsky 2011). The BM is the final destination for
mammalian HSCs, and their presence has been found as early as E16.5 in murine FBM
(Coşkun 2014). Earlier groups identified E17.5 as the earliest time point for HSC arrival
in the FBM, and E18.5 is a time point at which clear HSC activity can be seen (Ara 2003,
Christensen 2004, Bowie 2006, Bowie 2007). However, attempts to identify the earliest
FBM HSCs primarily utilized long bones (femur, tibia, hip) or did not state the source of
BM collected (Ara 2003, Christensen 2004, Bowie 2006, Bowie 2007, Coşkun 2014).
This allows for the possibility of HSCs colonizing the marrow space of other bones at
similar or earlier time points. Indeed, there are conflicting reports of the first embryonic
time point for vascularization within the BM cavity, with Coşkun et al. providing
evidence for E16.5 vascularization (Coşkun 2014) and Langen et al. providing evidence
for even earlier (E15-E15.5) (Langen 2017).
To thoroughly characterize the full HSC potential of the murine FBM, we isolated
and competitively transplanted the BM from the entire skeleton of E15.5, E16.5, E17.5,
E18.5, and P0 embryos and neonates (Figure 3-1). The embryonic skulls proved too
technically challenging to properly isolate without excessive inclusion of other tissues
and were excluded. We injected 1.5 x 106 CD45.2+ donor BM cells with 2 x 105
supportive BM cells per lethally irradiated recipient from each time point, as E15.5 and
E16.5 embryos contain ~1.5 x 106 total BM cells (Figure 3-1). Therefore, recipients of
E15.5 and E16.5 FBM received ~1 embryo equivalent (e.e.) of BM. We also injected
adult BM into lethally irradiated recipients as a positive control, and all recipients were
followed for at least 20 weeks for reconstitution of the hematopoietic system from donor
cells in the peripheral blood (PB) (Figure 3-1). Donor chimerism >1% was considered
true repopulation (Figure 3-1).
As expected, 1.5 x 106 adult BM cells were sufficient for long-term repopulation
in irradiated recipients, as 9/9 recipients displayed ~80% PB chimerism at 20 weeks posttransplant (Figure 3-2A). Inspection of lineage output (myeloid, B-lymphoid, Tlymphoid) from donor cells in the PB of each recipient of adult BM at 20 weeks posttransplant revealed a balanced distribution of lineages, suggesting that there were no
enrichments for lineage-biased HSCs (Figure 3-2B). Recipients of P0 BM displayed
similar levels of PB chimerism to adult BM recipients (Figure 3-3A) and all but one
myeloid-biased recipient (14/15) had normal PB lineage distributions at 20 weeks posttransplant (Figure 3-3B). Therefore, P0 BM appears to contain a sufficient number of
HSCs for long-term, balanced reconstitution of a lethally irradiated host.
Transplantation of 1.5 x 106 E18.5 FBM cells resulted in long-term reconstitution
of 14/14 recipients, although the levels of reconstitution in most recipients were lower
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Figure 3-1.

Primary transplant of FBM

1.5 x 106 CD45.2+ “donor” BM cells from E15.5-P0 and adult were transplanted into
lethally irradiate CD45.1+/CD45.2+ recipients, along with 2 x 105 CD45.1+ “support”
cells. Recipient peripheral blood (PB) was analyzed for donor contribution over a period
of 20 weeks.

Figure 3-2.

Primary transplantation of adult BM

A. Contribution of CD45.2+ donor adult BM to the PB of transplanted recipients over 20
weeks (n = 9). B. T-lymphoid, B-lymphoid, and myeloid lineage output within the
CD45.2+ compartment of PB in recipients at 20 weeks post-transplant (n = 9).
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Figure 3-3.

Primary transplantation of P0 BM

A. Contribution of CD45.2+ donor P0 BM to the PB of transplanted recipients over 20
weeks (n = 15). B. T-lymphoid, B-lymphoid, and myeloid lineage output within the
CD45.2+ compartment of PB in recipients at 20 weeks post-transplant (n = 15).
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than from adult or P0 BM (Figure 3-4A). While all recipients displayed tri-lineage donor
reconstitution at 20 weeks post-transplant, some recipients showed slight expansion of
the myeloid or B-lineages, suggesting the engraftment or expansion of lineage-biased
HSCs in these recipients (Figure 3-4B). Meanwhile, transplantation of E17.5 FBM
resulted in even greater donor PB stochasticity in irradiated recipients, and while 19/19
recipients displayed donor repopulation >1% at 20 weeks post-transplant, two recipients
were only reconstituted at 1.1% and 1.3% (Figure 3-5A). Likewise, there was greater
variability in the lineage reconstitution from donor cells in recipients, and several mice
showed enhancement of either myeloid or B-cell lineages (Figure 3-5B).As expected,
transplantation of 1.5 x 106 E16.5 FBM cells resulted in a marked reduction in
repopulating potential as only 8/14 recipients displayed long-term repopulation >1%,
which was quite variable among repopulated recipients (Figure 3-6A). These recipients
also displayed variable donor lineage output, with 2/8 long-term reconstituted mice
showing 95% and 96.6% B-lineage output from donor cells (Figure 3-6B).
Finally, we were able to detect long-term reconstitution in 8/18 recipients of 1.5 x
10 E15.5 FBM cells (Figure 3-7A). This is the first recorded demonstration of long-term
repopulating cells within the E15.5 FBM via transplantation. Interestingly, many of the
recipients with long-term reconstitution displayed donor chimerism < 10% at 4 weeks
post-transplant, followed by a steady increase in donor contribution until 20 weeks
(Figure 3-7A). This suggests a lack of functional hematopoietic progenitor cells in the
E15.5 FBM compared to later BM time points, as progenitors have transient repopulation
capacity and may preferentially contribute to early blood production post-transplant
(Pietras 2015) (Figure 3-7A). Similar to E16.5 transplants, donor E15.5 long-term
repopulating cells showed high variation in lineage production, as one recipient showed
only B-lineage production at 20 weeks post-transplant (Figure 3-7B).
6

Together, these data show that the first long-term repopulating cells in the murine
FBM are present at E15.5—one day earlier than previously reported (Coşkun 2014)
(Figure 3-7). Given that we were transplanting 1 e.e. into each recipient and only 50% of
recipients displayed long-term repopulating potential (Figure 3-8), these long-term
repopulating cells are still exceedingly rare. Interestingly, there were long-term
repopulating cells that displayed uni- or bipotential lineage reconstitution from E15.5E17.5, suggesting the presence of highly lineage-biased or even “lineage-bypassing”
HSCs (Yamamota 2013) at these time points (Figure 3-8). However, the presence of
lineage biases at P0 and E18.5 coupled with the increasing stochasticity in donor PB
chimerism from P0 to E15.5 suggests that these lineage-biased/bypassing HSCs are
present at all timepoints, but their functional readout is amplified at earlier timepoints due
to a reduction in total HSC numbers. Given that E18.5 is the first timepoint at which
100% of transplanted recipients show long-term tri-lineage repopulation, we conclude
that E18.5 marks the initiation point of a BM space containing robust repopulation
potential (Figure 3-8).
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Figure 3-4.

Primary transplantation of E18.5 FBM

A. Contribution of CD45.2+ donor E18.5 FBM to the PB of transplanted recipients over
20 weeks (n = 14). B. T-lymphoid, B-lymphoid, and myeloid lineage output within the
CD45.2+ compartment of PB in recipients at 20 weeks post-transplant (n = 14).

Figure 3-5.

Primary transplantation of E17.5 FBM

A. Contribution of CD45.2+ donor E17.5 FBM to the PB of transplanted recipients over
20 weeks (n = 19). B. T-lymphoid, B-lymphoid, and myeloid lineage output within the
CD45.2+ compartment of PB in recipients at 20 weeks post-transplant (n = 19).
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Figure 3-6.

Primary transplantation of E16.5 FBM

A. Contribution of CD45.2+ donor E16.5 FBM to the PB of transplanted recipients over
20 weeks (n = 14). B. T-lymphoid, B-lymphoid, and myeloid lineage output within the
CD45.2+ compartment of PB in recipients at 20 weeks post-transplant (n = 8).

Figure 3-7.

Primary transplantation of E15.5 FBM

A. Contribution of CD45.2+ donor E15.5 FBM to the PB of transplanted recipients over
20 weeks (n = 18). B. T-lymphoid, B-lymphoid, and myeloid lineage output within the
CD45.2+ compartment of PB in recipients at 20 weeks post-transplant (n = 8).
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Figure 3-8.

Primary transplant summary

Histogram summarizing the percentages of recipients receiving 1.5 x 106 BM cells from
E15.5-P0 and adult donors that displayed long-term reconstitution (20 weeks) from donor
cells, including the number of lineages detected at the terminal (20 weeks post-transplant)
bleed.
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Bona Fide HSCs Are Present in the E15.5 FBM
While we confirmed the presence of long-term repopulating cells in the E15.5
FBM, the gold standard for identification of bona fide HSCs is their ability to selfrenewal through secondary transplantation (Eaves 2015). Interestingly, the only attempt
to secondarily transplant any FBM-derived hematopoietic tissue that we are aware of was
only after a few weeks, and the recipients were only followed for ~4 weeks posttransplant (Bowie 2007). Therefore, while the presence of self-renewing bona fide HSCs
in the FBM and early neonatal BM is presumed, we decided to secondarily transplant BM
from E15.5, E16.5, E17.5, E18.5, P0, and adult primary recipients to confirm the
presence of bona fide HSCs in these tissues. To do this, we isolated several aliquots of 5
x 106 cells from single primary recipients and injected into lethally irradiated secondary
recipients, followed by analysis of PB chimerism and lineage output (Figure 3-9). We
also analyzed the contribution of donor cells to the BM HSPC compartments of primary
recipients (Figure 3-9).
As expected, adult BM donor cells contributed robustly to all primary recipient
BM HSPC compartments at levels similar to PB donor chimerism (~80%) (Figure
3-10A), and secondary recipients displayed robust donor contribution to the PB (Figure
3-10B). In line with the lineage output of primary recipients, secondary recipients of
adult BM displayed balanced lineage output in three independent transplants (Figure
3-10C). Similarly, P0 BM donor cells displayed robust contribution to all HSPC
compartments in primary recipient BM (Figure 3-11A), and secondary recipients of P0
BM showed long-term reconstitution in three independent transplants (Figure 3-11B).
The lineage output in secondary recipients of P0 BM was also balanced (Figure 3-11C).
Together, these data show for the first time the presence of a substantial pool of bona fide
HSCs in the P0 BM.
Analysis of the donor contribution to the HSPC compartments in primary
recipients of E18.5 BM revealed that some recipients displayed reduced chimerism in the
primitive HSPC compartments (LT-HSC, ST-HSC, MPPs) compared to the downstream
committed HSPC compartment [CMP, GMP, MEP, common lymphoid progenitor
(CLP)] (Figure 3-12A). This is a curious result, as one would expect that the donor
contribution to downstream compartments would reflect the chimerism of upstream
progenitors, and suggests that perhaps the progeny of E18.5 LT-HSCs, ST-HSCs, and
MPPs have a competitive advantage over supportive cells within primary recipients.
Nevertheless, secondary recipients of E18.5 FBM displayed long-term repopulation from
donor cells in three independent transplants (Figure 3-12B), with one transplant
displaying slightly higher levels of donor B-cell contribution than the other two (Figure
3-12C). These results provide the first evidence via long-term analysis of secondarily
transplanted recipients of bona fide HSCs in the E18.5 FBM.
Similar to E17.5 PB donor chimerism, the E17.5 HSPC compartment donor
chimerism of primary recipients displayed high stochasticity, suggesting the
transplantation of fewer numbers of HSCs (Figure 3-13A). Interestingly, the trend of low
chimerism in LT-HSCs compared to more committed progenitors found in recipients of
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Figure 3-9.

Secondary transplant of FBM

Schematic for secondary transplantation of fetal bone marrow (FBM) cells and BM
HSPC compartment analysis of primary recipients. Five aliquots of 5 x 106 primary
recipient BM cells were isolated from a single primary recipient and transplanted into
five lethally irradiate CD45.1+/CD45.2+ recipients. Simultaneously, the BM HSPC
compartments of each primary recipient was analyze for donor cell contribution.
Secondary recipient peripheral blood (PB) was analyzed for donor contribution over a
period of 20 weeks.
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Figure 3-10. Secondary transplantation of adult BM
A. The CD45.2+ adult BM donor contribution to different HSPC compartments in
primary recipients (n = 9). B. PB donor chimerism over 20 weeks in secondary recipients
transplanted with aliquots of 5 x 106 BM cells from the indicated color-coded primary
recipients in A. Data represent mean and s.d. from 5 transplanted mice. C. T-lymphoid,
B-lymphoid, and myeloid lineage donor cell output in secondary recipients at 20 weeks
post-transplant. Data represent mean and s.d. from 5 transplanted mice.

Figure 3-11. Secondary transplantation of P0 BM
A. The CD45.2+ P0 BM donor contribution to different HSPC compartments in primary
recipients (n = 9). B. PB donor chimerism over 20 weeks in secondary recipients
transplanted with aliquots of 5 x 106 BM cells from the indicated color-coded primary
recipients in A. Data represent mean and s.d. from 5 transplanted mice. C. T-lymphoid,
B-lymphoid, and myeloid lineage donor cell output in secondary recipients at 20 weeks
post-transplant. Data represent mean and s.d. from 5 transplanted mice.
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Figure 3-12. Secondary transplantation of E18.5 FBM
A. The CD45.2+ E18.5 FBM donor contribution to different HSPC compartments in
primary recipients (n = 9). B. PB donor chimerism over 20 weeks in secondary recipients
transplanted with aliquots of 5 x 106 BM cells from the indicated color-coded primary
recipients in A. Data represent mean and s.d. from 5 transplanted mice. C. T-lymphoid,
B-lymphoid, and myeloid lineage donor cell output in secondary recipients at 20 weeks
post-transplant. Data represent mean and s.d. from 5 transplanted mice.

Figure 3-13. Secondary transplantation of E17.5 FBM
A. The CD45.2+ E17.5 FBM donor contribution to different HSPC compartments in
primary recipients (n = 9). B. PB donor chimerism over 20 weeks in secondary recipients
transplanted with aliquots of 5 x 106 BM cells from the indicated color-coded primary
recipients in A. Data represent mean and s.d. from 5 transplanted mice. C. T-lymphoid,
B-lymphoid, and myeloid lineage donor cell output in secondary recipients at 20 weeks
post-transplant. Data represent mean and s.d. from 5 transplanted mice.

62

E18.5 FBM was seen in recipients of E17.5 FBM, although this difference was not as
pronounced (Figure 3-13A). Secondary recipients displayed long-term PB repopulation
from E17.5 donor cells (Figure 3-13B), and all transplants showed tri-lineage output
from donor cells at 20 weeks post-transplantation, although one transplant did show
higher donor B-lymphoid lineage output (Figure 3-13C). This is the first confirmed
existence of bona fide HSCs in E17.5 FBM, although it appears that there are fewer
HSCs at this timepoint compared to later timepoints.
Considering the reduced long-term repopulating potential in primary recipients of
E16.5 FBM as confirmed by this study and others (Coşkun 2014), it was critical to
determine if the E16.5 FBM was a source of bona fide HSCs. Upon examination of the
donor contribution to primary recipient HSPC BM populations, we found that most mice
showed low levels of chimerism in all compartments, but there was a trend for greater
donor chimerism in downstream progenitors (Figure 3-14A). Interestingly, upon
secondary transplant of E18.5 FBM, one of the secondary transplants contained only
1.26% donor contribution at 20 weeks (Figure 3-14B). However, upon inspection of the
primary transplant BM HSPC compartment donor contribution, the recipients of this
secondary transplant were injected with BM that contained a LT-HSC compartment
composed of only 1.57% donor cells (Figure 3-14A). Indeed, other secondary recipients
showed PB chimerism levels similar to the LT-HSC donor compartment of primary
recipients (Figure 3-14A-B). While all secondary transplants displayed tri-lineage output
from donor cells, two transplants showed reduced myeloid output at the expense of
lymphoid output, and in the case of one transplant this was similar to the lineage
distribution in the primary recipient (Figure 3-14C). These data provide the first
evidence of bona fide HSCs in the E16.5 FBM, although as the primary transplant data
suggests (Figure 3-6), transplantable HSCs are rare at this timepoint.
We next examined the HSPC BM donor contribution in recipients transplanted
with E15.5 FBM. As expected, the majority of recipients showed little to no
reconstitution in the progenitor compartments (Figure 3-15A). However, in the recipients
that did show reconstitution there was again a trend for more committed progenitors to
show higher levels of donor chimerism than LT-HSCs (Figure 3-15A). Three
independent secondary transplantations confirmed that E15.5 FBM donor cells could
contribute to long-term repopulation, suggesting the presence of bona fide HSCs in the
BM as early as E15.5 (Figure 3-15B). Interestingly, one secondary transplant showed
81% donor B-lymphoid lineage output and <1% myeloid lineage output (Figure 3-15C).
The secondary recipients constituting this transplant were injected with BM from a
primary recipient that also displayed a B-lymphoid biased lineage output, suggesting the
presence of bona fide lineage-biased HSCs in the E15.5 FBM. Therefore, the
heterogeneity associated with the HSC pool in the adult BM appears to be present as
early as E15.5.
These secondary transplants provide the first confirmation of the existence of rare,
bona fide HSCs in the BM as early as E15.5. Analysis of the BM HSPC compartments of
primary recipients suggest that the progeny of HSCs from all FBM timepoints (E15.5E18.5) may have a competitive advantage post-transplantation, as their donor chimerism
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Figure 3-14. Secondary transplantation of E16.5 FBM
A. The CD45.2+ E16.5 FBM donor contribution to different HSPC compartments in
primary recipients (n = 9). B. PB donor chimerism over 20 weeks in secondary recipients
transplanted with aliquots of 5 x 106 BM cells from the indicated color-coded primary
recipients in A. Data represent mean and s.d. from 5 transplanted mice. C. T-lymphoid,
B-lymphoid, and myeloid lineage donor cell output in secondary recipients at 20 weeks
post-transplant. Data represent mean and s.d. from 5 transplanted mice.

Figure 3-15. Secondary transplantation of E15.5 FBM
A. The CD45.2+ E15.5 FBM donor contribution to different HSPC compartments in
primary recipients (n = 9). B. PB donor chimerism over 20 weeks in secondary recipients
transplanted with aliquots of 5 x 106 BM cells from the indicated color-coded primary
recipients in A. Data represent mean and s.d. from 5 transplanted mice. C. T-lymphoid,
B-lymphoid, and myeloid lineage donor cell output in secondary recipients at 20 weeks
post-transplant. Data represent mean and s.d. from 5 transplanted mice.
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exceeds the chimerism from upstream compartments (Figures 3-12, 3-13, 3-14, and
3-15). This trend is not seen in primary recipients of P0 BM (Figure 3-11), suggesting
the presence of a shift in the functional characteristics of progenitors around birth.
Finally, heterogeneity in the BM HSC pool can be detected as early as E15.5 (Figure 315C), suggesting that HSCs either acquire this heterogeneity upon entry into the FBM or
prior to FBM colonization.
HSCs Can Be Found in All Sources of FBM at E15.5
While we have demonstrated the presence of bona fide HSCs in the E15.5 FBM,
others have only detected long-term repopulating cells in the FBM as early as E16.5
(Coşkun 2014). However, we assayed the entire skeleton except the skull while other
groups only assayed long bones (Coşkun 2014). This suggests that HSCs may be present
in other sources of FBM before the establishment of HSCs in the long bones at E16.5. To
test for the presence of HSCs in multiple bone sources at E15.5, we isolated BM from
three bone sources: 1.) the forelimbs, including the scapula, humerus, radius, and ulna, 2.)
the hindlimbs, including the pelvis, femur, tibia, and fibula, and 3.) the trunk, including
the spine, ribcage, and sternum. Each BM source was isolated from individual E15.5
embryos, and the entire BM suspension was injected into a lethally irradiated recipient
(Figure 3-16). In this way, the contribution from each BM source within an individual
embryo could be tracked for the presence of long-term repopulating cells.
Only 2/12 recipients transplanted with E15.5 forelimbs showed long-term repopulation
>1%, and the donor contribution in one of the recipients only reached 1.7% (Figure
3-17A). Therefore, while the forelimbs can contain HSCs at E15.5, these HSCs appear to
be rare and likely in low frequencies when present. Meanwhile, 5/14 recipients
transplanted with E15.5 hindlimbs displayed long-term repopulation >1%, and two of
these recipients reached a donor chimerism >50%, suggesting that HSCs are more
frequent and in greater numbers within the E15.5 hindlimbs compared to the forelimbs
(Figure 3-17B). Finally, 6/14 recipients transplanted with E15.5 trunks—which contain
the highest BM cellularity within the entire E15.5 skeleton—were reconstituted with
donor cells at levels >1% 20 weeks post-transplant, and 4/6 of these recipients displayed
donor chimerism >40% (Figure 3-17C). This suggests that the BM source containing the
most HSCs at E15.5 is likely to be the trunk, although given that the trunk has greater
cellularity than the forelimbs or hindlimbs, it is still possible that the other sources of BM
have greater frequencies of HSCs.
We were also able to track the contribution of different BM sources within an
E15.5 fetus towards long-term repopulation of recipients, allowing us to determine if
HSCs are present in multiple sites in the FBM at the same time (Figure 3-17A).
Interestingly, 2/11 donors contained transient repopulating cells in the hindlimbs alone
followed by long-term repopulating cells in the forelimb and trunk, while no donors
contained long-term repopulating cells that were only contained within the hindlimbs
(Figure 3-17D). In contrast, one donor contained transient and long-term repopulating
cells specific to the forelimbs while another donor contained trunk-specific transient
(arising at 8 weeks post-transplant) and long-term repopulating cells (Figure 3-17D).
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Figure 3-16. Transplantation of individual E15.5 fetal bones
Schematic depicting primary transplantation of BM cells from individual fetal bone
sources in E15.5 embryos. The forelimbs, hindlimbs, and trunk bones were dissected
from CD45.2+ donor embryos, processed to create single-cell suspensions, and injected
separately into lethally irradiated recipients along with 2 x 105 CD45.1+ supportive cells.
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Figure 3-17. HSCs are found in all E15.5 BM sources
A. The CD45.2+ donor cell contribution to the PB of irradiated recipients injected with
E15.5 forelimb FBM cells (n = 12). B. The CD45.2+ donor cell contribution to the PB of
irradiated recipients injected with E15.5 hindlimb FBM cells (n = 14). C. The CD45.2+
donor cell contribution to the PB of irradiated recipients injected with E15.5 trunk FBM
cells (n = 14). D. Histogram depicting the percentage of recipients with >1% donor cell
contribution to the PB at 4, 8, 12, and 20 weeks post-transplant from different bone
sources within the same E15.5 embryo (n = 11). For A-C, the recipient numbers correlate
across BM tissues, representing tissues coming from individual E15.5 embryos.
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A final donor displayed transient and long-term repopulating cells contained within the
forelimb and hindlimb BM, while 6/11 donors displayed no reconstitution from any bone
source (Figure 3-17D). It is difficult to make conclusions about the dynamics of HSC
arrival in the different sources of BM within the E15.5 fetus given that only the recipients
from 11 donors (33 total recipients) survived 20 weeks post-transplant, and only
recipients from 5/11 donors showed any level of reconstitution (Figure 3-17D).
However, given that no long-term reconstitution is present in hindlimbs alone, but
forelimbs and trunks display long-term reconstitution either alone or in combination with
hindlimbs, it is possible that the forelimbs and trunk may be preferentially colonized by
HSCs followed by the colonization of hindlimbs.
Together these data unequivocally point to the presence of HSCs at E15.5 in all
sources of BM, suggesting that while our transplantation of the entire skeleton is a more
robust method for identifying the HSC potential in early FBM, it should not preclude the
identification of HSCs in the long bones of E15.5 embryos.
The FBM HSPC Compartment Is Compositionally Distinct From FL and Adult BM
After confirming the existence of bona fide HSCs in the E15.5 FBM, we next
wanted to thoroughly characterize the immunophenotypic HSPC compartment from the
initial seeding of HSPCs at E15.5 to the proposed developmental shift in HSCs around 4
weeks post-birth (P28) from an actively cycling to a primarily quiescent phenotype
(Bowie 2006, Bowie 2007). Importantly, we also wanted to determine if the HSPC
compartment from the BM was similar in composition to the liver at the same
developmental timepoints. To do this, we isolated the liver and the BM from entire
skeletons of mice aged E15.5 to P28 and used flow cytometry to assess the frequencies of
several immunophenotypic progenitors within the LSK compartment, including LTHSCs, ST-HSCs, MPP2s, MPP3s, and MPP4s (Pietras 2015) (Figure 3-18).
Upon inspection of liver HSPCs, we found that HSPC frequencies in the fetal and
early neonatal liver remained relatively constant with MPP4s being the dominant
phenotype until around P6, at which point there was a slight shift to a more MPP3dominant phenotype (Figure 3-19A). However, there was a remarkable difference in the
HSPC frequencies within the BM at similar timepoints, as the E15.5-E18.5 HPSC
compartment was dominated by immunophenotypic MPP2 cells (Figure 3-19B). Indeed,
the MPP-2 and MPP-4 frequencies in the E15.5 FBM were 0.64 and 0.09 respectively,
and these values remained relatively unchanged until E19 (Figure 3-19B). Meanwhile,
the MPP-2 and MPP-4 frequencies in the E15.5 FL were 0.09 and 0.38 respectively,
remaining relatively constant until P6 (Figure 3-19A). Interestingly, while
immunophenotypic LT-HSCs could be identified in the early FBM, the frequency of this
population within the HSPC was ~0.01 from E15.5-E17.5 until jumping to 0.03 at E18.5,
a frequency similar to that seen in the P28 BM (Figure 3-19B).
By counting the number of cells within tissues per individual during our analyses,
we were able to calculate the projected total number of immunophenotypic progenitors
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Figure 3-18. Analysis of HSPCs across BM and liver ontogeny
Schematic depicting the method for analyzing the HSPC compartments of murine BM
and liver across development. Bones and livers were dissected from E15.5-P28 mice,
stained with the appropriate antibodies, and analyzed for the presence of several
progenitor cells (as defined by Pietras 2015) within the LSK compartment (LT-HSCs,
ST-HSCs, MPP2s, MPP3s, and MPP4s).
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Figure 3-19. Frequency and total number of HSPCs in BM and liver
A-B. The frequency of different HSPC populations within the liver LSK compartment
(A) and BM LSK compartment (B) from late gestation to adulthood in C57B6/J mice (n
=10-17 from 2-3 independent litters) . C-D. The calculated absolute number of
immunophenotypic HSPCs in the liver (C) or BM (D) from late gestation to adulthood in
C57B6/J mice (n = 10-17 from 2-3 independent litters). All data represent means with
SE.
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within the liver or BM of an individual mouse at each timepoint. It is thought that after
expanding in the FL, HSPCs migrate to the FBM from around E15.5 until after birth
(Medvinsky 2011, Khan 2016). Therefore, we expected to see a decrease in the total
number of HSPCs in the FL and a concomitant increase in FBM HSPC numbers starting
at E15.5. Three trends characterized the dynamics of HSPC numbers in the liver. First,
there was a considerable decrease in the total numbers of all progenitors from E15.5 until
right before birth, at which point there was a burst in the total numbers of all progenitors,
especially in the MPP2 and MPP3 compartments (Figure 3-19C). Second, following the
burst of progenitor numbers at P0, there was a precipitous drop in the total number of
progenitors at P2, which remained relatively constant until P8 (Figure 3-19C). Lastly,
HSPCs numbers dropped dramatically from P8 to P14, from ~60,000 to ~11,000 total
HSPCs (Figure 3-19C). Together, these data suggest that aside from an uncharacteristic
jump in HSPC numbers in the FL right after birth, liver HSPCs are largely disappearing
from E15.5 to P8 and are essentially exhausted at by P14 compared to earlier timepoints.
Tracking the total numbers of HSPC in the BM revealed the opposite trend. While
the P28 BM contained ~885,000 total immunophenotypic HSPCs—84% of which were
either MPP3s or MPP4s—the E15.5 FBM contained only 4,139 immunophenotypic
HSPCs, and this number steadily increased from E15.5 to P28 with only a small dip in
total numbers at E19 (Figure 3-19D). Indeed, the number of immunophenotypic HSCs
increases from only 64 at E15.5 to ~5,000 at P2 (Figure 3-19D). Closer inspection of the
E15.5 to P2 total HSPCs numbers also revealed that the shift in HSPC frequencies from
an MPP2-dominant phenotype to an “adult-like” (P28) phenotype around birth appears to
be mainly due to an increase in the total numbers of other HSPCs, not a decrease in the
number of MPP2s. For instance, total numbers of MPP2s increased by 10-fold from
E16.5 to P2, while LT-HSCs, ST-HSCs, MPP3s, and MPP4s increased by factors of 35,
13, 45, and 58, respectively (Figure 3-19D).
Together, these data show that the HSPC compartments of the FL and FBM are
distinct, even at similar developmental timepoints. Also, while the composition of the
HSPC compartment in the FL does not undergo dramatic change until around P6—a
similar timepoint at which HSPCs appear to be lost from the liver—the same
compartment in the FBM drastically changes right around birth from an MPP2-dominant
to an MPP3/MPP4-dominant phenotype, similar to the HSPC distribution in adult BM.
This shift appears to be due to an increase in the absolute number of HSPCs, not a
decrease in the numbers of MPP2 cells.
All FL HSPCs Have the Potential to Migrate to the FBM
The presence of an MPP2-dominant HSPC compartment in the E15.5 FBM was
intriguing, as we assumed that LT-HSCs would be the dominant HSPC subpopulation at
the earliest FBM timepoints followed by expansion of downstream progenitors. We
therefore decided to test whether all HSPC subsets had the ability to migrate from the FL
to the FBM during late gestation. Migration from the FL to the FBM is dependent on
CXCL12/CXCR4 chemoattraction, as CXCL12-/- mice display almost no repopulating
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ability from the E18.5 BM, and the HSCs in these animals appear to be trapped in the PB
(Ara 2003). This is thought to be due to the lack of Cxcl12 expression from FBM niche
cells, as the cell surface expression of CXCR4 in HSCs is thought to be a key component
to their retention in Cxcl12+ adult BM niches (Crane 2017).
We first isolated HSPCs from E15.5-P0 livers and analyzed each compartment for
the expression of cell surface CXCR4 to determine if they have the machinery necessary
to migrate towards a CXCL-12 gradient (Figure 3-20). We found that all HSPCs from
E15.5-P0 liver contained populations of CXCR4+ cells, suggesting that these cells would
have the ability to respond to CXCL-12 (Figure 3-20). We next performed a series of ex
vivo transwell migration assays to determine if CXCR4+ HSPCs in the E15.5-P0 liver
could migrate towards CXCL-12 (Figure 3-21). In this assay, we isolated HSPCs from
FL at gestational and P0 timepoints and dispensed the cells in transwell plates. The top
portion of the well contained the cells of interest and serum/cytokine-free media, while
the bottom portion of the well contained media with or without soluble CXCL-12
(Figure 3-21). After a 5-hour incubation to allow for migration of cells towards CXCL12, the bottom portion of the well was collected and plated in methylcellulose to
determine if any colony forming progenitors migrated in response to CXCL-12 (Figure
3-21).
As expected, no migration was observed towards wells lacking CXCL-12 (Figure
3-22A). However, all liver HSPCs from E15.5-P0 showed migratory potential towards
CXCL-12 (Figure 3-22B). This shows that all HSPCs from the FL have the potential to
migrate toward the FBM niche at the earliest timepoints, and suggests a model in which
the FBM is populated by a mixture of migratory HSPCs as well as HSPCs potentially
arising from resident LT- and ST-HSCs.
FBM MPP2s Are Functionally Distinct From FL and Adult MPP2s
Upon closer inspection of the frequency of HSPCs in the FBM around birth, we
noticed that the frequency of CD45+ cells in the BM sharply increases around E18.5 and
are sustained through P2, but the frequency of HSPCs within the CD45+ compartment
displays bimodal fluctuation, as CD45+ HSPCs peak at E15.5, sharply decrease around
E18.5, and then sharply increase again at the newborn stage (Figure 3-23). This
suggested to us that at early (E15.5-E18.5) timepoints, HSPCs are not contributing as
robustly to blood production in the FBM. However, by E18.5 and beyond, HSPCs begin
to ramp up blood production in the FBM. This reasoning—in combination with our
discovery that MPP2s are the primary HSPC subset present in the FBM—led us to test
FBM MPP2s for their functional properties, as immunophenotype is not necessarily
indicative of function.
MPP2s are a myeloid-biased population of MPPs downstream of LT- and STHSCs and display a relatively high frequency of megakaryocyte/erythroid colonies when
plated in CFU-assays (Pietras 2015). To determine the absolute CFU-potential of FBM
MPP2s compared to other HSPC sources, we sorted single immunophenotypic MPP2s
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Figure 3-20. FL HSPC CXCR4 cell surface expression
Representative flow cytometry plots depicting CXCR4 cell surface expression on FL
HSPCs from E15.5-P0
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Figure 3-21. Transwell migration assays
FL HSPCs were sorted from E15.5-P0 murine embryos and plated into the top portion of
transwell plates, while the bottom portion of the plates contained media with soluble
Cxcl-12 or cytokine-free media. After 5 hours, the bottom portion of the transwell was
plated in methylcellulose to test for CFU potential.

Figure 3-22. FL HSPCs respond to CXCL12
The migration potential of fetal and newborn FL HPSCs plated in transwell assays in the
presence of (A) cytokine-free media or (B) soluble CXCL-12 (n = 3). All data represent
means with SE.
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Figure 3-23. Frequencies of CD45+ and CD45+ HSPC BM
The frequency of (A) CD45+ cells in the bone marrow or (B) several HSPC populations
in CD45+ BM from C57B6/J embryos and neonates (n = 10-16 embryos from 2-3
independent litters). All data represent means with SE.
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from E16.5, E17.5, E18.5, and P0 BM and liver, as well as adult BM as controls, into
methylcellulose to assess the frequency and differentiation potential of CFU from the
MPP2 compartment (Figure 3-24A). Incredibly, we found that MPP2s from E16.5 FBM
displayed no CFU potential, while E17.5 and E18.5 FBM MPP2s had CFU frequencies of
0.01 and 0.03, respectively (Figure 3-24B). The first appearance of MPP2s with the
ability to produce substantial CFUs was right after birth at P0, in which there was a ~10fold expansion of CFU frequency compared to E18.5 (Figure 3-24B). Importantly, the
frequency of CFU in P0 MPP2s was similar to the CFU frequency in adult BM MPP2s,
and both MPP2 sources displayed high levels of colonies with megakaryocyte and
erythroid potential (Figure 3-24B). Meanwhile, liver MPP2s displayed high CFU
frequencies from E16.5-P0, ranging from 0.8 at E17.5 to 0.6 at P0 (Figure 3-24B). These
data show that while MPP2s in the FBM are immunophenotypically similar to FL MPP2s
and are presumably seeded from the FL, they have distinct in vitro colony-forming
potential compared to their FL counterparts at the same developmental timepoints.
Likewise, the first robustly functional FBM MPP2s appear to arise around birth,
concomitant with the shift in HSPC frequencies we previously observed (Figures 3-19
and 3-23).
Upon transplantation, MPP2s will transiently repopulate irradiated hosts with a
bias towards myeloid, platelet, and erythrocyte production (Pietras et al.). To assess the
functional potential of FBM MPP2s across late embryonic ontogeny, we isolated MPP2s
from E16.5, E18.5, and P0 BM and liver, as well as adult BM, and transplanted a limiting
dose of cells (100 cells) into lethally irradiated recipients (Figure 3-25). Erythrocytes and
platelets do not express cell surface CD45, therefore we utilized UBC-GFP mice, which
express a green fluorescent protein (GFP) transgene under the control of the human
Ubiquitin C (UBC) promoter in all blood cell types, to track the contribution of MPP2
cells to myeloid, B, T, platelet, and erythroid lineages in the PB of recipients (Schaefer
2001) (Figure 3-25). As expected, adult MPP2s were able to transiently reconstitute 50%
of irradiated recipients with combinations of myeloid, T-lymphoid, platelet, and
erythrocyte lineages, with a greater percentage of recipients showing myeloid, platelet,
and erythrocyte donor contribution compared to T-lymphoid reconstitution (Figures
3-26A and 3-27). Similar to our in vitro results, E16.5 FBM MPP2s were unable to
transiently reconstitute any lineages in the PB of irradiated recipients while E18.5 was the
first time point in which transplantable MPP2s were found, albeit at low levels (Figures
3-26A and 3-27). Indeed, E18.5 FBM MPP2s were able to transiently reconstitute 20% of
recipients with combinations of platelet, erythroid, and even B-lymphoid lineages
(Figures 3-26A and 3-27). Meanwhile, recipients transplanted with P0 FBM MPP2s
showed 40% transient reconstitution of all lineages except T-lymphoid, although donor
chimerism in these lineages was lower than in recipients transplanted with adult BM
(Figures 3-26A and 3-27). Also similar to our in vitro CFU assay results, the first FL
MPP2 cells displaying transient reconstitution of multiple lineages were from E16.5 FL,
and E16.5 and E18.5 FL MPP2s displayed transient reconstitution of all lineages—but
preferentially myeloid, platelet, and erythrocyte—in 67% and 83% of recipients,
respectively (Figures 3-26B and 3-27). Interestingly, there was a drop in the percentage
of recipients that were transiently reconstituted with P0 FL MPP2s to 40%, and these
MPP2s displayed contribution to all lineages except the myeloid lineage (Figures 3-26B

76

Figure 3-24. In vitro assay for MPP2 function
A. Single MPP2s from FL, FBM, newborn BM/liver, and adult BM were isolated and
plated directly into cytokine-supported methylcellulose to test for CFU potential. B. The
frequency of CFUs among MPP2s from BM and liver at different developmental
timepoints (n = 58-169 single cells from 1-3 independent experiments). Data represent
means with SE.
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Figure 3-25. In vivo assay for MPP2 function
Experimental schematic for in vivo analysis of MPP2 cell function. 100 MPP2s were
sorted from CD45.2+ donor UBC-GFP+/T FL, FBM, newborn liver/BM, or adult BM and
transplanted into lethally irradiated recipients along with 2 x 105 sorted CD45.1+ support
cells, and recipients were monitored for donor contribution to B-lymphoid, T-lymphoid,
myeloid, erythroid, and platelet production in the PB.
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Figure 3-26. FBM MPP2s are inert until E18.5
Donor chimerism of myeloid cells, B-/T-lymphoid cells, platelets, and erythrocytes in
recipients transplanted with either (A) BM or (B) liver cells over 20 weeks (n = 5-10
recipients per timepoint).
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Figure 3-27. Summary of MPP2 transplants
Histogram summarizing the percentage of recipients displaying transient donor
reconstitution of varying numbers of lineages after being transplanted with BM or liver
from different developmental timepoints (n = 5-10 recipients).
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and 3-27). Such a dramatic shift was not seen in our in vitro CFU assays, although there
was a trend for P0 FL MPP2s to display lower CFU frequency compared to earlier
timepoints (Figure 3-24B).
Together, these data unequivocally show that the pool of MPP2 cells in the FBM
display increasing functional output leading up to birth, at which point MPP2 cells more
closely resemble their adult BM counterparts. Perhaps even more interesting is the
observation that MPP2 cells from FBM and FL time-matched tissues display large
disparities in their functional output, with FBM MPP2 cells being more “immature” in
their functional capacity compared to FL MPP2s. This could possibly be due to an
accumulation of more functionally “mature” MPP2s in the FBM during late ontogeny,
may be reflective of an unwelcome HSPC niche in the FBM until birth, or could be some
combination of these possibilities.
The FBM Hematopoietic Progenitor Compartment Undergoes Drastic Remodeling
During Late Gestation
To better understand why MPP2s and other HSPCs may be functionally distinct
early in FBM colonization, we isolated CD45+Lineage-c-Kit+ hematopoietic progenitors
(HPs) and CD45-Ter119- stroma from E16.5, E18.5, P0, and adult BM, followed by 10X
scRNA-Seq analysis (Figure 3-28A). As HSPCs in the FBM are extremely rare, we also
utilized CITE-Seq (Stoeckius 2017) to label HSPCs within the HP compartment with
oligo-tagged antibodies that could later be combined with mRNA expression data to
immunophenotypically identify HSPCs in our 10X-generated scRNA-Seq dataset
(Figure 3-28). In total, we constructed and sequenced libraries from 5,985 adult BM,
6,208 P0 BM, 3,477 E18.5 FBM, and 5,312 E16.5 FBM HP cells.
Unbiased clustering and gene expression analysis allowed us to prospectively
identify several distinct cell populations in each library, and we primarily relied upon the
expression of cell-specific markers and previously published datasets to manually
annotate all clusters (Cabezas-Wallscheid 2014, Kowalczyk 2015, Paul 2015, Wilson
2015, Dahlin 2015, de Graf 2016, Nestowara 2016, Dwyer 2016, Velten 2017, Chhiba
2017, Dahlin 2018, Giladi 2018, Rodriguez-Fraticelli 2018, Tusi 2018, Zheng 2018,
Pellin 2019, Baccin 2019) (Figure 3-29). We also utilized Uniform Manifold
Approximation and Projection (UMAP) (McInnes 2018) to produce dimensionality maps
reflecting similar expression relationships between clusters. Indeed, UMAP
dimensionality reduction on annotated clusters from the adult HP library placed several
pre/pro-B cell and B-cell lineage clusters in close proximity, as well as placing an HSPC
(Prog) population at the apex of monocyte/granulocyte and megakaryocyte/erythroid
lineages, suggesting that our method for annotating clusters was robust (Figure 3-29A).
Adult, P0, and E18.5 BM libraries contained similar populations, including
progenitors, several granulocyte and monocyte clusters, mast cell clusters,
megakaryocyte/erythroid progenitors, and B-cell clusters (Figure 3-29A-C). The most
apparent differences between E18.5/P0 BM and adult BM were the lack of pre/pro-B-cell
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Figure 3-28. Single cell RNA-sequencing of FBM
Schematic for the isolation and 10X scRNA-Seq of BM hematopoietic progenitors (HP)
or stromal cells. A. BM was isolated from E16.5, E18.5, P0, and adult C57B6/J mice and
sorted for hematopoietic progenitors (CD45+Lineage-c-Kit+) or stromal cells (CD45-Ter119-), followed by 10X scRNA-Seq in conjunction with CITE-Seq. B. CITE-Seq utilizes
oligo-tagged antibodies containing specific barcodes that can be captured by the 10X
technology, allowing parallel sequencing of mRNA expression and cell-surface protein
expression of single cells.
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Figure 3-29. Hematopoietic clusters in FBM scRNA-Seq data
UMAP projections depicting the cell clusters of HP libraries from (A) adult, (B) P0, (C)
E18.5, and (D) E16.5 BM. Bas, basophil lineage; Bcell, B-cell lineage; DC, Dendritic
cells; Eos, eosinophil lineage; EryP, erythroid progenitors; Mast, mast cell lineage;
MegP, megakaryocyte progenitors; Mono, monocyte lineage; MyP, myeloid progenitors;
Neu, neutrophil lineage; Pre/Pro-B, Pre/Pro-B Cells; Prog, HSPCs; TCell, T-Cell lineage;
T/NK, T/NK cell lineage; UD, undefined cluster.
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clusters in E18.5/P0 BM, as well as a large expansion of the neutrophil cluster in adult
BM (Figure 3-29A-C). There was also a greater presence of progenitor cells in the P0
BM compared to adult and E18.5 BM, suggesting an expansion of this population around
birth (Figure 3-29A-C). However, the most striking observation was the presence of
several large mast and T-cell lineage clusters in the E16.5 FBM (Figure 3-29D). Within
the E16.5 FBM HP library, mast cell and T-cell clusters comprised 38.8% and 40.6% of
all cells, respectively (Figure 3-29D). Meanwhile, T-cell clusters comprised only 1.11.8% of cells from all other libraries, and mast cell clusters comprised only 4.7-8.6% of
cells (Figure 3-29). Our E16.5 FBM HP library also lacked any definable myeloid,
erythroid, megakaryocyte, or lymphoid progenitors, but did contain a small population of
undefined progenitor cells (Figure 3-29D). Therefore, the HP compartment of E16.5
FBM is heavily biased towards the mast cell and T-cell lineages, which are rapidly
reduced by E18.5 followed by an expected expansion of progenitor cells right after birth
(Figure 3-29).
Immunophenotypic MPP2s Display Highly Heterogeneous Transcriptional
Programs Compared to LT-HSCs
By incorporating CITE-Seq (Stoeckius 2017) into our 10X pipeline, we were able
to identify the same immunophenotypic populations we previously assayed for our
functional studies in our scRNA-Seq dataset (Figure 3-30A). While cell-surface protein
expression does not always mimic mRNA expression, we were able to compare our
CITE-Seq expression data with corresponding mRNA expression to verify that our CITESeq antibodies labelled similar cell populations (Figure 3-30B). To determine which
clusters MPP2 cells preferentially resided in, we identified immunophenotypic MPP2s
using CITE-Seq expression and calculated the proportions of MPP2s in the clusters of
each library (Figure 3-31).
Immunophenotypic MPP2s could be found in 15/18 clusters in the adult BM HP
library (Figure 3-31A). The HSPC (Prog) and megakaryocyte progenitor clusters
compromised 18% and 15% of immunophenotypic MPP2s, but surprisingly, 27% of
immunophenotypic MPP2s fell into the cluster we annotated as “Bcell1” due to its
expression of several B-lineage markers (Figure 3-31A). Likewise, 16/20 clusters from
our P0 BM HP library contained MPP2s, with 74% of MPP2s falling into the monocyte1, Prog-1, Prog-2, and megakaryocyte progenitor clusters (Figure 3-31B). Displaying
slightly less heterogeneity, E18.5 BM MPP2s fell into 11/20 clusters and were found
primarily in the Prog, myeloid progenitor-1, B-lineage, and monocyte-3 clusters,
although other clusters such as more monocyte, erythroid/megakaryocyte progenitors,
and T-cell lineage clusters each contained >5% of immunophenotypic MPP2s at this time
point (Figure 3-31C). Finally, our E16.5 FBM HP library contained MPP2s with similar
heterogeneity compared to E18.5 FBM, with 9/17 clusters containing MPP2s (Figure
3-31D). However, at E16.5 53% of immunophenotypic MPP2s were contained within the
monocyte/mast cell cluster, suggesting that the greatest enrichment of homogeneous
MPP2s from our dataset is in the E16.5 FBM (Figure 3-31D).
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Figure 3-30. CITE-Seq to identify HSPCs
CITE-Seq can be used to prospectively identify immunophenotypic HSPCs. A. CITE-Seq
expression dot plots for identification of immunophenotypic LT-HSCs and MPP2s. B.
UMAP projection of P0 BM depicting Sca-1 mRNA and CITE-Seq expression.
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Figure 3-31. Cluster distribution of HSPCs
Circle graphs depicting the distribution of immunophenotypic MPP2s or LT-HSCs
contained within each cell cluster of (A) adult, (B) P0, (C) E18.5, or (D) E16.5 HP
libraries.
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Given previous observations that MPP2s are a highly heterogeneous population
(Pietras 2015), we also used our CITE-Seq data to identify LT-HSCs and we
hypothesized they would contain less heterogeneity than MPP2s. Immunophenotypic LTHSCs could be found in 9/18 clusters in our adult BM HP library, but 78% of LT-HSCs
were only found in the Prog and Bcell1 clusters (Figure 3-31A). This adult Bcell1 cluster
either represents a B-lymphoid-biased progenitor population—as both
immunophenotypic LT-HSCs and MPP2s are found at high levels in this cluster—or
perhaps contains non-functional immunophenotypic progenitors. Meanwhile, only 5/20
clusters in our P0 BM HP library contained immunophenotypic LT-HSCs, and 83% fell
into the Prog-1 and Prog-2 clusters (Figure 3-31B). Similarly, low heterogeneity was
seen in E18.5 immunophenotypic LT-HSCs, as they only fell into 3/20 clusters, with 81%
of LT-HSCs residing in the Prog cluster (Figure 3-31C). Finally, there was slightly more
heterogeneity present in E16.5 LT-HSCs, as 7/17 clusters contained immunophenotypic
LT-HSCs (Figure 3-31D). However, the majority of these cells also fell into the same
monocyte/mast cell cluster as the MPP2s, suggesting that this cluster contains the
majority of all immunophenotypic HSPCs (Figure 3-31D).
Together, these analyses confirm that MPP2s are a highly heterogenous
population of cells, but also suggest that the majority of immunophenotypic MPP2s
contain a monocyte/mast cell transcriptional signature at E16.5, shifting to a signature
more indicative of myeloid and megakaryocyte/erythroid progenitors by E18.5.
Meanwhile, immunophenotypic LT-HSCs appear to be more heterogeneous at E16.5 and
are primarily composed of cells with monocyte/mast cell transcriptional signatures,
suggesting that the LT-HSC compartment in the early FBM may have reduced HSC
function.
The Stem Cell-Specific Transcriptional Profiles of Immunophenotypic LT-HSCs
and MPP2s Shift Around Birth
Recently, the Gӧttgens group developed the “hscScore” algorithm to assist
researchers in identifying LT-HSCs and downstream progenitors in scRNA-Seq datasets
(Hamey 2019). This algorithm assigns a score to each cell based on the expression of
genes validated to enrich for LT-HSCs (Wilson 2016). For reference, applying this
algorithm to previous scRNA-Seq datasets showed that the most enriched HSC
populations have an hscScore around 0.4-0.5, while MPP populations typically have an
hscScore ranging from 0.1-0.3 (Hamey 2019). Given that our MPP2 functional assays
showed that FBM MPP2s do not become functional until right before birth and that our
CITE-Seq assisted scRNA-Seq analyses placed E16.5 immunophenotypic LT-HSCs
primarily in a cluster with monocyte/mast cell gene expression signatures, we utilized the
hscScore algorithm to identify changes in the stem cell signature of MPP2s and LT-HSCs
across FBM ontogeny.
We subclustered our immunophenotypic MPP2s and LT-HSCs and generated an
hscScore for subclusters at each timepoint (Figures 3-32 and 3-33). While the majority of
immunophenotypic MPP2s displayed hscScores <0.1 across development, at E18.5 and
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Figure 3-32. MPP2 hscScores across ontogeny
hscScore was used to quantify stem cell associated transcriptional programs in MPP2
cells across BM ontogeny. A. Subclustering of immunophenotypic MPP2 cells from each
HP library. B. hscScore for the representative subclusters at each developmental
timepoint.
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Figure 3-33. LT-HSC hscScores across ontogeny
hscScore was used to quantify stem cell associated transcriptional programs in LT-HSC
cells across BM ontogeny. A. Subclustering of immunophenotypic LT-HSC cells from
each HP library. B. hscScore for the representative subclusters at each developmental
timepoint.
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P0 there was a gradual increase in the number of MPP2s with hscScores > 0.15, and adult
immunophenotypic MPP2s contained cells with hscScores ranging from 0.15-0.45
(Figure 3-32). This provides further evidence that the MPP2 compartment during early
FBM ontogeny is primarily composed of cells lacking the necessary transcriptional
programs that are indicative of functional progenitors.
The immunophenotypic LT-HSC compartment in the FBM also displayed
interesting dynamics from E16.5-P0. At E16.5, the majority of LT-HSCs consisted of
hscScores < 0.2, suggesting that at this timepoint many LT-HSCs may not function
properly (Figure 3-33). By E18.5, one subcluster of LT-HSCs was already displaying
hscScores greater than 0.35 while two other subclusters had hscScores < 0.2 (Figure
3-33). In the BM of newborn mice, hscScorehi and hscScorelo LT-HSC subsets existed,
with the “hi” subset being comprised of cells with scores around 0.4 and the “lo” subset
consisting of cells ranging from ~0.1-0.3 (Figure 3-33). Finally, the adult BM contained
LT-HSCs with hscScorehi (~0.4) and hscScoremid (~0.3) subclusters (Figure 3-33).
In sum, the hscScore values provide clues to the maturation process of MPP2s and
LT-HSCs in the FBM and suggest that these progenitor cells can undergo dramatic
transcriptional changes from E16.5 to P0 in favor of a phenotype more indicative of
functional progenitors.
The FBM Stromal Compartment Contains Putative Niche Cells for HSPCs
Our observation that immunophenotypic MPP2s and LT-HSCs appear to
accumulate transcriptional programs necessary for stem cell identify during late gestation
suggests that changes in the FBM niche around birth may play a role in this maturation
process. Therefore, we isolated CD45-Ter119- stroma from E16.5, E18.5, P0, and adult
BM, followed by 10X scRNA-Seq analysis to visualize changes in the cellular
composition of the FBM stroma across development (Figure 3-28A). In total, we
constructed and sequenced libraries from 7,380 adult BM, 16,412 P0 BM, 7,272 E18.5
FBM, and 9,786 E16.5 FBM stromal cells.
Similar to our analysis of the HP compartment, we utilized unbiased clustering
based on gene expression to prospectively identify several cell populations in each
library, relying upon the expression of cell-specific markers and previously published
datasets to manually annotate all clusters (Cai 2017, Baccin 2019, Mende 2019, Severe
2019, Baryawno 2019, Mende 2019, Tikhonova 2019, Wolock 2019) (Figure 3-34).
Again, we utilized UMAP (McInnes 2018) to produce dimensionality maps reflecting
similar expression relationships between clusters. Indeed, UMAP dimensionality
reduction on annotated clusters from the adult stromal library placed several fibroblast
and chondrocyte clusters in close proximity, as well as the arterial and sinusoidal
endothelial cells (Figure 3-34A).
Across development, several chondrocyte and fibroblast clusters were detected, as
well as many pericyte clusters, including clusters with transcriptional signatures for
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Figure 3-34. Stromal clusters in FBM scRNA-Seq data
UMAP projections depicting the cell clusters of stroma libraries from (A) adult, (B) P0,
(C) E18.5, and (D) E16.5 BM. CARs, CXCL12-abundant reticular cells; C,
chondrocytes; C/F, chondrocyte/fibroblast; ECs, endothelial cells; AECs, arterial
endothelial cells; SECs, sinusoidal endothelial cells; F, fibroblasts; Osteo, osteolineage;
P, pericytes; Schwann, schwann cells; UD, undefined cluster.
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smooth muscle cells, Schwann cells, and myofibroblasts (all of which were considered
“pericyte” clusters) (Figure 3-34). However, there were a few key differences between
the fetal/neonatal stromal composition and the adult stroma. For instance, no clear
osteolineage population could be annotated in E16.5 to P0 stroma, only clusters which
contained gene signatures for osteoblasts in addition to chondrocyte or fibroblast markers
(Figure 3-34). In addition, the presence of several chondrocyte/fibroblast clusters—in
which transcripts for both cell types were highly upregulated—were enriched in the
E16.5-P0 BM stroma libraries, suggesting that the stroma of the fetal/neonatal stroma has
a higher composition of mesenchymal progenitor or multipotent cells (Figure 3-34).
Sinusoidal and arterial endothelial cells could not be distinguished in E16.5-P0 BM as in
adult BM, although this does not preclude their existence, and may simply be due to the
reduction in total endothelial cell numbers in the fetal/neonatal BM (Figure 3-34). Most
importantly, the presence of a clear CAR cell cluster was absent from E16.5-P0 BM,
suggesting that this critical adult BM HSC niche cell is only substantially present after P0
(Figure 3-34).
CAR cells are a well-documented population of cells that regulate HSC
maintenance in the adult BM, and express high levels of Cxcl12 and Kitl (Crane 2017,
Gao 2018). Since we could not accurately annotate a CAR cell population in E16.5-P0
BM, we assessed the Cxcl12 and Kitl expression among all clusters from these time
points to determine putative cell populations for HSC maintenance (Figures 3-35 and
3-36). As expected, the CAR cluster in our adult BM stroma library was highly enriched
for Cxcl12 expression, as were arterial endothelial cells—one of the proposed
foundational niche cells where many CARs and HSCs reside (Figure 3-35A). The adult
CAR cluster was also enriched for Kitl expressing cells, along with arterial endothelial
cells and a cluster of pericytes that closely resemble smooth muscle (P-1) (Figure
3-36A).
Meanwhile, Cxcl12 and Kitl expression was more broadly distributed and
expressed at lower levels in E16.5-P0 BM stroma libraries (Figures 3-35 and 3-36). The
three clusters with the highest Cxcl12 expression in P0 stroma were an undefined cluster
(UD-3; with some CAR and fibroblast/osteoblast signatures), a fibroblast cluster (F-3,
displaying potential adipocyte signatures), and a pericyte cluster (P-2, enriched for
smooth muscle signatures, as well as a few adipocyte signatures) (Figure 3-35B).
Interestingly, F-3 and P-2 were also enriched for Kitl among P0 clusters, suggesting that
these cell populations may be important niche cells for P0 HSCs (Figure 3-36B).
However, it is important to note that the level of Cxcl12 and Kitl in these clusters was
much lower than the adult CAR cluster. Inspection of the top Cxcl12-expressing clusters
in E18.5 FBM stroma revealed two fibroblast clusters (F-1 and F-1, both of which
contained adipolineage gene signatures) and one pericyte cluster (P-2, expressing smooth
muscle and myofibroblast-specific transcripts) (Figure 3-35C). These clusters were also
all enriched for Kitl expression among E18.5 clusters (Figure 3-36C). Finally, E16.5
FBM stroma clusters enriched for Cxcl12 expression included four fibroblast clusters (F1 through F-4, all of which contained some cells with adipolineage gene signatures) and
one undefined cluster (UD, which contained no clear expression of any lineage-specific
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Figure 3-35. Stomal Cxcl12 expression across BM ontogeny
Violin plots depicting Cxcl12 expression within (A) adult, (B) P0, (C) E18.5, and (D)
E16.5 single cell stromal clusters. CARs, CXCL12-abundant reticular cells; C,
chondrocytes; C/F, chondrocyte/fibroblast; ECs, endothelial cells; AECs, arterial
endothelial cells; SECs, sinusoidal endothelial cells; F, fibroblasts; Osteo, osteolineage;
P, pericytes; Schwann, schwann cells; UD, undefined cluster.
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Figure 3-36. Stromal Kitl expression across BM ontogeny
Violin plots depicting Kitl expression within (A) adult, (B) P0, (C) E18.5, and (D) E16.5
single cell stromal clusters. CARs, CXCL12-abundant reticular cells; C, chondrocytes;
C/F, chondrocyte/fibroblast; ECs, endothelial cells; AECs, arterial endothelial cells;
SECs, sinusoidal endothelial cells; F, fibroblasts; Osteo, osteolineage; P, pericytes;
Schwann, schwann cells; UD, undefined cluster.
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genes) (Figure 3-35D). All of these clusters with the exception of F-2 showed mid to low
expression of Kitl, but were still relatively enriched for Kitl expression compared to other
E16.5 FBM clusters (Figure 3-36D).
Together, our scRNA-Seq analysis of BM stromal populations presents a model in
which the fetal and neonatal BM contains low levels of definable osteoblast, CAR cells,
and endothelial cell subsets, but do contain putative niche cells for HSC maintenance.
These putative niches appear to primarily consist of cells with fibroblast and,
surprisingly, adipolineage gene signatures. Interestingly, an “adipo-CAR” subpopulation
of CAR cells has been recently identified (Baccin 2019).
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CHAPTER 4.

DISCUSSION

Our study represents a thorough dissection of the FBM hematopoietic
compartment, and we are the first to report the presence of bona fide HSCs within the
E15.5 FBM (Figure 4-1). Interestingly, the lineage output of these early FBM HSCs
suggested that lineage-biased HSCs exist in the FBM space as early as E15.5. Due to our
assessment of the BM compartment from the entire murine fetal skeleton compared to
previous studies only using long bones (Christensen 2004, Coşkun 2014), we assumed
that HSCs were present in other sources of BM. However, upon transplantation of BM
from different sources, we found that HSCs were present in the forelimbs, hindlimbs, and
trunk of E15.5 embryos (Figure 4-1). We are also the first to assess the BM
immunophenotypic HSPC compartment from initial seeding to adulthood and found that
MPP2s are the predominant HSPC population in the FBM and appear to have the ability
to migrate to and seed the FBM directly from the FL (Figure 4-1).
However, immunophenotypic MPP2s are not functional in vitro or in vivo until
birth (E18.5-P0), and display reduced repopulating capacity compared to adult BM and
time-matched FL MPP2s—the same timepoint in which there is a shift in the frequencies
of HSPCs in the BM to the more MPP3/MPP4-dominant phenotype seen in adult BM
(Figure 4-1). This suggests the presence of intrinsic or extrinsic mechanisms controlling
MPP2 functional maturation. To identify these mechanisms, we isolated stromal and HP
populations from E16.5, E18.5, P0, and adult BM, and constructed the first known
scRNA-Seq dataset spanning the HP and stromal compartment across BM ontogeny
(Figure 3-28). Our preliminary studies have shown that the FBM stroma and HP
compartments are distinct from the adult BM compartments, and this disparity in cell
composition is even more drastic at E16.5 (Figures 3-29 and 3-34). For instance, the
E16.5 FBM HP compartment is composed primarily of cells with T-cell lineage and mast
cell lineage gene signatures, and immunophenotypic MPP2s and LT-HSCs show a
marked reduction in stem cell associated transcriptional programs (Figures 3-29, 3-32,
and 3-33). Moreover, no definable CAR cell gene signatures can be attributed to cell
clusters from E16.5-P0 stromal libraries, and the primary cell clusters expressing factors
important for HSPC maintenance in the BM niche are various fibroblast and pericyte
clusters (Figures 3-34, 3-35, and 3-36). This suggests that the reduced function of FBM
MPP2s—as well as the reduced expression of stem cell signatures in MPP2 and LTHSCs in the FBM—may be due to a semi-incompatible FBM niche.
In this section, I will discuss the implications and potential limitations of this
study, as well as outline future experiments to answer more questions generated from our
results.
The Presence of Bona Fide HSCs in the E15.5 FBM
Our study indicates the presence of bona fide HSCs in the E15.5 FBM (Figure
3-15), which has never been demonstrated. Previously, the earliest timepoint at which
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Figure 4-1.

A revised developmental timeline of FBM hematopoiesis
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HSCs could be found in the FBM was E16.5 (Coşkun 2014). Why were we able to
identify HSCs one day earlier? We initially thought that this was due to our approach to
isolate the entire embryonic skeleton, but we were able to detect HSC activity in all bones
analyzed, suggesting that the BM source is not a limiting factor in finding transplantable
HSCs at E15.5 (Figure 3-17). Therefore, the observed HSC activity in E15.5 FBM could
be due to various technical caveats.
First, the process of dissecting fetal skeletons and removing any contaminating
tissues is not straightforward, and it is almost impossible to exclude all contaminating
muscle or connective tissue. There is a possibility that some HSCs reside in the muscle or
connective tissue of E15.5 embryos and are contaminating our BM preparations. Indeed,
McKinney-Freeman et al. demonstrated that muscle HSCs (msHSCs) with long-term
multilineage repopulating potential can be found in the muscle tissue of 6-8 week old
mice, and they speculated that these msHSCs may be quiescent “developmental
leftovers” from early in development (McKinney-Freeman 2002). However, the highest
levels of long-term donor contribution were still relatively low (23%) after transplanting
246,000 CD45+ cells, and the CD45- cell fraction contained no HSCs (McKinneyFreeman 2002). In addition, the isolation of cell suspensions from muscle tissue required
digestion with collagenase and trypsin followed by centrifugation in Percoll, while we
simply crushed fetal bones followed by filtration (McKinney-Freeman 2002). This
suggests that HSCs from muscle tissue are not contaminating our FBM preparations,
although isolating E15.5 muscle and connective tissue followed by transplantation would
unequivocally prove the lack of contaminating msHSCs.
Another source of contamination could be circulating blood at E15.5. Given that
the mouse skeletons we use undergo several washes with PBS prior to BM isolation, it is
unlikely that HSCs circulating in the PB are contaminants. It is important to note that a
study identified the peak of HSC activity in the fetal PB at E14.5, followed by a drop at
E15.5 (Christensen 2004). However, only 6/10 recipients displayed any donor
contribution from E15.5 PB after transplantation of an entire embryo equivalent (e.e.) of
blood into each recipient, while 1/7 recipients were reconstituted with 0.1 e.e. of PB
(Christensen 2004). Given that a substantial amount of PB is needed to provide donor
reconstitution at E15.5 and that our method for skeleton BM preparations includes
several washes of dissected skeletons, we suggest that HSCs from the PB are not a source
of contamination in our E15.5 FBM preps.
A final source of technical error may come from variation in the true
developmental age of E15.5 embryos. To secure embryos at desired developmental stages
we employed timed pregnancies, in which we placed a female with a male overnight
(after 5pm) and checked for the presence of a vaginal plug in the morning (before 10am).
If a vaginal plug was detected, it was presumed that the female was pregnant, and the
embryos were designated “E0.5.” Obviously, this allows for several hours of variation in
the true developmental age of the embryo. However, given that we injected FBM
suspensions from 18 E15.5 embryos from multiple litters (Figure 3-7), we conclude that
error in developmental staging was likely not to blame for our observations. In future
experiments, it would be beneficial to employ the identification of specific morphological
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characteristics of E15.5 embryos when deciding which embryos to use for
transplantation.
An understanding of BM development supports the possibility of HSCs residing
in the BM at E15.5. The fetal bones of the limbs and trunk are formed from mesodermderived mesenchymal cells, which accumulate in the bone space at around E11 and form
clusters in a process called “mesenchymal condensation” (Hall 2000, Olsen 2000)
(Figure 4-2A). Centrally located mesenchymal cells begin differentiating into
chondrocytes that will proliferate and form a cartilage plate for later bone formation,
while peripherally located mesenchymal cells differentiate into perichondrial cells
(Matsushita 2020) (Figure 4-2B). At around E13-E14, the cartilage plate begins to
expand through successive differentiation of hypertrophic chondrocytes, followed by the
invasion of the central portion of the plate by perichondrial cells that subsequently
differentiate into osteoblasts forming the bone collar (Kobayashi 2014b) (Figure 4-2C).
Finally, around E15-E16 the central portion of the cartilage plate becomes vascularized,
the BM space is formed, and cartilage begins to be replaced by osteoblast-derived bone
(Kobayashi 2014b) (Figure 4-2D). E15.5 FBM HSC activity coincides with a recent
report showing definitive vessel formation within the bone cavity at ~E15 (Langen 2017).
However, this same report provides confocal images clearly depicting Emcn+ vasculature
adjacent to the bone cavity even earlier (E14.5), suggesting that the vasculature is primed
to receive the necessary cues to begin vasularization of the bone (Langen 2017). It is
possible that the first detectable BM-associated HSCs arrive at the fetal bone from the FL
before E15.5 and are “lying in wait” in the vasculature adjacent to the bone until they can
enter the bone cavity. Indeed, nearly two decades ago Kumaravelu et al. showed that
E12-E13 forelimbs appeared to contain 0.5-1 HSCs capable of reconstitution posttransplant (Kumaravelu 2002). Therefore, there may even be cues in the mesenchymal
condensate or cartilage plate before the formation of BM that facilitate the migration of
HSCs to sites of future bone formation, and it would be interesting to determine if these
theoretical HSCs migrate from the FL or directly from the AGM.
Potential Mechanisms for the Shift in HSPC Frequencies Around Birth
One of the most interesting revelations from our study was the shift in FBM
HSPC frequencies right around birth from an MPP2-dominant phenotype to an MPP3/4dominant phenotype (Figure 3-19). While the early MPP2-dominant phenotype may only
represent a subset of MPP2s considering their lack of functional ability until at least
E18.5 (Figures 3-24 and 3-26), the shift at birth is still an interesting observation for
follow up studies and we speculate that it could be due to a number of birth-related
factors (Figure 4-3).
One potential contributor to the shift in HSPC frequencies around birth could be
acute exposure to ambient oxygen upon delivery of newborn pups (Figure 4-3A). Indeed,
by collecting cells from BM and cord blood in hypoxic (3% O2) vs ambient (21% O2)
conditions, Mantel et al. found that ambient air collection decreased the number of LTHSCs at the expense of ST-HSCs and MPPs, suggesting that LT-HSCs initiate rapid
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Figure 4-2.

Development of the BM space

A. Mesoderm-derived mesenchymal cells form clusters in a process called “mesenchymal
condensation.” B. Central mesenchyme begins differentiating into chondrocytes ( the
cartilage plate), while peripheral chondrocytes differentiate into perichondrial cells. C.
The cartilage plate expands and perichondrial cells begin to differentitate into osteoblasts
to form the bone collar. D. Vascularization of the central cartilage plate forms the BM
space, and chondrocytes begin to be replaced by osteoblast-derived bone.
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Figure 4-3.

Potential effectors of HSPC frequency at birth

Putative explanations for HSPC immunophenotypic shift at birth, including (A) acute
ambient oxygen exposure and/or changes in BM niche oxygen concentrations, (B) acute
exposure to pathogens, or (C) hormonal changes in the uterus during parturition.
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differentiation in response to high O2 concentrations (Mantel 2015). However, we see a
marked increase in the total numbers of LT-HSCs and other HSPCs after birth,
suggesting there is substantial differentiation and self-renewal—as well as continual
migration of HSPCs from the FL—within the LT-HSC compartment during this time. It
is important to note that the normal adult BM microenvironment in which HSCs reside is
thought to be highly hypoxic (Morrison 2014), and the oxygen levels of the HSC/HSPC
niche in the fetal and newborn BM have yet to be assessed and may undergo significant
changes as the cellular composition of the niche changes during development. For
instance, the findings of Mantel et al. may support our results if the E16.5-E18.5 FBM
displays oxygen levels closer to ambient air, but then becomes hypoxic during or after
birth. In future studies it will be important to assess O2 levels in the FBM niche to see if
this is a contributing factor to HSPC frequency dynamics during birth.
Upon delivery the neonate transitions from a theoretically sterile environment in
the uterus to an environment filled with microbes and pathogens and can even be
colonized by microbes while in the maternal vaginal canal (Dominguez-Bello 2010).
Many groups have demonstrated that the gut microbiome of adult mice is critical for
normal steady-state hematopoiesis, including the production of several myeloid cells in
the BM (Balmer 2014). In one of the few studies analyzing the effects of dysregulated gut
microbiome on BM HSPCs, Josefsdottir et al. showed that germ-free or antibiotic-treated
mice have fewer numbers of LT-HSCs and downstream progenitors, and this is likely due
to increased quiescence within the LT-/ST-HSC compartments (Josefsdottir 2017). This
suggests that various bacterial metabolites or their action on other cellular components of
the BM niche may be important for HSPC proliferation. These metabolites may also be
contributing factors to the burst of HSPCs we see in the FBM around birth. We plan to
test this hypothesis in future studies by analyzing the fetal and newborn BM
compartments in germ-free mice or in fetuses/neonates bore from antibiotic-treated
mothers (Figure 4-3B).
Finally, hormonal changes within the uterine environment may play a role in fetal
hematopoiesis (Figure 4-3C). During parturition, the uterus undergoes several changes to
facilitate proper delivery. The initiation of labor in mice can be identified by a reduction
in progesterone levels in the uterus, which are required for normal uterine quiescence
(Sugimoto 1997). This drop in progesterone is concomitant with a breakdown of the
uterine wall, myometrial contractions, and cervical ripening, all of which are mediated by
the production or degradation of a myriad of hormones (Ratajczak 2008). Prostaglandins
[primarily prostaglandin F2α (PGF2α) and prostaglandin E2 (PGE2)] are highly upregulated
in the uterus around birth and are thought to have a key role in these processes, as PGF2α/mice do not initiate parturition (Sugimoto 1997). Interestingly, exposure of murine BM
to PGE2 appears to facilitate HSPC expansion, survival, and homing ability (North 2007,
Porter 2013), and many fetal tissues—including the placenta—express several
prostaglandin receptors. It is therefore enticing to imagine uterine hormones somehow
affecting fetal hematopoietic programs. The mechanisms involved in labor initiation are
well-studied due to the prevalence of premature births (Ratajczak 2008), and we are
currently assessing the literature for potential HSPC regulators.
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Migration of HPSCs to the FBM
The accepted model of HSC accumulation in the BM suggests that HSCs migrate
from the FL in a CXCL12/CXCR4-dependent manner, seed the BM, and likely expand
from E18.5 to P21 (Ara 2003, Bowie 2006, Bowie 2007, Medvinsky 2011). To our
knowledge, our study is the first to show that several HSPC subsets from the E15.5-P0
liver can migrate toward a CXCL12 gradient, suggesting that the FBM is seeded by
several progenitors, not solely HSCs (Figure 3-22). However, this does not explicitly
prove that all HSPCs migrate and seed the FBM at E15.5, and we can think of three
models for HSPC seeding of the FBM (Figure 4-4).
The first model (Figure 4-4A) suggests that only LT-HSCs migrate from the FL
to the FBM at E15.5, followed by a propensity for rapid MPP2-biased differentiation.
This model can be supported by what is known about the dynamics of LT-HSC
differentiation into the various HSPC subsets, as MPP2s have been shown to be the first
HSPC subset produced by LT-HSCs in in vitro differentiation assays (Pietras 2015).
MPP2s also appear to share some of the same transcriptional programs as LT-HSCs, as
Mpl-/- mice display defects in LT-/ST-HSC and MPP2 production, while no other HSPC
subset appears to be affected (Pietras 2015). Finally, Pietras et al. also found that
myeloid-biased HSPCs (MPP2/MPP3) were rapidly expanded shortly after
transplantation of LT-HSCs, suggesting that LT-HSCs preferentially reconstitute the
myeloid compartment of irradiated recipients after transplantation (Pietras 2015). The
notion that LT-HSCs are indeed the primary migratory cells from the FL to the FBM and
that the expansion of MPP2s in the E15.5 FBM is a result of the preferential
differentiation of LT-HSCs toward a myeloid-biased HSPC is tempting to consider,
because it would suggest that the behavior of LT-HSCs in adult BM transplantation is a
mimicry of the inherent behavior they exhibit during ontogeny while seeding the FBM.
The second model (Figure 4-4B) proposes that all HSPCs can migrate to the
FBM at E15.5, and this model is supported by our in vitro migration assays (Figure
3-22). However, what is not accounted for in our study is the enhanced presence of
MPP2s. There are many reasons migratory MPP2s could be the dominant compartment in
the FBM. It could be that FL MPP2s can migrate toward a greater number or more
specific FBM-derived signals compared to other HSPCs. Indeed, Christensen et al. found
that FL LT-HSCs migrate in response to both CXCL12 and SCF gradients, while adult
LT-HSCs appear to preferentially migrate toward CXCL12 (Christensen 2004). FL
MPP2s may also express higher levels of adhesion molecules (cadherins, selectins,
integrins) or matrix metalloproteinases for more efficient retention or invasion of the
FBM niche, respectively (Ciriza 2013). FL MPP2s may also have greater CXCL12
sensitivity, which could be assessed by exposing FL HSPCs to various CXCL12
concentration gradients. However, given that FBM MPP2s appear to have little functional
ability post-transplant and adult MPP2s are also a transient population after
transplantation (Pietras 2015), it is unlikely that migratory FL MPP2s undergo rapid selfrenewal and expansion upon FBM entry.
The final model (Figure 4-4C) is a combination of the first and second models,
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Figure 4-4.

Models for HSPC migration and expansion in the FBM

Three models for HSPC migration and expansion in the fetal bone marrow: A. LT-HSCs
migrate independently of other HSPCs and expand the HSPC pool in the FBM, with a
bias toward MPP2 expansion. B. All HSPCs migrate from the FL to the FBM, with
MPP2s possibly displaying an enhanced migratory potential. C. A mixture of the first two
models, in which all HSPCs migrate from the FL to the FBM, but LT-HSCs also
preferentially produce MPP2s.
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suggesting that all FL HSPCs migrate into the FBM while LT-HSCs preferentially
differentiate into MPP2s. Given the results of our migration assays, the preponderance of
MPP2s at early FBM timepoints, and the preference for LT-HSCs to produce myeloidbiased HSPCs (Pietras 2015), we conclude that this is currently the best available model.
This model also raises more questions about the heterogeneity within HSPC subsets, as it
would suggest the presence of migratory FL HSPCs and FBM LT-HSC-derived HSPCs
coexisting in the FBM space.
Functional Heterogeneity and Maturation of BM HSPCs
Upon noticing that the frequency of MPP2s in the CD45+ compartment of the
early FBM was relatively high compared to later timepoints and that there was a lag in
CD45+ blood production until around birth (Figure 3-23), we hypothesized that FBM
MPP2s may display reduced functional potential until late in gestation. Our hypothesis
was supported, as FBM MPP2s did not display robust in vitro or in vivo functional
potential until P0 (Figures 3-24 and 3-26). Determining the reasons for this discrepancy
in functional output is still ongoing, but our preliminary scRNA-Seq analysis (Figure
3-28) has provided some clues.
Utilization of CITE-Seq antibodies to prospectively identify immunophenotypic
HSPCs allowed us to locate MPP2s within annotated cell clusters in our scRNA-Seq
libraries (Figures 3-30 and 3-31). Given the functional heterogeneity of the MPP2
compartment even within adult BM (Figures 3-24 and s3-26) (Pietras 2015), it was not
surprising to find that adult immunophenotypic MPP2s are found within several distinct
cell clusters, spanning myeloid progenitors to B-cell lineages (Figure 3-31). Therefore, it
is more appropriate to think of the immunophenotypic MPP2 as a mixture of cells that
contains a subset of myeloid-biased progenitors—at least by conventional differentiation
assays. This cell cluster heterogeneity among immunophenotypic MPP2s was consistent
from E16.5 to P0 (Figure 3-31). Since no cell surface molecules have been identified to
enrich for different cell subsets within the MPP2 compartment, one possibility for the
observed “maturation” of MPP2s from E16.5 to P0 may not be due to maturation at all,
but simply an accumulation of the functional MPP2 subset through migration or
differentiation from LT-HSCs (Figure 4-5A). We are currently analyzing the different
subsets of immunophenotypic MPP2s for putative cell surface markers to enrich for
functional MPP2s.
We were also able to incorporate the hscScore algorithm (Wilson 2015, Hamey
2019) into our scRNA-Seq dataset, which provides a value for the “stemness” of each
single cell based on the expression of HSC-associated genes. Incorporation of hscScore
to other scRNA-Seq datasets has shown a progressive decline in hscScore from LT-HSCs
to committed progenitors, and MPP2s have been previously assessed for hscScore
(Hamey 2019). After subclustering immunophenotypic MPP2s, we observed a
progressive increase in hscScore from E16.5 to P0, and this was mainly due to the
accumulation of a small subpopulation of hscScorehi cells (Figure 3-32). This could
represent an increase in the proposed functional subset of immunophenotypic MPP2s.
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Figure 4-5.

Hypotheses for FBM MPP2 functional maturation

A. Accumulation of a subset of functional MPP2s through migration from the FL or
differentiation of LT-HSCs. In this scenario, there is not a true “maturation” step, but
merely an expansion of a subset of immunophenotypic MPP2s which contain intrinsic
functional competency. B. Niche maturation contributing to the maturation of the MPP2
compartment. In this scenario, the development of the FBM niche results in the
prevalence of factors important for MPP2 functional maturation, indicating extrinsic
control on the MPP2 compartment.
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Importantly, we observed the same increase in hscScorehi cells from immunophenotypic
LT-HSCs from E16.5 to P0, suggesting an accumulation of the functional LT-HSC subset
across late gestation as well (Figure 3-33). Also, immunophenotypic LT-HSCs showed
greater cell cluster heterogeneity at E16.5 compared to E18.5 and P0, supporting a model
for enrichment of the functional LT-HSC subset around birth (Figure 3-31). Future
experiments will be aimed at determining if immunophenotypic LT-HSCs—and other
HSPC subsets—also display a trend toward increased functional competency around birth
compared to earlier timepoints via in vitro and in vivo methods.
It is important to note that hscScore was developed using expression data on
highly transplantable HSCs (Wilson 2015, Hamey 2019). Therefore, the observed
correlation between MPP2 hscScore and functional maturation may simply be due to the
expression of factors important for engraftment or homing during transplantation and
may provide little information regarding the maturation of MPP2s important for
homeostatic maintenance in the embryo. More studies are needed to fully dissect the
heterogeneous MPP2 compartment during adulthood and development, as there may be a
subpopulation of these cells that are important for proper blood production during steady
state which cannot be assayed by conventional methods.
Maturation of the FBM Niche
Our scRNA-Seq data revealed a dramatic reconstruction in the cellular
composition of the hematopoietic niche from E16.5 to P0, as well as of the stromal niche
from perinatal timepoints compared to the adult (Figures 3-29 and 3-34). Given that
niche interactions with HSPCs are vital to their maintenance and a number of aberrations
in the niche can disrupt their function (Crane 2017, Gao 2018), we suspect that the
reconstruction of the FBM niche during late gestation could be a source for the functional
maturation of MPP2s and other HSPCs (Figure 4-5B).
In the adult BM, stromal cells appear to be the most well-studied components of
the HSC niche, with a focus on the arterial and sinusoidal niches. Both sources of BM
vasculature are thought to be in close association with Nestin+ perivascular cells, which
express high levels of the HSC maintenance factors Cxcl12 and Kitl (Crane 2017, Gao
2018). These perivascular cells are colloquially called “CXCL12 abundant reticular
cells,” or CAR cells, and their ablation invariably results in HSC mobilization, reduction
in quiescence, and overall reduced function. As expected, we were able to annotate a
clear CAR cell population in our adult BM scRNA-Seq data, but the presence of Cxcl12
and/or Kitl expression in newborn or fetal BM libraries was severely reduced, and
appeared to be equally distributed among several fibroblast and pericyte cell types
(Figures 3-34, 3-35, and 3-36). Of note, Isern et al. identified rare Nestin+ cells within the
E17.5-E18.5 FBM that expressed low levels of Cxcl12, Kitl, and other HSC maintenance
factors (Isern 2014). They also found that deletion of Nestin+ cells in E15.5 mice resulted
in a significant increase in the number of HSCs found in the E17.5 liver with a
concomitant decrease in HSC numbers in the E17.5 FBM via an in vitro long-term
culture initiating cell assay (Isern 2014), suggesting that Nestin+ cells in the FBM are
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important for proper migration of HSCs to the FBM. However, they did not test HSCs or
any other HSPC for in vivo functional potential at this timepoint. If these Nestin+ cells are
truly a niche for HSPCs in the FBM, it is possible that the low HSPC numbers and
functional impairment of MPP2s is simply a reflection of a reduction in available niche
space due to the rarity of Nestin+ cells—as well as their reduced expression of critical
niche factors. Indeed, it is still unclear if some other cell type is a contributor to the
expansion and functional maturation of HSPCs during the perinatal period, as the authors
note that FBM Nestin+ cells appear to be mostly quiescent (Isern 2014). However, they
only assess the total number of Nestin+ cells from P0 to adulthood (Isern 2014).
Hematopoietic cells are also thought to contribute to the maintenance of HSPCs in
the adult BM niche. As described earlier, megakaryocytes, macrophages, regulatory Tcells, and others are all thought to control HSC function (Crane 2017, Gao 2018).
Incredibly, we found that the hematopoietic progenitor (HP) compartment of the E16.5
FBM consisted of several mast cell and T-cell lineage clusters, comprising nearly 80% of
all cells (Figure 3-29). It is generally thought that HSCs give rise to common lymphoid
progenitors in the bone marrow, which then migrate to the thymus for T-cell maturation
(Kondo 1997). Therefore, the T-cell lineage clusters in our E16.5 dataset likely represent
some sort of T-cell primed lymphoid progenitor. Considering that they are present as
early as E16.5, these progenitors may even be comprised of migratory cells from the FL
to the FBM before seeding the fetal thymus, as pre-thymic T-cell progenitors have been
identified in the FL as early as E12 (Watanabe 1997, Kawamoto 2000).
In the adult mouse, mast cell progenitors are thought to arise from an upstream
myeloid progenitor in the BM, where they will then migrate to different tissues and
undergo differentiation (Dahlin 2015b). Meanwhile, fetal mast cell progenitors have been
found in E9-E11 YS, followed by their appearance in the FL (Sonoda 1983). Rodewald et
al. identified a Thy1loc-Kit+ mast cell progenitor that appeared in the fetal blood at E14.5,
peaked in prevalence at E15.5, then decreased until disappearance around birth
(Rodewald 1996). Interestingly, he could not find a similar population in the FL during
mid or late gestation, suggesting that it was either arising from a different source or
underwent immunophenotypic changes upon entry into the fetal blood stream (Rodewald
1996). It is alluring to speculate whether this mast cell progenitor population is taking
residence in the FBM around this time point and is the contributor to the several mast cell
lineage cell clusters we have identified in our E16.5 FBM library. Alternatively, the
abundant MPP2 population could be giving rise to these mast cell progenitors at early
FBM timepoints and contributing to the pool that Rodewald observed in his studies.
T-cells and mast cells have been shown to play significant roles in innate
immunity (St. John 2013, Seyda 2016), and the accumulation of their progenitors in the
early FBM may be indicative of an effort to expand T-cell and mast cell lineages for the
ensuing onslaught of pathogen exposure following birth. Therefore, the early FBM niche
may be preferentially geared toward production of these lineages at the expense of
functional niche space for HSPCs. It is also important to note that mast cell progenitors
and their progeny express high levels of c-Kit on their cell surface. Given that we sorted
for c-Kit+ cells for our scRNA-Seq analyses, it is possible that some of the mast cell
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lineage clusters in our E16.5 FBM library consist of mature mast cells. If this is the case,
the E16.5 FBM may be a characterized by high levels of inflammation, which has been
shown to affect HSPC mobilization, survival, proliferation, and myeloid-biased
differentiation (Pietras 2017).
Conclusions and Future Directions
This study represents one of the only comprehensive assessments of
hematopoiesis in the perinatal BM, revealing that bona fide HSCs colonize all sources of
fetal bone by E15.5, birth appears to have a role in shifting HSPC frequencies, and
specific HSPC populations undergo functional changes right around birth (Figure 4-1).
We also provide the first scRNA-Seq data set for HP and stromal cells spanning the
perinatal BM, which we hope will be utilized for future studies to elucidate specific
mechanisms controlling hematopoietic and stromal cell processes during this critical
window in development. Our study leaves several questions left to be answered
concerning the FBM niche: Are there undiscovered subpopulations of MPP2s with
disparate contributions to steady-state hematopoiesis? Do other HSPCs display similar
functional maturation in the FBM during late gestation? Is there a specific regulatory
niche that HSPCs reside in, and is it substantially rearranged around birth? Can maternal
hormonal changes affect fetal hematopoiesis?
Our future studies will be focused on answering many of these questions. To
identify intrinsic differences between immunophenotypic HSPC populations across FBM
ontogeny, we are performing gene ontology analyses using our scRNA-Seq data (Figure
4-6A). This will allow us to understand the transcriptional programs specific to HSPCs at
each timepoint. To define putative niches for HSPCs in the FBM, we are utilizing
algorithms such as RNA-Magnet (Baccin 2019), which assesses BM-specific ligandreceptor expression profiles between cell populations (Figure 4-6B). Importantly, we will
be comparing HP vs HP, HP vs stroma, and stroma vs stroma libraries to fully visualize
the changing cellular interactome in the FBM. Our hope is that these analyses will
identify novel hematopoietic factors in the FBM niche that can be therapeutically
exploited to enhance HSC expansion/function/differentiation in the clinic.
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Figure 4-6.

Ongoing scRNA-Seq analyses

Ongoing scRNA-Seq analyses, including (A) Gene Ontology analysis to identify changes
in immunophenotypic progenitors across development and (B) RNA-Magnet analysis to
identify putative stromal/hematopoietic niches for HSPCs during perinatal bone
development.
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